Compositions with permeation enhancers for drug delivery

Hydrogel compositions with permeation enhancers and matrix agents facilitate drug delivery across the tympanic membrane, addressing systemic side effects and antibiotic resistance by maintaining high drug concentrations at the infection site.

CA2994702CActive Publication Date: 2026-11-03CHILDRENS MEDICAL CENT CORP +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CA2994702
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-08-05
Filing Date
2016-08-05
Publication Date
2026-11-03
Estimated Expiration
2036-08-05

AI Technical Summary

Technical Problem

The impermeable nature of the tympanic membrane poses a barrier to effective drug delivery for treating middle ear infections, leading to systemic side effects and antibiotic resistance due to inadequate drug concentration at the infection site.

Method used

Compositions combining therapeutic agents with chemical permeation enhancers and matrix forming agents form hydrogels that enhance drug flux across the tympanic membrane, providing sustained drug delivery and high local concentrations without systemic exposure.

Benefits of technology

Achieves effective, non-invasive treatment of middle ear infections with reduced systemic side effects and antibiotic resistance by ensuring high drug concentrations at the infection site.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which in- creases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY RELATED APPLICATIONS

[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application, U.S.S.N. 62 / 201,199, filed August 5, 2015. BACKGROUND

[0002] Twelve to 16 million physician visits per year in the United States are attributed to otitis media (OM), making it the most common specifically treated childhood disease. [1] Acute OM (AOM) has a prevalence of 90% within the first 5 years of life, [2] and 90-95% of all U.S. children have at least one documented middle ear effusion by age 2. [3] 25% percent of all prescriptions written for children are for treatment of acute otitis media. Recurrence of the disease is also striking, with one third of all children in the U.S. having 6 or more episodes of AOM by age 7. [4] Moreover, epidemiological studies suggest that the prevalence of recurrent OM among children, particularly infants, is on the rise. [5] The incidence of OM in children of other industrialized nations is similar to that in the U.S. In the developing world, OM remains a significant cause of childhood mortality due to the development of chronic suppurative otitis media which frequently results in permanent hearing sequelae, and due to intracranial complications estimated to result in more than 25,000 deaths worldwide. [6]

[0003] Acute OM is the most common reason for antimicrobial prescribing in U.S. children and due to the high prevalence of disease and frequent recurrences is believed to be partially responsible for the ongoing increase in antibiotic resistance among pathogenic bacteria. Despite the success in reducing antimicrobial use in children by approximately 25% over the past decade, the increase in antimicrobial resistance has continued.

[0004] Present treatment of ear infections consists of systemic oral antibiotics, a treatment which requires multiple doses over 5-10 days and systemic exposure to antibiotics. The rise in antibiotic resistance, coupled with the many multifactorial etiology of OM pose difficulties in diagnosis and treatment of OM. Furthermore, current treatment presents a number of drawbacks including patient compliance issues due to gastrointestinal side effects, lack of an effective concentration of drug at the site of infection, and the potential for opportunistic infections. Even after acute signs of infection subside, generally within 72 hours, the root cause of the infection may persist for the remainder of the treatment, and beyond, even up to 2 months. Thus, making compliance with a physician's prescription important to prevent reoccurrence of infection.

[0005] Local, sustained delivery of active therapeutics directly to the middle ear for the treatment of OM could allow for much higher concentrations of the drug in the middle ear than from systemic administration, while minimizing systemic exposure and its adverse effects. However, the tympanic membrane (TM), while only 10 cell-layers thick, presents a barrier that is largely impermeable to all but the smallest, moderately hydrophobic molecules. Despite being the thinnest layer of skin, it is still a barrier to trans-tympanic membrane diffusion. Therefore, the direct treatment of middle ear infections is problematic. The shortcomings of the current treatment of ear diseases, such as middle ear infections, suggest the need for a new treatment which is noninvasive and direct acting. SUMMARY

[0006] Provided herein are compositions and methods aimed at non-invasive trans-tympanic otitis media (OM) treatment with sustained drug flux across the tympanic membrane (TM) (See, e.g., Figure. 1). Chemical permeation enhancers (CPEs), commonly employed for trans-dermal delivery, can enable such a trans-tympanic flux. In certain embodiments, a single application of an optimized formulation could provide high concentrations of antibiotics localized to the middle ear, resulting in eradication of bacterial otitis media without the drawbacks of oral therapy. Such formulations may also useful in the treatment of other diseases of the ear requiring drug delivery across the tympanic membrane.

[0007] Typical OM treatments consists of a 10-day course of broad spectrum oral antibiotics. The widespread use of systemic antibiotics against a disease of such high prevalence and recurrence is believed to be partially responsible for the ongoing increase in antibiotic resistance seen in pathogenic bacteria in the nasopharynx. In most cases, antibiotic-resistant infections like pneumonia, skin, soft tissue, and gastrointestinal infections require prolonged and / or costlier treatments, extend hospital stays, necessitate additional doctor visits and healthcare use, and result in greater disability and death compared with infections that are easily treatable with antibiotics. Compliance with multi-dose regimens can also be difficult in some parts of the world. Compliance and antibiotic resistance may also be more problematic in the long-term prophylaxis of recurrent OM. An effective sustained local therapy could address the issue of compliance, affect the development of drug-resistant and chronic suppurative otitis media, and reduce the need for tympanostomy tube placement (devices implanted in the TM to enhance middle ear drainage in recurrent OM). [8]

[0008] The TM is a tri-layer membrane whose outer layer is a stratified squamous keratinizing epithelium continuous with the skin of the external auditory canal. The inner-most layer is a simple cuboidal mucosal epithelium. Between these epithelia is a layer of fibro-elastic connective tissue and associated blood vessels and nerves. The human TM is only about 100 µm thick, but the 6-10 cell layer outer epithelium forms an impenetrable barrier against all but the smallest lipophilic molecules due to its keratin- and lipid-rich stratum corneum.

[11]

[0009] Localized, sustained drug delivery directly to target tissues has several advantages over systemic application, including fewer adverse systemic effects, smaller quantities of drug used, potentially better therapeutic outcomes, and reduced costs. The impermeability of the TM is a central challenge for the development of local therapies.

[0010] Chemical permeation enhancers (CPEs) are used to safely increase small molecule flux in transdermal drug delivery. Several are FDA approved for use in humans. These agents are often surfactants, comprising a heterogeneous group of amphiphilic organic molecules with hydrophilic heads and hydrophobic tails. Several classes of surfactants have been studied. Surfactants reversibly modify lipids by adsorption at interfaces and removal of water-soluble agents that act as plasticizers. Cationic surfactants are known to produce greater increases in permeant flux than anionic surfactants, which in turn increase permeability more than nonionic surfactants. A broad range of non-surfactant chemical enhancers (e.g., terpenes) has also been used with mechanisms of action including denaturation of proteins within and between keratinocytes, and / or modification or disruption of lipids that results in increased lipid bilayer fluidity.

[0011] In a composition provided herein, the therapeutic agents and permeation enhancers are combined with matrix forming agents, to form compositions which form a hydrogels under suitable conditions. Such conditions may include exposure to body heat during administration (e.g., in the ear canal), or following mixing of two components of the composition or matrix- forming agent. The matrix forming agent is a compound or mixture of compounds that forms a gel after administration. The compositions are generally liquid at ambient conditions, however, once administered to a subject, the matrix forming agent or combination of matrix forming agents causes a phase transition to a hydrogel. Hydrogels have a highly porous structure that allows for the loading of drugs and other small molecules, and subsequent drug elution out of the gel creates a high local concentration in the surrounded tissues over an extended period. In certain embodiments, the drugs are loaded in the liquid composition. Hydrogels can conform and adhere to the shape of the surface to which they are applied and tend to be biocompatible.

[0012] For the compositions provided herein, the combination of the permeation enhancer with the matrix forming agent and therapeutic agent provides a composition with improved flux of the therapeutic agent, and also improved, or not significantly impaired, properties of the resulting hydrogel relative to the hydrogel formed by the composition in the absence of the permeation enhancer. For example, the phase transition temperature of the composition with the permeation enhancer may be lower than the composition without the permeation enhancer, or even if higher, may still fall into a useful range for formation of a hydrogel upon exposure to a biological surface (e.g., a phase transition temperature between about 0 °C and about 37 °C. As another example, the storage modulus and / or loss modulus of the composition with the permeation enhancer may be about the same <com:Math><semantics>(e.g.,withinabout20%)<annotation encoding="application / x-tex">(e.g., within about 20\%)< / annotation>< / semantics>< / com:Math> as for the composition without the permeation enhancer, or the storage modulus of the composition with the permeation enhancer may be higher than the composition without the permeation enhancer. As another example, the storage modulus and / or loss modulus of the composition with the permeation enhancer may be about the same (e.g., within about 20% or 3 kPa, whichever is greater) as for the composition without the permeation enhancer, or the storage modulus of the composition with the permeation enhancer may be higher than the composition without the permeation enhancer. For the compositions provided herein, the combination of the permeation enhancer with the matrix forming agent and therapeutic agent provides a composition with improved flux of the therapeutic agent, and additional improved properties including, but not limited to extended drug release, adherence of the composition to the tympanic membrane over time, degradation, or combinations thereof, and also improved, or not significantly impaired, properties of the resulting hydrogel relative to the hydrogel formed by the composition in the absence of the permeation enhancer.

[0013] In one aspect, provided herein are compositions comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is less than about 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of (b) the permeation enhancer or combination of permeation enhancers.

[0014] In one aspect, provided herein are compositions comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is less than about 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition or greater than about 500 Pa, whichever is smaller, at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of (b) the permeation enhancer or combination of permeation enhancers.

[0015] In certain embodiments, condition (i), the phase transition temperature of the composition is less than the phase transition temperature of the reference composition plus about 5 °C, is met. In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, is met. In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, or greater than about 500 Pa, whichever is smaller, is met. In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, or greater than about 1000 Pa, whichever is smaller, is met. In certain embodiments, condition (iii), the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition, is met. In certain embodiments, condition (iii), the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition, is met. In certain embodiments, both conditions (i) and (ii) are met. In certain embodiments, both conditions (ii) and (iii) are met. In certain embodiments, both conditions (i) and (iii) are met. In certain embodiments, each of conditions (i), (ii), and (iii) are met.

[0016] In certain embodiments, the polymer is biodegradable. In certain embodiments, the polymer is a copolymer. In certain embodiments, the copolymer is biodegradable or comprisess biodegradable monomers. In certain embodiments, the copolymer is a block copolymer. In certain embodiments the copolymer comprises at least one block of hydrophobic monomers. In certain embodiments, the copolymer comprises at least one block of hydrophobic monomers, and at least one block of non-hydrophobic monomers.

[0017] In certain embodiments, the copolymer comprises a vinylic polymer (e.g. PE, PVC, PVDC, PS), a polyacrylate (e.g., polyacrylic acid polymethacrylic acid), a polyether (e.g., PEO, PPO, POM), a fluoropolymer (e.g., PTFE), a polysiloxane (e.g., PDMS), a polysaccharide (e.g., cellulose, dextran, hyaluronic acid, chitosan), a polyester (e.g, PET, a polyhydroxyalkanoate (e.g., PHB)), a polyamide (e.g., poly(lactic acid), poly(glycolic acid)), a polyphosphoester, a polyurethane, or a polycarbonate, or copolymers of combinations thereof. In certain embodiments, the copolymer comprises polyethylene oxide, polypropylene oxide, a poloxamer, poloxamer 407, poloxamer 188, a poloxamine, methylcellulose, hydroxypropyl methylcellulose, ethyl(hydroxyethyl) cellulose, xyloglucan, cellulose, acetate phthalate, latex, poly(acrylic acid), N-isopropylacrylamide-based systems, hyaluronic acid, chitosan, dextran, or gellan gum, or a derivative thereof, or a copolymer of a combination thereof. In certain embodiments, the copolymer comprises a poloxamer. In some embodiments, the copolymer comprises poloxamer 407. In certain embodiments, the copolymer comprises phosphoester monomers. In certain embodiments, the copolymer comprises a poloxamer and phosphoester monomers.

[0018] In certain embodiments, the composition has a high degree of hydrophobicity. In certain embodiments, the composition is optically transparent.

[0019] In certain embodiments, the phase transition temperature of the composition is at or below the body temperature of a subject. In certain embodiments, the phase transition temperature of the composition is between about 10 °C and about 40 °C. In certain embodiments, the phase transition temperature of the composition is between about 20 °C and about 40 °C. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the same composition without the permeation enhancer plus about 5 °C.

[0020] In certain embodiments, the composition is useful in treating a disease. In some embodiments, the composition is useful in treating an infectious disease. In some embodiments, the composition is useful in treating an ear disease <com:Math><semantics>(e.g.,thebarrieristhetympanicmembrane)<annotation encoding="application / x-tex">(e.g., the barrier is the tympanic membrane)< / annotation>< / semantics>< / com:Math>. In some embodiments, the composition is useful in treating otitis media.

[0021] In another aspect, provided herein are compositions for treating an infectious disease or ear disease comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a copolymer comprising phosphoester monomers.

[0022] The therapeutic agent may be an antibiotic agent, anesthetic agent, anti-inflammatory agent, analgesic agent, anti-fibrotic agent, anti-sclerotic agent, or anticoagulant agent. In certain embodiments, the therapeutic agent is an antibiotic selected form the group consisting of ciprofloxacin, cefuroxime, cefadroxil, cefazolin, cefalotin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftobiprole, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, bacitracin, colistin, polymyxin B, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, meticillin, nafcillin, oxacillin, penicillin, piperacillin, ticarcillin, mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, and trimethoprim-sulfamethoxazole. In some embodiments, the antibiotic is ciprofloxacin. In some embodiments, the antibiotic is amoxicillin, azithromycin, cefuroxime, ceftriaxone, or trimethoprim. In some embodiments, the antibiotic is levofloxacin.

[0023] The permeation enhancer may be a surfactant, terpene, amino amide, amino ester, azide- containing compound, alcohol, or anesthetic agent. The permeation enhancer may be a surfactant, terpene, amino amide, amino ester, azide-containing compound, alcohol, pyrrolidone, sulfoxide, fatty acid, or anesthetic agent. In some embodiments, the permeation enhancer is a surfactant (e.g., cationic surfactant, anionic surfactant, nonionic surfactant). In some embodiments, the permeation enhancer is a terpene. In some embodiments, the composition comprises a surfactant permeation enhancer and a terpene permeation enhancer.

[0024] In certain embodiments, the permeation enhancer is sodium dodecyl sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, cetyl trimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80. In certain embodiments, the permeation enhancer is sodium octyl sulfate, sodium dodecyl sulfate, octyl trimethylammonium bromide, dodecyl trimethylammonium bromide, Polysorbate 20, or Polysorbate 80. In some embodiments, the permeation enhancer is sodium dodecyl sulfate.

[0025] In certain embodiments, the permeation enhancer is sodium lauroyl sarcosinate, sorbitan monooleate, octoxynol-9, diethyl sebacate, sodium polyacrylate (2500000 molecular weight (MW)), or octyldodecanol.

[0026] In certain embodiments, the permeation enhancer is an azone-like compound. In certain embodiments, the permeation enhancer is a compound similar to azone (e.g., laurocapram) of the [Image disponible dans le document PDF, Image available in the PDF document] formula: . In certain embodiments, the permeation enhancer is a compound containing piperazine. In certain embodiments, the permeation enhancer is 1- benzyl-4-(2-((1,1-biphenyl)-4-yloxy)ethyl)piperazine.

[0027] In certain embodiments, the permeation enhancer is a terpene (e.g., limonene). In certain embodiments, the permeation enhancer is limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, or ethylpiperazine carboxylate. In some embodiments, the permeation enhancer is limonene.

[0028] In certain embodiments, the permeation enhancer is bupivacaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivicaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, or trimecaine. In some embodiments, the permeation enhancer is bupivacaine.

[0029] In some embodiments, the permeation enhancer is a combination of a surfactant and a terpene. In some embodiments, the permeation enhancer is a combination of a surfactant, a terpene, and an anesthetic. In some embodiments, the permeation enhancer is a combination of a surfactant selected from: sodium octyl sulfate, sodium dodecyl sulfate, octyl trimethylammonium bromide, dodecyl trimethylammonium bromide, Polysorbate 20, and Polysorbate 80; and a terpene. In some embodiments, the permeation enhancer is a combination of a surfactant selected from: sodium octyl sulfate, sodium dodecyl sulfate, octyl trimethylammonium bromide, dodecyl trimethylammonium bromide, Polysorbate 20, and Polysorbate 80; and limonene. In some embodiments, the permeation enhancer is sodium dodecyl sulfate, limonene, or bupivacaine, or a combination thereof. In some embodiments, the permeation enhancer is a combination of sodium dodecyl sulfate and limonene. In some embodiments, the permeation enhancer is a combination of sodium dodecyl sulfate, limonene, and bupivacaine.

[0030] The compositions may also include additional therapeutic agents, including anti- inflammatory agents (e.g., dexamethasone), anesthetics (e.g., bupivacaine), or <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactamase inhibitors. In some embodiments, a therapeutic agent or additional therapeutic agent also acts as a permeation enhancer. In some embodiments, an amino amide (e.g., bupivacaine) or amino ester (e.g., tetracaine) local anesthetic acts as both a permeation enhancer and a therapeutic agent. In some embodiments, the composition comprises an amino amide (e.g., bupivacaine) or amino ester (e.g., tetracaine) local anesthetic acting as both a permeation enhancer and a therapeutic agent, and does not comprise an additional therapeutic agent. In some embodiments, the composition comprises bupivacaine acting as both a permeation enhancer and a therapeutic agent, and does not comprise an additional therapeutic agent.

[0031] In certain embodiments, the therapeutic agents comprises between about 0.01 percent to about 10 percent of the composition. In certain embodiments, the percent weight of permeation enhancer in the composition is between about 0.1% to about 1%, between about 1% to about 3%, or between about 3% to about 10%. In certain embodiments, the percent weight of matrix forming agent in the composition is between about 1% to about 10%, between about 10% to about 20%, between about 20% to about 30%, between about 30% to about 40%, or between about 40% to about 50%. Unless otherwise state, percent compositions herein refer to weight of the component per volume of the composition.

[0032] In certain embodiments, the matrix forming agent comprises monomers of Formula (M): [Image disponible dans le document PDF, Image available in the PDF document] (M).

[0033] In certain embodiments, the matrix forming agent is a block copolymer of Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(𝑰).<annotation encoding="application / x-tex">(\mathbf{I}).< / annotation>< / semantics>< / com:Math>

[0034] For Formulae (M) and (I): each occurrence of Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; each occurrence of R<com:Sup>3< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>b< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G<com:Sup>1< / com:Sup> and G<com:Sup>2< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 0 and 200, inclusive, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1.

[0035] In certain embodiments, the matrix forming agent comprises a block copolymer comprising poloxamer 407 (P407), or a similar analog, linked by its terminal hydroxyl groups to polyphosphoester (PPE) blocks (See Figure 7). Hydrophobic PPE side chains may increase the hydrogel modulus, decrease erosion of the hydrogel in situ, enhance micelle packing during gelation, decrease the gelation temperature, or a combination thereof. The thermo-responsiveness and bioadhesion characteristics of the composition may be tuned by selection of side chains (e.g., alkyl side chains, acryl side chains).

[0036] In another aspect, provided herein are a matrix forming agent or a combination of matrix forming agents of Formula (I'): [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(𝑰′).<annotation encoding="application / x-tex">(\mathbf{I'}).< / annotation>< / semantics>< / com:Math> wherein each occurrence of Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; each occurrence of R<com:Sup>3A< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>b< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G<com:Sup>1A< / com:Sup> and G<com:Sup>2A< / com:Sup> is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and

[0037] each of p, q, r, s, and t is independently an integer between 0 and 200, inclusive, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1.

[0038] In another aspect, provided herein are compositions comprising a a matrix forming agent or a combination of matrix forming agents of Formula (I'), [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(𝑰′).<annotation encoding="application / x-tex">(\mathbf{I'}).< / annotation>< / semantics>< / com:Math>

[0039] In another aspect, provided herein are methods for treating an infectious disease comprising administering a composition comprising a therapeutic agent, permeation enhancer, and a matrix forming agent, as described herein, to a subject in need thereof.

[0040] In another aspect, provided herein are methods for treating an ear disease comprising administering a composition comprising a therapeutic agent, permeation enhancer, and a matrix forming agent, as described herein, to a subject in need thereof. In certain embodiments, the composition is administered into the ear canal or to the tympanic membrane. In certain embodiments, the disease is otitis media. In certain embodiments, the disease is an ear infection. In certain embodiments, the disease is a bacterial infection (e.g., a H. influenzae, S. pneumoniae, or M. catarhallis infection).

[0041] In another aspect, provided herein are methods for eradicating a biofilm comprising administering to a subject in need thereof, or contacting a biofilm with, a composition described herein.

[0042] In another aspect, provided herein are methods for inhibiting the formation of a biofilm comprising administering to a subject in need thereof, or contacting a surface with, a composition described herein.

[0043] In an additional aspect, provided herein are methods for delivering a composition described herein, the method comprising administering into an ear canal of a subject the composition, wherein the composition contacts the surface of a tympanic membrane. The composition may be administered with an eye dropper, syringe, double barrel syringe, or catheter (e.g., angiocatheter).

[0044] In an additional aspect, the provided herein are kits comprising a container, a composition described herein, and instructions for administering the composition to a subject in need thereof. The kit may further comprise a device for administration of the composition to a subject, such as a dropper, syringe, catheter, double barrel syringe, or combination thereof. [0044a] In further embodiments, the present disclosure provides: - a composition comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is about 37 °C or less than 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is about 15% or greater than 15% of the storage modulus of the reference composition or about 500 Pa or greater than 500 Pa, whichever is smaller, at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the 14a reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers; wherein the polymer is of Formula (I'): [Image disponible dans le document PDF, Image available in the PDF document] (I'), wherein: each occurrence of Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>; each occurrence of <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; each occurrence of <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>; each occurrence of <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G<com:Sup>1A< / com:Sup> and G<com:Sup>2A< / com:Sup> is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive; - a composition comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a 14b combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is about 37 °C or less than 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is about 15% or greater than 15% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers; wherein the polymer is of Formula (I'): [Image disponible dans le document PDF, Image available in the PDF document] (I'), wherein: each occurrence of Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>; each occurrence of <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; each occurrence of <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>; each occurrence of <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of <com:Math><semantics>G1A<annotation encoding="application / x-tex">G^{1A}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>G2A<annotation encoding="application / x-tex">G^{2A}< / annotation>< / semantics>< / com:Math> is independently hydrogen, 14c halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive; - a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer of Formula (I'): [Image disponible dans le document PDF, Image available in the PDF document] (I'), wherein: each occurrence of Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>; each occurrence of <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, –OR<com:Sup>b< / com:Sup>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; each occurrence of <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>; each occurrence of <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of <com:Math><semantics>G1A<annotation encoding="application / x-tex">G^{1A}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>G2A<annotation encoding="application / x-tex">G^{2A}< / annotation>< / semantics>< / com:Math> is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive; 14d - a composition for treating an infectious disease comprising: (a) a therapeutic agent; (b) a permeation enhancer, wherein the permeation enhancer increases the flux of the therapeutic agent across a barrier; and (c) the matrix forming agent as described herein; - a composition for treating an ear disease comprising: (a) a therapeutic agent; (b) a permeation enhancer, wherein the permeation enhancer increases the flux of the therapeutic agent across the tympanic membrane; and (c) the matrix forming agent as described herein; - the composition for use as described herein for treating an infectious disease in a subject; - the composition for use as described herein for treating an ear disease in a subject; - the composition for use as described herein for eradicating a biofilm in a subject; - the composition for use as described herein, wherein the composition is for administration to an ear canal of a subject, such that it contacts the surface of a tympanic membrane; and -the composition for use as described herein, wherein the composition is for administration to an ear canal of a subject.

[0045] The compositions, composition components (e.g., matrix forming agents, therapeutic agents, and permeation enhancers), methods, kits, and uses of the present disclosure may also incorporate any feature described in: Khoo et al., Biomaterials. (2013) 34, 1281-8; U.S. Patent No. 8,822,410; U.S. Patent Application No. 12 / 993,358, filed May 19, 2009; U.S. Patent Application No. 11 / 734,537; filed April 12, 2007; WIPO Patent Application No. PCT / US2009 / 003084, filed May 19, 2009, and WIPO Patent Application No. PCT / US2007 / 009121, filed April 12 2007.

[0046] The details of certain embodiments of the invention are set forth in the Detailed Description of Certain Embodiments, as described below. Other features, objects, and advantages of the invention will be apparent from the Definitions, Examples, Figures, and Claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] The accompanying drawings, which constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention.

[0048] Figure 1. Scheme for trans-tympanic antibiotic delivery.

[0049] Figures 2A-2D. Images of the tympanic membrane (TM) (2A) normal, untreated TM; (2B) TM with otitis media; (2C) TM with gels containing ciprofloxacin; (2D) TM with gels containing ciprofloxacin and permeation enhancers. Space bar = <com:Math><semantics>20μm<annotation encoding="application / x-tex">20 \mu m< / annotation>< / semantics>< / com:Math>.

[0050] Figure 3. Graph showing enhanced TM flux from gels containing permeation enhancers. (P407 is poloxamer 407, Cipro = ciprofloxacin, and 3CPE refers to 1% sodium dodecyl sulfate, 0.5% bupivacaine, 2% limonene)

[0051] Figure 4. Graphs showing acoustic brainstem response (ABR) threshold shifts after application of 18% poloxamer 407 (P407) containing chemical permeation enhancers. Horizontal line denotes no change.

[0052] Figures 5. Linear oscillatory shear rheology measurements (100 rads<com:Sup>-1< / com:Sup>, 1 % strain, 1°C min<com:Sup>-1< / com:Sup>) for storage and loss modulus of 18% P407 and 18% P407 with 1% sodium dodecylsulfate, 2% limonene, and 0.5 % bupivacaine (3CPE).

[0053] Figure 6. Isobologram showing concentration of CPE B against concentration of CPE A, and indicating the conditions for synergism and antagonism between CPEs.

[0054] Figures 7A-7C. (7A) Syntheses of poloxamer-polyphosphoester block copolymers. (7B) Exemplary phosphoester pendant groups for modulating hydrophobicity. (7C) Exemplary phosphoester groups for enhancing bioadhesiveness.

[0055] Figure 8. Cross-linkable hyaluronic acids (HA) derivatives. Top: HA aldehyde derivative. Bottom: HA hydrazide derivative.

[0056] Figure 9. FTIR for P407-PBP, a poloxamer 407-poly(butoxy)phosphoester, and starting material P407. The additional stretches indicating addition of butoxyphosphoester monomers are indicated.

[0057] Figure 10. Linear oscillatory shear rheology measurements (100 rads<com:Sup>-1< / com:Sup>, 1 % strain, 1°C min<com:Sup>-1< / com:Sup>) for storage and loss modulus of 18% P407-PBP alone (Polymer), with 1% sodium dodecyl sulfate (SDS), with 2% limonene (LIM), with 0.5% bupivacaine (Bup), or with 1% sodium dodecylsulfate, 2% limonene, and 0.5 % bupivacaine (3CPE).

[0058] Figure 11. P407-PBP with n-butyl groups and DP of 5. Figure 11(A) Chemical structure of the P407-polybutylphosphoester with n-butyl side groups; and FTIR spectra of P407 and P407-PBP. Figure 11(B) Chemical structure of the P407-polybutylphosphoester with s-butyl side groups and corresponding FTIR spectra

[0059] Figure 12(A). Nuclear magnetic resonance (NMR) of pentablock copolymers P407-PBP. Figure 12(B). Effect of <com:Math><semantics>n<annotation encoding="application / x-tex">n< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>s<annotation encoding="application / x-tex">s< / annotation>< / semantics>< / com:Math>-butylphosphoester and degree of polymerization on storage and loss shear moduli of 18 % aqueous solutions of P407 derivatives, as a function of temperature. Polymers tested include: P407-PBP, with n- or s- butyl groups, and degree of polymerization (DP) of 2.5 or 5. Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD, n = 4.

[0060] Figure 13. Gelation of aqueous solutions of 18%[P407]. Figure 13 (A), Gelation of aqueous solutions of 18%[P407] without CPE; Figure 13 (B), 3CPE-18%[P407]; Figure 13(C) 18%[P407-PBP], and Figure 13(D), 3CPE-18%[P407-PBP], as a function of temperature. Note: <com:Math><semantics>3CPE=2%<annotation encoding="application / x-tex">3CPE = 2\%< / annotation>< / semantics>< / com:Math> limonene, 1 % SDS, and 0.5 % bupivacaine. Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD, n = 4.

[0061] Figure 14. Schematic of the gelation of P407-PBP aqueous solution, facilitated by hydrophobic interactions of polyphosphoester end groups at elevated temperature (23 °C)

[0062] Figure 15. Effects of individual CPEs and polymer concentrations on formulation rheology. Figure 14(A) Effect of individual CPEs on gelation temperature. Figure 15(B) Effect of individual CPEs on the storage and loss shear moduli of Cip-18%[P407-PBP] solutions at 37 °C. Figure 15(C) Effect of P407-PBP concentration on gelation temperature. All formulations contain 3CPE. Figure 15(D) Effect of P407-PBP concentration on storage and loss shear moduli at 37 °C (from the dotted line in Figure 15(B). Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD, n = 4.

[0063] Figure 16. Ex vivo transfer of ciprofloxacin across the TM into a receiving chamber. The hydrogel formulation Cip-3CPE-18%[P407-PBP] enables high cross-TM drug flux. Data are mean <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD, n = 4.

[0064] Figure 17. Representative photomicrographs of Cip-3CPE-12%[P407-PBP] in normal and diseased chinchilla ears. Figure 17(A) Hematoxylin and eosin (H&E)-stained sections of TM cross-sections in healthy TMs and of TMs after 7 days of OM, without or after treatment with Cip-3CPE-12%[P407-PBP]. Scale bar represents 12 μm. Figure 17(B) H&E-stained cross- sections of the umbo-malleus region after 7 days of OM, without or after treatment with Cip- 3CPE-12%[P407-PBP]. Scale bar represents 20 μm.

[0065] Figure 18. In vivo efficacy, pharmacokinetics, impact on hearing sensitivity, and effect on tissue for Cip-3CPE-12%[P407-PBP]. Figure 18(A) Percentage of animals with OM (defined as non-zero cfu values in their middle ear fluid aspirates) before (Day 0) and after receiving Cip- <com:Math><semantics>3CPE−12%[P407−PBP]<annotation encoding="application / x-tex">3CPE-12\%[P407-PBP]< / annotation>< / semantics>< / com:Math> (n = 10), Cip-3CPE-18%[P407] (n = 5), 1% ciprofloxacin ear drop (n = 8), or no treatment (<com:Math><semantics>n=10<annotation encoding="application / x-tex">n = 10< / annotation>< / semantics>< / com:Math>). Day 0 reflects status immediately prior to administration of therapeutics. *p = <com:Math><semantics>0.0065<annotation encoding="application / x-tex">0.0065< / annotation>< / semantics>< / com:Math> by Fisher's exact test. Figure 18(B) The time course of bacterial colony forming units (cfu) from middle ear fluid from animals with OM from NTHi treated with Cip <com:Math><semantics>(n=4)<annotation encoding="application / x-tex">(n = 4)< / annotation>< / semantics>< / com:Math>, Cip-3CPE-18%[P407] <com:Math><semantics>(n=5)<annotation encoding="application / x-tex">(n = 5)< / annotation>< / semantics>< / com:Math>, Cip-3CPE-12%[P407-PBP] <com:Math><semantics>(n=10)<annotation encoding="application / x-tex">(n = 10)< / annotation>< / semantics>< / com:Math>, or no treatment <com:Math><semantics>(n=10)<annotation encoding="application / x-tex">(n = 10)< / annotation>< / semantics>< / com:Math>. Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD. (Log10 cfu is set to zero instead of minus infinity for the purpose of this illustration.). Figure 18(C) Concentration of ciprofloxacin over time in the middle ear fluid of the same animals as in Figure 18(A). The black dotted line indicates the MIC for NTHi. Inset is magnified drug concentration range of <com:Math><semantics>0−10μg / mL<annotation encoding="application / x-tex">0 - 10 \,\mu\text{g / mL}< / annotation>< / semantics>< / com:Math>. Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD. Figure 18(D) Shifts in ABR thresholds in response to acoustic clicks and brief (8 ms) tone bursts of varied frequencies. All data here had the threshold median prior to the treatment subtracted from them. The lines across the graph indicate the interquartile range of values prior to treatment (<com:Math><semantics>n=<annotation encoding="application / x-tex">n =< / annotation>< / semantics>< / com:Math> 8). Measurements following application of 200 µL of Cip-3CPE-12%[P407-PBP] formulation are in black <com:Math><semantics>(n=8)<annotation encoding="application / x-tex">(n = 8)< / annotation>< / semantics>< / com:Math>: Black boxes and the lines within indicate the interquartile ranges and medians respectively. Small black squares indicate the means, and crosses indicate the range.

[0066] Figure 19. Cumulative release of ciprofloxacin at 37 °C from Cip and from Cip- 18%[P407], Cip-3CPE-18%[P407], Cip-18%[P407-PBP], and Cip-3CPE-18%[P407-PBP] under infinite sink conditions. 2 mg ciprofloxacin were contained in each gel and solution at time zero. Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD, n = 4.

[0067] Figure 20. Cytotoxicity of 12%[P407-PBP] and Cip-3CPE-12%[P407-PBP]. Figure 20(A) Survival rates (determined by MTS assay) of human fibroblasts (hFB), PC12 cells, and keratinocytes, after incubating with 12%[P407-PBP] and Cip-3CPE-12%[P407-PBP] for 1 or 3 days. Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD (n = 4). Figure 20(B) Live / dead assay of hFB, done to confirm the data in Figure 20(A) by a different assay, after incubation for 1 or 3 days with 12%[P407-PBP] or Cip-3CPE-12%[P407-PBP]. White in the GFP panel indicates live cells and white in the TRITC panel indicates dead cells. Figure 20 (C) hFB cell survival rates were obtained by counting live and dead cells in Figure 20(B) and calculating % cell survival = live cells / (live cells + dead cells). Cell counting was done using ImageJ. Data are means <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> SD (n = 4). For all images, pair-sample t-test was applied.

[0068] Figure 21(A). Permeation enhancement effect of individual CPEs. All curves show the cumulative amount of ciprofloxacin permeated across the TM over time. All solutions are made with 12% P407-PBP, 1% Ciprofloxacin, and 1% CPE except the group 'no CPE' which does not contain CPEs. Figure 21(B). Permeation enhancement of effect combinations of CPEs. All curves show the cumulative amount of ciprofloxacin permeated across the TM over time. All solutions are made with 12% P407-PBP, 1% Ciprofloxacin. In particular, stearyl methacrylate (SM) and SDS and bupivacaine (BUP) = <com:Math><semantics>1.5%<annotation encoding="application / x-tex">1.5\%< / annotation>< / semantics>< / com:Math> SM (solubility limit), <com:Math><semantics>1%<annotation encoding="application / x-tex">1\%< / annotation>< / semantics>< / com:Math> SDS, <com:Math><semantics>0.5%<annotation encoding="application / x-tex">0.5\%< / annotation>< / semantics>< / com:Math> BUP; BP and SDS and BUP = 1.5% BP (solubility limit), 1% SDS, 0.5% BUP; LIM and SDS and BUP = 2% LIM, 1% SDS, 0.5% BUP.

[0069] Figure 22(A). Dose-response curves of SDS, LIM and BUP. The cumulative amount of ciprofloxacin that permeated across the TM after 48 hours increases with the concentration of the CPE in the formulation. All formulations were prepared with: 12% P407-PBP, 4% Ciprofloxacin, and corresponding concentrations (x-axis) of the individual CPEs. The colored dots demonstrate the permeation when two CPEs are added. For example, the dot beside the label "BUP" in the SDS plot represents the permeation when 1%BUP+1%SDS are added to the formulation, instead of 2% SDS. Figure 22 (B). Trans-tympanic permeation of levofloxacin formulations in comparison with ciprofloxacin formulations. Levofloxacin free drug solution = 1.5% Levofloxacin aqueous solution; Levo, P407-PBP+3CPEs = 1.5% Levofloxacin, 12% P407- PBP, 1% SDS, 2% LIM, 0.5% BUP; Cipro, P407-PBP+3CPEs = 1% Ciprofloxacin, 12% P407- PBP, 1% SDS, 2% LIM, 0.5% BUP; Cipro free drug solution = 1% Ciprofloxacin aqueous solution. Figure 22(C). Permeation of ciprofloxacin (left) and dexamethasone (right) across the TM over time. 4% Cip-0.1% Dex = 4% ciprofloxacin and 0.1% dexamethasone aqueous solution; 4%Cip-0.1%Dex-3CPE = 4% ciprofloxacin, 0.1% dexamethasone, 1% SDS, 2% LIM, 0.5% BUP; 4%Cip-0.1%Dex-3CPE-18%[P407]= 4% ciprofloxacin, 0.1% dexamethasone, 1% SDS, 2% LIM, 0.5% BUP, 18%P407.

[0070] Figure 23(A). Streptococcus pneumoniae (SP) cure rate, showing change in percentage of infected ears over time, for 4% Ciproflaxin formulation with either Ciproflaxin-3CPE or Ciproflaxin-3CPE-12%[P407-PBP]. Figure 23(B). Middle ear fluid (MEF) Ciproflaxin concentration over time for various concentrations of Ciproflaxin-3CPE-12%[P407-PBP] and 1% Ciproflaxin-3CPE. Figure 23 (C). Ex vivo permeation data for formulation of 18% poloxamer 407 (P407) for various concentrations of Ciproflaxin-3CPE-12%[P407-PBP] and 4% Ciproflaxin-18%[P407]. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[0071] Provided herein are compositions and methods for administering a therapeutic agent to a subject through a barrier. In some embodiments, the composition is for administering a therapeutic agent to the ear of a subject, and the barrier is a tympanic membrane. The compositions and methods provide for the efficient delivery of the agent to the middle and / or inner ear of the subject. In one aspect, the composition comprises a combination of a permeation enhancer, a therapeutic agent, and a matrix forming agent. The permeation enhancer increases the flux of the therapeutic agent across the barrier (e.g., tympanic membrane), compared to the flux for a composition lacking the permeation enhancer. In various aspects, the composition is a single application composition for localized, sustained delivery of a therapeutic agent across the tympanic membrane. In various aspects, the composition is a multiple application composition for localized, sustained delivery of a therapeutic agent across the tympanic membrane. The inventive compositions and methods are particularly useful in treating otitis media by providing sustained release and delivery of an antibiotic to the middle ear.

[0072] In one aspect, provided herein are compositions comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; the phase transition temperature is less than about 37 °C; and and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of (b) the permeation enhancer or combination of permeation enhancers.

[0073] In another aspect, provided herein are compositions comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; the phase transition temperature is less than about 37 °C; and and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition or greater than about 500 Pa, whichever is smaller, at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of (b) the permeation enhancer or combination of permeation enhancers.

[0074] In certain embodiments, condition (i), the phase transition temperature of the composition is less than the phase transition temperature of the reference composition plus about 5 °C, is met. In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, is met. In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, or 500 Pa, whichever is smaller, is met. In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, or greater than about 1000 Pa, whichever is smaller, is met. In certain embodiments, condition (iii), the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition, is met. In certain embodiments, condition (iii), the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition, is met. In certain embodiments, both conditions (i) and (ii) are met. In certain embodiments, both conditions (ii) and (iii) are met. In certain embodiments, both conditions (i) and (iii) are met. In certain embodiments, each of conditions (i), (ii), and (iii) are met.

[0075] In certain embodiments, the therapeutic agent is a single therapeutic agent. In certain embodiments, the therapeutic agent is combination of two or more therapeutic agents (<com:Math><semantics>e.g.<annotation encoding="application / x-tex">e.g.< / annotation>< / semantics>< / com:Math>, two, three, four). In certain embodiments, the permeation enhancer is a single therapeutic agent. In certain embodiments, the therapeutic agent is combination of two or more therapeutic agents (e.g., two, three, four). In certain embodiments, the matrix forming agent is a single matrix forming agent. In certain embodiments, the matrix forming agent is a combination of two or more matrix forming agents (e.g., two, three, four). In certain embodiments, a therapeutic agent or permeation enhancer may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, a therapeutic agent may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, a permeation enhancer may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, a local anesthetic may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, an amino amide or amino ester local anesthetic may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, an amino amide or amino ester local anesthetic may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, an amino ester local anesthetic may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, bupivacaine may act as both a therapeutic agent and a permeation enhancer. In certain embodiments, tetracaine may act as both a therapeutic agent and a permeation enhancer.

[0076] In certain embodiments, the permeation enhancer or combination of permeation enhancers is present in an amount effective to increase the flux of the therapeutic agent across a barrier compared to the reference composition (e.g., the composition without the permeation enhancer). In certain embodiments, the permeation enhancer or combination of permeation enhancers is present in an amount effective to increase the flux of the therapeutic agent across a barrier compared to the reference composition (e.g., the composition without the permeation enhancer) by at least about 1.05 fold, at least about 1.10 fold, at least about 1.2 fold, at least about, at least about 1.3 fold, at least about 1.4 fold, at least about 1.5 fold, at least about 1.6 fold, at least about 1.7 fold, at least about 1.8 fold, or at least about 1.9 fold. In certain embodiments, the permeation enhancer or combination of permeation enhancers is present in an amount effective to increase the flux of the therapeutic agent across a barrier compared to a reference composition by at least about 2 fold, at least about 2.5 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 10 fold, at least about 25 fold, at least about 50 fold, at least about 100 fold, at least about 250 fold, at least about 500 fold, or at least about 1000 fold. In certain embodiments, the permeation enhancer or combination of permeation enhancers is present in an amount effective to increase the flux of the therapeutic agent across a barrier compared to a reference composition by between about 1.5 fold and about 100 fold.

[0077] In certain embodiments, the polymer is a copolymer. In some embodiments, the polymer is biodegradable. In certain embodiments, the copolymer is a block copolymer. In certain embodiments the copolymer comprises at least one block of hydrophobic monomers. In certain embodiments, the copolymer is biodegradable, or contains at least one biodegradable block.

[0078] As used herein "hydrophobic" refers to a polymer which tends to not dissolve in water and is fat soluble. As used herein "a high degree of hydrophobicity" refers to a polymer which has a low water water solubility and that has a high degree of fat solubility. In some embodiments, a hydrophobic polymer comprises hydrophobic side-chains. In some embodiments, a polymer with a high degree of hydrophobicity comprises hydrophobic side- chains. Hydrophobic side-chains include but are not limited to, side-chains comprising hydrocarbon radicals, such as alkyl <com:Math><semantics>(e.g.,methyl)<annotation encoding="application / x-tex">(e.g., methyl)< / annotation>< / semantics>< / com:Math>, alkenyl, alkynyl, carbocyclyl and aryl. Hydrophobic moieties may also include groups selected from heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, and heteroaryl, wherein the heteroatom containing group is substantially similar to a hydrocarbon group (e.g., only 1 or 2 carbons is replaced with a heteroatom). Hydrophobic side-chains may contain groups that are the same as or are derivatives of the side chains of hydrophobic amino acids, including but not limited to, glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, amino isobutyric acid, alloisoleucine, tyrosine, and tryptophan. A non-hydrophobic or hydrophilic polymer is a polymer that tends to dissolve in water.

[0079] In certain embodiments, the polymer or copolymer comprises a vinylic polymer (e.g., PE, PVC, PVDC, PS), a polyacrylate (e.g., polyacrylic acid polymethacrylic acid), a polyether (e.g., PEO, PPO, POM), a fluoropolymer (e.g., PTFE), a polysiloxane (e.g., PDMS), a polysaccharide (e.g., cellulose, dextran, hyaluronic acid, chitosan), a polyester (e.g., PET, a polyhydroxyalkanoate (e.g., PHB)), a polyamide (e.g., poly(lactic acid), poly(glycolic acid)), a polyphosphoester, a polyurethane, or a polycarbonate, or copolymers of combinations thereof. In certain embodiments, the copolymer comprises a natural polymer. In some embodiments, the copolymer comprises a polysaccharide, proteoglycan, glycosaminoglycan, collagen, fibrin, gelatin, or a derivative thereof, or copolymers of combinations thereof.

[0080] Exemplary polymer types suitable for the polymer or copolymer include, but are not limited to: polyethers (e.g., polyethylene oxide, polypropylene oxide, polyethylene oxide- polypropylene oxide co-polymers), poloxamers, poloxamines, celluloses and hemicelluloses (e.g., methylcellulose, hydroxypropyl methylcellulose, ethyl(hydroxyethyl) cellulose, xlyoglucan), acetates, phthalates, latexes, polyacrylates (e.g., polyacrylica acid), N- alkylacrylamides (e.g., poly(N-isoproylacrylamide), hyaluronic acids, chitosan, dextran and gellan gum, and derivatives thereof. In some embodiments, the polymer or copolymer comprises polyethylene oxide or polypropylene oxide. In some embodiments, the copolymer comprises a polyethylene / polypropylene copolymer or polyethylene / polypropylene block copolymer. In some embodiments, the copolymer comprises a poloxamer. In some embodiments, the copolymer comprises poloxamer 407, poloxamer 188, poloxalene, poloxamer 124, poloxamer 237, or poloxamer 338. In some embodiments, the copolymer comprises poloxamer 407. In certain embodiments, the polymer or copolymer comprises phosphoester monomers. In certain embodiments, the copolymer comprises a poloxamer and phosphoester monomers.

[0081] Additional exemplary polymers suitable for the polymer or copolymer include aliphatic polyesters such as poly(lactic acid), poly(glycolic acid) and poly(lactic acid-co-glycolic acid); poly(trimethylene carbonate); polydioxanone and copolymers; poly(butylenes succinate) (such as polybutylene succinate / adipate copolymers, sold as BIONOLLE®, Showa Highpolymer Co. Ltd.) and poly(butylene adipate); polyanhydrides, such as poly(adipic anhydride) and poly(sebacic acid-co-1,3-bis(p-carboxyphenoxy) carboxyphenoxy) propane; poly(ortho ester)s; poly(ester amide)s, such as polymers based on 1,4-butanediol, adipic acid, and 1,6- aminohexanoic acid (BAK1095, Bayer AG, Leverkusen); poly(ester urethane)s; poly(ester anhydride)s; poly(ester carbonate)s, such as tyrosine-poly (alkylene oxide)-derived poly(ether carbonate)s; polyphosphazenes, polyarylates, such as tyrosine-derived polyacrylates; poly(ether ester)s, such as poly(butylene terephthalate)-poly(ethylene glycol) copolymers (PolyActiveo®), poly(ε-caprolactone)-poly(ethylene glycol)) block copolymers and poly(ethylene oxide)- poly(hydroxy butyrate) block copolymers; polypropylfumerates; polyacetals; polyethers; biodegradable polycyanoacrylates; biodegradable polyurethanes; polyphosphoesters; poly(amide-enamines); polyamides; poly(amino acids); polycaprolactones; and polyhydroxyalkanoates.

[0082] In certain embodiments, the polymer or copolymer comprises poly (lactic acid) (PLA), poly (glycolic acid) (PGA), a copolymers of PLA and PGA, (e.g., poly (lactide-co-glycolide) (PLG)), poly (caprolactone) (PCL), poly (lactide-co-caprolactone) (PLC), or poly (glycolide-co- caprolactone) (PGC).

[0083] In certain embodiments, the copolymer is a block copolymer of formula A-B-A, wherein B is a hydrophobic block and each A is a non-hydrophobic blocks. In certain embodiments, the copolymer is a block copolymer of formula C-A-B-A-C, wherein each B or C is a hydrophobic blocks, and A are non-hydrophobic blocks. Polymers A-B-A and C-A-B-A-C may also comprise terminal groups attached to end block A or C. In certain embodiments, B and C are different polymers, In certain embodiments, B and C are the same polymer. In certain embodiments, each block A is a polymer of between 1 and 400 monomers. In certain embodiments, block A is a polymer of between 20 and 200 monomers. In certain embodiments each block B, is a polymer of between 1 and 400 monomers. In certain embodiments, block B is a polymer of between 20 and 200 monomers. In certain embodiments each block C, is a polymer of between 1 and 400 monomers. In certain embodiments, block C is a polymer of between 20 and 200 monomers. In certain embodiments, each block A comprises a single type of monomer. In certain embodiments, each block A comprises more than one type of monomer. In certain embodiments, each block B comprises a single type of monomer. In certain embodiments, each block B comprises more than one type of monomer. In certain embodiments, each block C comprises a single type of monomer. In certain embodiments, each block C comprises more than one type of monomer.

[0084] In certain embodiments, polymer A is a hydrophilic polyether (e.g., polyethylene oxide). In certain embodiments, polymer A is a hydrophilic polyester (e.g., polyglycolic acid). In certain embodiments, poylmer B is a hydrophobic polyether (e.g., polypropylene oxide). In certain embodiments, polymer B is a hydrophobic polyester (e.g., polylactic acid). In certain embodiments, poylmer B is a hydrophobic polyether (e.g., polypropylene oxide). In certain embodiments, polymer B is a hydrophobic polyester (e.g., polylactic acid). In certain embodiments, polymer C is a polyphosphoester.

[0085] The composition may be a liquid prior to warming above the phase transition temperature. In some embodiments, the phase transition temperature is at or below the body temperature of a subject (e.g., about 37 °C). Thus, the composition may form a gel when administered to a subject, e.g., when the composition contacts a biological surface. In some embodiments, the phase transition temperature is between about 0 °C and about 37 °C, between about 10 °C and about 37 °C, between about 15 °C and about 37 °C, between about 20 °C and about 37 °C, between about 25 °C between about 30 °C and about 37 °C, between about 30 °C and about 35 °C, or between about 35 °C and about 40 °C. In some embodiments, the phase transition temperature is between about 20 °C and about 37 °C. In some embodiments, the phase transition temperature is between about 0 °C and about 60 °C, between about 10 °C and about 50 °C, between about 20 °C and about 40 °C, or between about 25 °C and about 35 °C. In some embodiments, the phase transition temperature is between about 20 °C and 25 °C, between about 25 °C and about 30 °C, between about 30 °C and about 35 °C, or between about 35 °C and about 40 °C. In some embodiments, the phase transition temperature is between about 10 °C and about 50 °C. In some embodiments, the phase transition temperature is between about 20 °C and about 40 °C. In some embodiments, the phase transition temperature is between about 15 °C and about 40 °C.

[0086] For any composition comprising a matrix forming agent, the phase transition temperature of the composition may change if an additive is added to the composition. The phase transition temperature of a composition with an additive versus a reference composition without the additive may be higher, lower, or the same depending on characteristics of the composition and the additive. The term reference composition as used herein, refers to a composition which contains the same components as the composition to which it is being compared, with the exception of a specified component (e.g., the permeation enhancer). Unless otherwise stated, the difference in % weight / volume from including or excluding the permeation enhancer is made up by a change in % weight / volume of the solvent (e.g., water). In certain embodiments, the reference composition comprises the therapeutic agent and the matrix forming agent, but not the permeation enhancer. In certain embodiments, the reference composition comprises the matrix forming agent, but not the therapeutic agent or the permeation enhancer. In certain embodiments, the reference composition comprises the permeation enhancer and the matrix forming agent, but not the therapeutic agent.

[0087] In certain embodiments, the phase transition temperature of the composition is greater than the phase transition temperature of the reference composition (e.g., the composition without the permeation enhancer). In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the reference composition (e.g., the composition without the permeation enhancer) plus about 5 °C, 4 °C, about 3 °C, about 2 °C, or about 1 °C. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the reference composition (e.g., the composition without the permeation enhancer) plus about 5 °C. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the reference composition (e.g., the composition without the permeation enhancer) plus about 37 °C. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the reference composition (e.g., the composition without the permeation enhancer) plus about 30 °C, about 20 °C, or about 10 °C. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the reference composition (e.g., the composition without the permeation enhancer).

[0088] In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the reference composition (e.g., the composition without the permeation enhancer) plus about 5 °C, plus about 2 °C, or plus about 1 °C, and is higher than about 0 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, or about 30 °C. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of the reference composition (<com:Math><semantics>e.g.<annotation encoding="application / x-tex">e.g.< / annotation>< / semantics>< / com:Math>, the composition without the permeation enhancer) plus about 5 °C, and is higher than about 20 °C.

[0089] As a non-limiting example consider the following compositions. The phase transition temperature of a composition "A" comprising: (i) 1% ciprofloxacin and (ii) 18% poloxamer 407 / polybutylphosphoester copolymer is about 33 °C. For the corresponding composition "B" comprising the component of "A" and (iii) 1% sodium dodecyl sulfate, the phase transition temperature decreases to about 31 °C. For the corresponding composition "C" comprising the components of "A" and (iii) 0.5% bupivacaine, the phase transition temperature remains about 33 °C. Compositions "B" and "C" would both meet the criteria for the phase transition temperature of the composition with the permeation enhancer being less than, or slightly higher <com:Math><semantics>(e.g.,<5∘C)<annotation encoding="application / x-tex">(e.g., < 5^{\circ}C)< / annotation>< / semantics>< / com:Math> than, the phase transition temperature of the composition without the permeation enhancer.

[0090] In certain embodiments, the composition is a gel at temperatures above the phase transition temperature and below about 60 °C, below about 50 °C, or below about 40 °C. In certain embodiments, the composition is a gel at temperatures above the phase transition temperature and below about 50 °C. In certain embodiments, the composition is a gel at temperatures between about 0 °C and about 60 °C, between about 10 °C and about 50 °C, between about 20 °C and about 40 °C, or between about 25 °C and about 35 °C. In some embodiments, the composition is a gel is at temperatures between about 20 °C and 25 °C, between about 25 °C and about 30 °C, between about 30 °C and about 35 °C, or between about 35 °C and about 40 °C. In some embodiments, the composition is a gel at temperatures between about 10 °C and about 50 °C. In some embodiments, the composition is a gel at temperatures between about 20 °C and about 40 °C. In some embodiments, the composition is a gel at temperatures between about 15 °C and about 40 °C.

[0091] For any composition comprising a matrix forming agent, the storage modulus and loss modulus of the composition may change if an additive is added to the composition. The storage modulus of a composition with an additive versus the same composition without the additive may be higher, lower, or the same depending on characteristics of the composition and the additive. The loss modulus of a composition with an additive versus a reference composition without the additive may be higher, lower, or the same depending on characteristics of the composition and the additive. In certain embodiments, the reference composition comprises the therapeutic agent and the matrix forming agent, but not the permeation enhancer. In certain embodiments, the reference composition comprises the matrix forming agent, but not the therapeutic agent or the permeation enhancer. In certain embodiments, the reference composition comprises the permeation enhancer and the matrix forming agent, but not the therapeutic agent.

[0092] In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, or greater than about 500 Pa, whichever is smaller, is met. In certain embodiments, condition (ii), the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition, or greater than about 1000 Pa, whichever is smaller, is met. In certain embodiments, the storage modulus of the composition is greater than about 15%, greater than about 30%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, or greater than about 100% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is greater than about 30% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is greater than about 50% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is greater than about 70% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is greater than about 80% or about 90% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is greater than about 100% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is greater than about 110%, greater than about 120%, greater than about 130%, greater than about 140%, greater than about 150%, greater than about 175%, or greater than about 200% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the storage modulus of the composition is less than about 200%, less than about 500%, or less than about 1000% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the given temperature is about 37 °C. In certain embodiments, the given temperature is a temperature between the phase transition temperature and about 37 °C.

[0093] In certain embodiments, the loss modulus of the composition is less than about 200%, less than about 150%, less than about 125%, less than about 110%, or less than about 100% of the storage modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the loss modulus of the composition is greater than about 50%, less than about 75%, or greater than about 90% of the loss modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the loss modulus of the composition is between about 50%, and about 150%, between about 70%, and about 130%, between about 80%, and about 120%, or between about 90%, and about 110% of the loss modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, the loss modulus of the composition is between about 80%, and about 120% of the loss modulus of the reference composition (e.g., the composition without the permeation enhancer) at a given temperature. In certain embodiments, condition (iii), the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition at a temperature of about 37 °C. In certain embodiments, the given temperature is about 37 °C. In certain embodiments, the given temperature is a temperature between the phase transition temperature and about 37 °C.

[0094] In certain embodiments, the composition comprises at least about 0.1% permeation enhancer. In certain embodiments, the composition comprises at least about 0.5% permeation enhancer. In certain embodiments, the composition comprises at least about 1% permeation enhancer. In certain embodiments, the composition comprises at least about 2% permeation enhancer. In certain embodiments, the composition comprises at least about 3% permeation enhancer. In certain embodiments, the composition comprises at least about 4% permeation enhancer. In certain embodiments, the composition comprises at least about 5% permeation enhancer. In certain embodiments, the composition comprises at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% permeation enhancer. In certain embodiments, the composition comprises at least about 0.5% weight per volume composition (wt / vol) permeation enhancer. In certain embodiments, the composition comprises at least about 1% wt / vol permeation enhancer. In certain embodiments, the composition comprises at least about 2% wt / vol permeation enhancer. In certain embodiments, the composition comprises at least about 3% wt / vol permeation enhancer. In certain embodiments, the composition comprises at least about 4% wt / vol permeation enhancer. In certain embodiments, the composition comprises at least about 5% permeation enhancer. In certain embodiments, the composition comprises at least about 6% wt / vol permeation enhancer. In certain embodiments, the composition comprises at least about 7% wt / vol permeation enhancer. In certain embodiments, the composition comprises at least about 8% wt / vol permeation enhancer, In certain embodiments, the composition comprises at between about 0.1% and about 1% permeation enhancer. In certain embodiments, the composition comprises at between about 0.5% and about 3% permeation enhancer. In certain embodiments, the composition comprises at between about 0.5% and about 10% permeation enhancer. In certain embodiments, the composition comprises at between about 2% and about 10% permeation enhancer.

[0095] In certain embodiments, the composition is applied to a surface of temperature equal to or above the phase transition temperature. In some embodiments, the surface is a biological surface. In certain embodiments, the surface is skin. In certain embodiments, the surface is a surface in the ear canal of a subject. In certain embodiments, the subject is a tympanic membrane. In certain embodiments, the surface is a surface in the respiratory tract of a subject (e.g., in the nasal cavity or buccal cavity). In certain embodiments, the surface is a surface in the mouth (e.g., surface of teeth or gums) of a subject. The composition may be administered to an interior body surface, for example, by intradermal or interdermal delivery or during a surgical procedure. In certain embodiments, the surface is an intradermal surface. In certain embodiments, the surface is the surface of an organ (e.g., heart, lung, spleen, pancreas, kidney, liver, stomach, intestine, bladder). In certain embodiments, the surface is connective tissue. In certain embodiments, the surface is muscle tissue (e.g., smooth muscle, skeletal muscle, cardiac muscle). In certain embodiments, the surface is nervous tissue (e.g., brain, spinal cord). In certain embodiments, the surface is epithelial tissue. In certain embodiments, the surface is a surface of the alimentary canal (e.g., colon, rectum). In certain embodiments, the surface is epithelial tissue. In certain embodiments, the surface is a surface of the reproductive tract (e.g., vagina, cervix). In certain embodiments, the surface is bone. In certain embodiments, the surface is vascular tissue. In certain embodiments, the surface is a wound bed. In certain embodiments, the surface is a biofilm. In certain embodiments, the surface is hair or fur. In certain embodiments, the surface is the surface of a medical implant.

[0096] Generally, for addition of a permeation enhancer a small change or no change in the phase transition temperature, storage modulus, or loss modulus is preferred. A small change is considered a phase transition temperature change of less than 5 °C, or a modulus change of less than 10%. For changes in the phase transition temperature, a lower phase transition temperature for the composition with the permeation enhancer is preferred. A shift to a lower phase transition temperature may referred to as a 'left-shift' or 'L-shift' as opposed to a 'right-shift' or 'R-shift'. For changes in the storage modulus, a higher storage modulus for the composition with the permeation enhancer is preferred. For changes in the loss modulus, a lower loss modulus for the composition with the permeation enhancer is preferred.

[0097] In certain embodiments, the phase transition temperature of the composition is within about 5 °C, within about 3 °C, or within about 1 °C of the phase transition temperature of a reference composition, wherein the composition comprises permeation enhancer P1 and the reference composition does not comprise permeation enhancer P1. In certain embodiments, the storage modulus of the composition is within about 10%, within about 5%, or within about 2% °C of the storage modulus of a reference composition, wherein the composition comprises permeation enhancer P1 and the reference composition does not comprise permeation enhancer P1. In certain embodiments, the loss modulus of the composition is within about 10%, within about 5%, or within about 2% °C of the loss modulus of a reference composition, wherein the composition comprises permeation enhancer P1 and the reference composition does not comprise permeation enhancer P1. In certain embodiments, the phase transition temperature of the composition is within about 5 °C, within about 3 °C, or within about 1 °C of the phase transition temperature of a reference composition, and the storage modulus of the composition is within about 10%, within about 5%, or within about 2% °C of the storage modulus of the reference composition, wherein the composition comprises permeation enhancer P1 and the reference composition does not comprise permeation enhancer P1.

[0098] In certain embodiments, permeation enhancer P1 is a surfactant (anionic, cationic, nonionic, zwitterionic), terpene, anesthetic, amino amide, amino ester, azide-containing compound, or alcohol. In certain embodiments, permeation enhancer P1 is a surfactant (anionic, cationic, nonionic, zwitterionic), terpene, anesthetic, amino amide, amino ester, azide-containing compound, pyrrolidone, sulfoxide, fatty acid, or alcohol. In certain embodiments, permeation enhancer P1 is a surfactant (e.g., sodium dodecyl sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, cetyl trimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80). In certain embodiments, permeation enhancer P1 is a terpene (e.g., limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, ethylpiperazine carboxylate). In certain embodiments, permeation enhancer P1 is a terpene. In certain embodiments, the composition comprises between 0.5-6.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-3.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-2.0% terpene by weight. In certain embodiments, the composition comprises 2.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-3.0% limonene by weight. In certain embodiments, the composition comprises between 1.5- 2.0% limonene by weight. In certain embodiments, the composition comprises 2.0% limonene by weight. In certain embodiments, permeation enhancer P1 is an anesthetic (e.g., bupivacaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivicaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, trimecaine). In some embodiments, permeation enhancer P1 is bupivacaine. In some embodiments, permeation enhancer P1 is sodium dodecyl sulfate. In some embodiments, permeation enhancer P1 is limonene. In some embodiments, permeation enhancer P1 is a combination of at least two of a surfactant, terpene, and anesthetic. In some embodiments, permeation enhancer P1 is a combination of bupivacaine, sodium dodecyl sulfate, and limonene. In certain embodiments, permeation enhancer P1 is sodium lauroyl sarcosinate, sorbitan monooleate, octoxynol-9, diethyl sebacate, sodium polyacrylate (2500000 MW), or octyldodecanol.

[0099] In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of a reference composition, wherein the composition comprises permeation enhancer P2 and the reference composition does not comprise permeation enhancer P2. In certain embodiments, the storage modulus of the composition is within about 10%, within about 5%, or within about 2% °C of the storage modulus of a reference composition, wherein the composition comprises permeation enhancer P2 and the reference composition does not comprise permeation enhancer P2. In certain embodiments, the storage modulus of the composition is within about 100%, within about 10%, within about 5%, or within about 2% °C of the storage modulus of a reference composition, wherein the composition comprises permeation enhancer P2 and the reference composition does not comprise permeation enhancer P2. In certain embodiments, the loss modulus of the composition is within about 10%, within about 5%, or within about 2% °C of the loss modulus of a reference composition, wherein the composition comprises permeation enhancer P2 and the reference composition does not comprise permeation enhancer P2. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of a reference composition, and the storage modulus of the composition is within about 10%, within about 5%, or within about 2% °C of the storage modulus of a reference composition, wherein the composition comprises permeation enhancer P2 and the reference composition does not comprise permeation enhancer P2.

[00100] In certain embodiments, permeation enhancer P2 is a surfactant (anionic, cationic, nonionic, zwitterionic), terpene, anesthetic, amino amide, amino ester, azide-containing compound, or alcohol. In certain embodiments, permeation enhancer P2 is a surfactant (anionic, cationic, nonionic, zwitterionic), terpene, anesthetic, amino amide, amino ester, azide-containing compound, pyrrolidone, sulfoxide, fatty acid, or alcohol. In certain embodiments, permeation enhancer P2 is a surfactant (e.g., sodium dodecyl sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, cetyl trimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80). In certain embodiments, permeation enhancer P2 is a terpene (e.g., limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, ethylpiperazine carboxylate). In certain embodiments, permeation enhancer P2 is a terpene. In certain embodiments, the composition comprises between 0.5-6.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-3.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-2.0% terpene by weight. In certain embodiments, the composition comprises 2.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-3.0% limonene by weight. In certain embodiments, the composition comprises between 1.5- 2.0% limonene by weight. In certain embodiments, the composition comprises 2.0% limonene by weight. In certain embodiments, permeation enhancer P2 is an anesthetic (e.g., bupivacaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivicaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, trimecaine). In some embodiments, permeation enhancer P2 is bupivacaine. In some embodiments, permeation enhancer P2 is sodium dodecyl sulfate. In some embodiments, permeation enhancer P2 is limonene. In some embodiments, permeation enhancer P2 is a combination of at least two of a surfactant, terpene, and anesthetic. In some embodiments, permeation enhancer P2 is a combination of bupivacaine, sodium dodecyl sulfate, and limonene. In certain embodiments, permeation enhancer P2 is sodium lauroyl sarcosinate, sorbitan monooleate, octoxynol-9, diethyl sebacate, sodium polyacrylate (2500000 MW), or octyldodecanol.

[00101] In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of a reference composition, wherein the composition comprises permeation enhancer P3 and the reference composition does not comprise permeation enhancer P3. In certain embodiments, the storage modulus of the composition is greater than the storage modulus of a reference composition, wherein the composition comprises permeation enhancer P3 and the reference composition does not comprise permeation enhancer P3. In certain embodiments, the loss modulus of the composition is greater than the loss modulus of a reference composition, wherein the composition comprises permeation enhancer P3 and the reference composition does not comprise permeation enhancer P3. In certain embodiments, the phase transition temperature of the composition is less than the phase transition temperature of a reference composition, and the storage modulus of the composition is greater than the storage modulus of a reference composition, wherein the composition comprises permeation enhancer P3 and the reference composition does not comprise permeation enhancer P3.

[00102] In certain embodiments, permeation enhancer P3 is a surfactant (anionic, cationic, nonionic, zwitterionic), terpene, anesthetic, amino amide, amino ester, azide-containing compound, or alcohol. In certain embodiments, permeation enhancer P3 is a surfactant (anionic, cationic, nonionic, zwitterionic), terpene, anesthetic, amino amide, amino ester, azide-containing compound, pyrrolidone, sulfoxide, fatty acid, or alcohol. In certain embodiments, permeation enhancer P3 is a surfactant (e.g., sodium dodecyl sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, cetyl trimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80). In certain embodiments, permeation enhancer P3 is a terpene (e.g., limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, ethylpiperazine carboxylate). In certain embodiments, permeation enhancer P3 is a terpene. In certain embodiments, the composition comprises between 0.5-6.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-3.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-2.0% terpene by weight. In certain embodiments, the composition comprises 2.0% terpene by weight. In certain embodiments, the composition comprises between 1.5-3.0% limonene by weight. In certain embodiments, the composition comprises between 1.5- 2.0% limonene by weight. In certain embodiments, the composition comprises 2.0% limonene by weight. In certain embodiments, permeation enhancer P3 is an anesthetic (e.g., bupivacaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivicaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, trimecaine). In some embodiments, permeation enhancer P3 is bupivacaine. In some embodiments, permeation enhancer P3 is sodium dodecyl sulfate. In some embodiments, permeation enhancer P3 is limonene. In some embodiments, permeation enhancer P3 is a combination of at least two of a surfactant, terpene, and anesthetic. In some embodiments, permeation enhancer P3 is a combination of bupivacaine, sodium dodecyl sulfate, and limonene. In certain embodiments, permeation enhancer P3 is sodium lauroyl sarcosinate, sorbitan monooleate, octoxynol-9, diethyl sebacate, sodium polyacrylate (2500000 MW), or octyldodecanol.

[00103] In certain embodiments, the composition is useful in treating a disease. In some embodiments, the composition is useful in treating an infectious disease. In some embodiments, the composition is useful in treating an ear disease (e.g., the barrier is the tympanic membrane). In some embodiments, the composition is useful in treating otitis media.

[00104] As described, the gelation temperature (phase transition temperature) of the composition is one factor in determining whether the suitability of the composition (e.g., to allow for sustained delivery to the tympanic membrane). The temperature at which the storage modulus exceeds the loss modulus is considered the gelation temperature. Compositions herein may have a gelation temperature lower or higher than 37 °C, but preferably lower than 37 °C to accelerate gelation right after administration upon exposure of the composition, in particular the matrix forming agent, to body heat.

[00105] The timing of the sol-gel transition will impact the ease of administration. In general a faster in situ transition is useful for administration to subjects (e.g., children resisting compliance). In certain embodiments, the composition gels within about 5 s, about 10 s, about 20 s, about 30 s, about 1 minute, about 5 minutes, or about 10 minutes of administration (e.g., to the ear canal). In some embodiments, the composition gels in the range of about 1 s to about 20 s after administration.

[00106] In certain embodiments, the composition is stored cold (e.g., refrigerated at about 5 °C) prior to administration. Cold storage may be useful for compositions with gelation temperatures below room temperature to prevent gelation prior to administration or during handling.

[00107] In one aspect, provided herein are compositions comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a block copolymer containing hydrophobic monomers (e.g., phosphoester monomers); wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is less than about 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 70% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers.

[00108] In one aspect, provided herein are compositions comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a block copolymer containing hydrophobic monomers (e.g., phosphoester monomers); wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is less than about 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition or greater than about 500 Pa, whichever is smaller, at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers.

[00109] In another aspect, provided herein are compositions for treating an infectious disease comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a copolymer comprising phosphoester monomers.

[00110] In another aspect, provided herein are compositions for treating an ear disease comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across the tympanic membrane; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a copolymer comprising phosphoester monomers.

[00111] In another aspect, provided herein are compositions comprising: (a) a diagnostic agent or a combination of diagnostic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across the tympanic membrane; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a copolymer comprising phosphoester monomers.

[00112] In another aspect, provided herein are compositions for treating an infectious disease comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent comprises a polysaccharide derivative comprising cross-linkable functional groups.

[00113] In another aspect, provided herein are compositions for treating an ear disease comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across the tympanic membrane; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent comprises a polysaccharide derivative comprising cross-linkable functional groups.

[00114] The compositions provided herein typically include a permeation enhancer (e.g., a surfactant, terpene), a therapeutic agent (e.g., an antibiotic), and a matrix forming agent (e.g., a poloxamer derivative, a polyphosphoester containing polymer, a polysaccharide derivative). The permeation enhancer is an agent that alters the stratum corneum of the tympanic membrane to increase the flux of the therapeutic agent across the tympanic membrane. The permeation enhancer facilitates delivery of the therapeutic agent into the middle and / or inner ear. Therapeutic agents include agents that have a therapeutic benefit in the ear. In certain embodiments, the matrix forming agent is a liquid at ambient conditions, which once administered to a subject, gels (e.g., becomes more viscous). In certain embodiments, the matrix forming agents gels upon mixing of two components of the composition. In some embodiments, each component comprises a matrix forming agent (e.g., two polysaccharide derivatives which undergo cross-linking upon mixing). In some embodiments, one component comprises the matrix forming agent, and the second component comprises an activator or catalyst which causes gelation when mixed with the matrix forming agent. In certain embodiments, the pharmaceutical composition does not substantially interfere with the hearing of the subject. Matrix Forming Agents

[00115] The matrix forming agent is a compound or mixture of compounds that forms a gel after administration. In certain embodiments, the matrix forming agent forms a gel after administration into a subject's ear canal. The gel composition acts a reservoir containing the therapeutic agent and permeation enhancer, allowing for sustained release of the therapeutic agent across a barrier (e.g., tympanic membrane). In certain embodiments, the gel maintains contact with the tympanic membrane. In some embodiments, the gel maintains contact for between 0.5 and 1 hours, between 1 and 4 hours, between 1 and 8 hours, between 1 and 16 hours, or between 1 and 24 hours. In some embodiments, the gel maintains contact for between 1 day and 3 days, between 1 and 7 days, or between 1 and 14 days. In some embodiments, the gel allows flux of the therapeutic agent across the tympanic membrane for between 0.5 and 1 hours, between 1 and 4 hours, between 1 and 8 hours, between 1 and 16 hours, or between 1 and 24 hours. In some embodiments, the gel maintains contact for between 1 day and 3 days, between 1 and 7 days, or between 1 and 14 days. Such a reservoir maintains contact with the tympanic membrane increasing the time for the therapeutic agent to cross the tympanic membrane and be delivered to the middle or inner ear. Such a reservoir maximizes exposure of the tympanic membrane to permeation enhancers and the therapeutic agent, and facilitates sustained flux of the therapeutic agent into the middle and inner ear.

[00116] In various embodiments, the composition is a sustained release formulation. In various aspects, sustained release of either the permeation enhancer and / or the therapeutic agent can be at a constant rate to deliver an effective amount of either the permeation enhancer or therapeutic agent to the surface of the tympanic membrane, the middle ear, or the inner ear. In various embodiments, the sustained release provides a sufficient flux of therapeutic agent over about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days. In various embodiments, the sustained release provides a sufficient flux of therapeutic agent over a range of about 7 to about 10 days. In various embodiments, the sustained release may be at a constant rate over a range of about 7 days to about 14 days. In various embodiments, the sustained release provides a sufficient flux of therapeutic agent over a range of about 14 to about 21 days. In various embodiments, the sustained release provides a sufficient flux of therapeutic agent over a range of about 21 to about 30 days. As used herein, sufficient flux is the flux necessary for the therapeutic agent to be present in the middle ear in a therapeutically effective amount or prophylactically effective amount. In some embodiments, the sufficient flux is sufficient to provide an antibiotic agent in a concentration equal or greater to the minimum inhibitory concentration of an infectious microorganism. In some embodiments, the infectious microorganism is H. influenza, S. pneumoniae, or M. catarrhalis.

[00117] In various aspects, the sustained release profile is obtained by the addition of a matrix- forming agent to the composition. In various embodiments, the composition may further comprise a matrix forming agent. In various embodiments, the matrix forming agents may undergo a change in viscosity, in situ, based on a phase change, a change in solubility, evaporation of a solvent, or mixing of components comprising the matrix forming agent. Such matrix forming agents gel, in situ after administration into a patient's ear canal to form a reservoir containing the therapeutic agent and permeation enhancer, allowing sustained release of the therapeutic agent. Such a reservoir maintains contact with the tympanic membrane increasing the time for the therapeutic agent to permeate the tympanic membrane, and be delivered to the middle or inner ear. Such a reservoir maximizes exposure of the tympanic membrane to permeation enhancers and the therapeutic agent.

[00118] In certain embodiments, the matrix forming agent is a hydrogel, or forms a hydrogel upon administration. Matrix forming agents may include, but are not limited to, polyelectrolyte complexes, thermo-responsive gelling agents, pre-polymers, alginates, un-crosslinked polymers, and monomers, thermo-responsive gelling agents (e.g., poloxamer-polyphosphoester copolymers), and polymers with cross-linkable functional groups. In certain embodiments, the matrix forming agent is separated into a first and second component which form a matrix or gel upon mixing. In some embodiments, a first matrix forming agent component is a first polymer comprising a first type of cross-linkable functional group, and a second matrix forming agent component is a second polymer comprising a second type of cross-linkable functional group, wherein the two types of cross-linkable functional groups form cross-links between the two polymers upon mixing of the first and second component. In some embodiments, a first matrix forming agent component comprises polymers with cross-linkable functional groups, and a second matrix forming agent component comprises an activator, wherein the cross-linkable functional groups form cross-links between the polymers upon mixing of the first and second component. In some embodiments, the activator is an acid, a base, or a catalyst.

[00119] Matrix forming agents may further include biocompatible agents. Matrix forming agents may further include biodegradable agents. In certain embodiments the matrix forming agent is degraded and extruded from the body of a patient within 3 days of application, within 7 days of application, with 10 days of application, or within 14 days of application. In various embodiments, the matrix forming agent has little or no effect on hearing threshold when applied into a subject's ear canal. In various aspects, the matrix-forming agents may comprise between about 0 to about 40 percent of the composition. In various embodiments, the matrix-forming agents may comprise between about 0 to about 10 percent of the composition, comprise between about 10 to about 20 percent of the composition, comprise between about 20 to about 30 percent of the composition, comprise between about 30 to about 40 percent of the composition, or comprise between about 40 to about 50 percent of the composition.

[00120] The polymer may be a block copolymer. Exemplary polymer types suitable for the block copolymer include, but are not limited to: polyethylene oxide / polypropylene oxide based systems, poloxamers, poloxamer 407, poloxamer 188, poloxamines, methylcellulose, hydroxypropyl methylcellulose, ethyl(hydroxyethyl) cellulose, xyloglucan, cellulose, acetate phthalate, latex, poly(acrylic acid), thermoresponsive polysaccharides (including cellulose derivatives, chitosan, dextran and gellan gum). In some embodiments, the matrix forming agent comprises a polyethylene / polypropylene copolymer or polyethylene / polypropylene block copolymer. In some embodiments, the matrix forming agent comprises a poloxamer. In some embodiments, the matrix forming agent comprises poloxamer 407, poloxamer 188, poloxalene, poloxamer 124, poloxamer 237, or poloxamer 338.

[00121] Exemplary poloxamers include, but are not limited to: poloxamer 407, poloxamer 188, poloxalene, poloxamer 124, poloxamer 237, or poloxamer 338, Pluronic® 10R5, Pluronic® 17R2, Pluronic® 17R4, Pluronic® 25R2, Pluronic® 25R4, Pluronic® 31R1, Pluronic® F 108 Cast Solid Surfactant, Pluronic® F 108 NF, Pluronic® F 108 Pastille, Pluronic® F 108NF Prill Poloxamer 338, Pluronic® F 127 NF, Pluronic® F 127 NF 500 BHT Prill, Pluronic® F 127 NF Prill Poloxamer 407, Pluronic® F 38, Pluronic® F 38 Pastille, Pluronic® F 68, Pluronic® F 68 LF Pastille, Pluronic® F 68 NF, Pluronic® F 68 NF Prill Poloxamer 188, Pluronic® F 68 Pastille, Pluronic® F 77, Pluronic® F 77 Micropastille, Pluronic® F 87, Pluronic® F 87 NF, Pluronic® F 87 NF Prill Poloxamer 237, Pluronic® F 88, Pluronic® F 88 Pastille, Pluronic® FT L 61, Pluronic® L 10, Pluronic® L 101, Pluronic® L 121, Pluronic® L 31, Pluronic® L 35, Pluronic® L 43, Pluronic® L 61, Pluronic® L 62, Pluronic® L 62 LF, Pluronic® L 62D, Pluronic® L 64, Pluronic® L 81, Pluronic® L 92, Pluronic® L44 NF INH surfactant Poloxamer 124, Pluronic® N 3, Pluronic® P 103, Pluronic® P 104, Pluronic® P 105, Pluronic® P 123 Surfactant, Pluronic® P 65, Pluronic® P 84, Pluronic® P 85, Synperonic® PE / F 108, Synperonic® PE / P105, Synperonic® PE / P84, Synperonic®, Synperonic® PE / L31, Synperonic® PE / L61, Synperonic® PE / L101, Synperonic® PE / L121, Synperonic® PE / L42, Synperonic® PE / L62, Synperonic® PE / L92, Synperonic® PE / L44, Synperonic® PE / L64, Synperonic® PE / P84, Synperonic® PE / P75, Synperonic® PE / P103, Synperonic® PE / F87, Synperonic® PE / F127, Synperonic® PE / F38, Synperonic® PE / F68, Kolliphor® P 188, Kolliphor® P 407, Kolliphor® P 188 micro, Kolliphor® P 407 micro, Kolliphor® P237, Kolliphor® P 338, Kolliphor® EL, Kolliphor® HS 15, Kolliphor® PS 80, Kolliphor® PS 60, Kolliphor® RH 40, Kolliphor® TPG S, Kolliphor® CS L, Kolliphor® CS A, Kolliphor® CS S, Kolliphor® CS B, Kolliphor® CS 20, and Kolliphor® CS 12. In some embodiments, the matrix forming agent comprises any of the foregoing poloxamers, a derivative thereof, or a block copolymer thereof.

[00122] In various embodiments, of the present inventions the polyelectrolyte complex may include, but is not limited to a, chitosan-chondroitin sulfate complex, gelatin, carboxymethycellulose, glycosaminoglycans and poly (vinyl alcohol). In various aspects, the relative ratios of chitosan to chondroitin sulfate may be between about 1:0.09 to about 1:1.4. In certain embodiments, the polyelectrolyte complex is a chitosan-chondroitin sulfate complex.

[00123] In certain embodiments, the percent weight of matrix forming agent in the composition is between about 1% to about 10%, between about 10% to about 20%, between about 20% to about 30%, between about 30% to about 40%, between about 40% to about 50%, or between about 50% to about 90%. In some embodiments, the percent weight of matrix forming agent in the composition is between 1% to about 10%. In some embodiments, the percent weight of matrix forming agent in the composition is between about 10% to about 20%. In some embodiments, the percent weight of matrix forming agent in the composition is between 20% to about 30%. Polymers comprising Polyphosphoester Monomers or Blocks

[00124] In certain embodiments, the matrix forming comprises a copolymer with phosphoester monomers. The copolymer comprises at least one phosphoester monomer and at least one non- phosphoester monomer. In some embodiments, the copolymer comprises a polyphosphoester block. In some embodiments, the copolymer comprises a polyphosphoester block and a non- polyphosphoester block. In some embodiments, the block copolymer comprises a polyphosphoester block, and another blocks selected from the group consisting of polyethylene oxide, polypropylene oxide, poloxamers, poloxamer 407, poloxamer 188, poloxamines, methylcellulose, hydroxypropyl methylcellulose, ethyl(hydroxyethyl) cellulose, xyloglucan, acetates, phthalates, latex, poly(acrylic acid), N-isopropylacrylamides, cellulose, chitosan, dextran, hyaluronic acid, and derivatives thereof. In some embodiments, the polymer comprises thermoresponsive polysaccharides (e.g., cellulose derivatives, chitosan, dextran and gellan gum). In some embodiments, the block copolymer comprises polyphosphoester blocks, and comprises a polyethylene / polypropylene copolymer or polyethylene / polypropylene block copolymer. In some embodiments, the block copolymer comprises polyphosphoester blocks, and comprises a poloxamer. In some embodiments, the composition has a high degree of hydrophobicity. In some embodiments, the block copolymer has a high degree of hydrophobicity. In some embodiments, the composition is optically transparent. In some embodiments, the block copolymer comprises polyphosphoester blocks, and comprises poloxamer 407. In some embodiments, each block contains between 1 and 200 monomers.

[00125] In certain embodiments, the polyphosphoester copolymer or polyphosphoester blocks comprise monomers of Formula (M): [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(𝑴),<annotation encoding="application / x-tex">(\mathbf{M}),< / annotation>< / semantics>< / com:Math> wherein for each monomer, Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>, wherein: each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; and each occurrence of R<com:Sup>b< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring.

[00126] In certain embodiments, the polyphosphoester copolymer or polyphosphoester blocks comprise monomers of Formula (M-i): [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(M−i),<annotation encoding="application / x-tex">(M-i),< / annotation>< / semantics>< / com:Math> wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is as defined herein.

[00127] In certain embodiments, the polyphosphoester copolymer or polyphosphoester blocks comprise monomers of Formula (M-ii): [Image disponible dans le document PDF, Image available in the PDF document] (M-ii), wherein <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> are as defined herein.

[00128] In certain embodiments, the matrix forming agent comprises polyphosphoester blocks comprising monomers of Formula (M-i), and polyphosphoester blocks comprising monomers of formula (M-ii). In some embodiments, the matrix forming agent comprises polyphosphoester blocks comprising monomers of both Formulae (M-i) and (M-ii)

[00129] In certain embodiments, the matrix forming agent is a polymer of Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] (I), wherein: each occurrence of Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; each occurrence of R<com:Sup>3< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>b< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G<com:Sup>1< / com:Sup> and G<com:Sup>2< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 0 and 200, inclusive, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1.

[00130] Phosphoester monomers and polyphosphoester blocks described herein may comprise group Y. In certain embodiments, each Y in a copolymer is the same substituent. In certain embodiments, each Y in a copolymer is one of two specific substituents. In certain embodiments, each Y in a copolymer is one of three specific substituents. In certain embodiments, each Y in a copolymer is one of four specific substituents. In certain embodiments, each Y in a copolymer is one of five specific substituents. In certain embodiments, each Y in a copolymer is one of six specific substituents. In certain embodiments, each Y in a copolymer is one of seven or more specific substituents. In some embodiments, Y is <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math>. In some embodiments, Y is <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>.

[00131] In certain embodiments, p is 0. In certain embodiments, p is an integer between 1 and 100, inclusive. In some embodiments, p is an integer between 10 and 100, inclusive. In some embodiments, p is an integer between 10 and 50, inclusive. In some embodiments, p is an integer between 10 and 25, inclusive. In some embodiments, p is an integer between 1 and 10, inclusive.

[00132] In certain embodiments, t is 0. In certain embodiments, t is an integer between 1 and 100, inclusive. In some embodiments, t is an integer between 10 and 100, inclusive. In some embodiments, t is an integer between 10 and 50, inclusive. In some embodiments, t is an integer between 10 and 25, inclusive. In some embodiments, t is an integer between 1 and 10, inclusive.

[00133] In certain embodiments, q is 0. In certain embodiments, q is an integer between 1 and 100, inclusive. In some embodiments, q is an integer between 10 and 100, inclusive. In some embodiments, q is an integer between 10 and 50, inclusive. In some embodiments, q is an integer between 10 and 25, inclusive. In some embodiments, q is an integer between 1 and 10, inclusive.

[00134] In certain embodiments, r is 0. In certain embodiments, r is an integer between 1 and 100, inclusive. In some embodiments, r is an integer between 10 and 100, inclusive. In some embodiments, r is an integer between 10 and 50, inclusive. In some embodiments, r is an integer between 10 and 25, inclusive. In some embodiments, r is an integer between 1 and 10, inclusive.

[00135] In certain embodiments, s is 0. In certain embodiments, s is an integer between 1 and 100. In some embodiments, s is an integer between 10 and 100, inclusive. In some embodiments, s is an integer between 10 and 50, inclusive. In some embodiments, s is an integer between 10 and 25, inclusive. In some embodiments, s is an integer between 1 and 10, inclusive. In certain embodiments, both q and s are 0. In certain embodiments, exactly one of q and s is 0.

[00136] G<com:Sup>1< / com:Sup> and G<com:Sup>2< / com:Sup> are terminal groups of the polymer. As generally defined herein G<com:Sup>1< / com:Sup> and G<com:Sup>2< / com:Sup> are hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group. In some embodiments, <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> are the same. In some embodiments, <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> are both hydrogen. In some embodiments, G<com:Sup>1< / com:Sup> and G<com:Sup>2< / com:Sup> are different.

[00137] In certain embodiments, G<com:Sup>1< / com:Sup> is hydrogen. In certain embodiments, G<com:Sup>1< / com:Sup> is optionally substituted alkyl. In certain embodiments, G<com:Sup>1< / com:Sup> is optionally substituted acyl. In certain embodiments, <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math> is optionally substituted optionally substituted phosphate <com:Math><semantics>(e.g.,−P(=O)(OH)2,<annotation encoding="application / x-tex">(e.g., -P(=O)(OH)_2,< / annotation>< / semantics>< / com:Math> <com:Math><semantics>−P(=O)(O−alkyl)2<annotation encoding="application / x-tex">-P(=O)(O-alkyl)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−P(=O)(OH)(O−alkyl)<annotation encoding="application / x-tex">-P(=O)(OH)(O-alkyl)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−P(=O)(OH)(O−Y)<annotation encoding="application / x-tex">-P(=O)(OH)(O-Y)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−P(=O)(O−alkyl)(O−Y)<annotation encoding="application / x-tex">-P(=O)(O-alkyl)(O-Y)< / annotation>< / semantics>< / com:Math>. In certain embodiments, G<com:Sup>1< / com:Sup> is an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, benzoyl). In certain embodiments, G<com:Sup>1< / com:Sup> is hydrogen. In certain embodiments, G<com:Sup>1< / com:Sup> is optionally substituted alkyl. In certain embodiments, G<com:Sup>1< / com:Sup> is optionally substituted acyl. In certain embodiments, G<com:Sup>1< / com:Sup> is optionally substituted optionally substituted phosphate <com:Math><semantics>(e.g.,−P(=O)(OH)2,−P(=O)(O−alkyl)2,−P(=O)(OH)(O−alkyl),<annotation encoding="application / x-tex">(e.g., -P(=O)(OH)_2, -P(=O)(O-alkyl)_2, -P(=O)(OH)(O-alkyl),< / annotation>< / semantics>< / com:Math> -P(=O)(OH)(O-Y), -P(=O)(O-alkyl)(O-Y)). In certain embodiments, G<com:Sup>1< / com:Sup> is an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, benzoyl). In certain embodiments, <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math> is optionally substituted aryl, e.g., optionally substituted phenyl. In certain embodiments, <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math> is unsubstituted aryl, <com:Math><semantics>e.g.<annotation encoding="application / x-tex">e.g.< / annotation>< / semantics>< / com:Math>, unsubstituted phenyl. In certain embodiments, <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math> is optionally substituted heteroaryl, e.g., optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered bicyclic heteroaryl. In certain embodiments, G<com:Sup>1< / com:Sup> is unsubstituted heteroaryl, e.g., unsubstituted 5- 6 membered heteroaryl, or unsubstituted 9-10 membered bicyclic heteroaryl.

[00138] In certain embodiments, G<com:Sup>2< / com:Sup> is hydrogen. In certain embodiments, G<com:Sup>2< / com:Sup> is optionally substituted alkyl. In certain embodiments, G<com:Sup>2< / com:Sup> is optionally substituted acyl. In certain embodiments, <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> is optionally substituted optionally substituted phosphate <com:Math><semantics>(e.g.,−P(=O)(OH)2,<annotation encoding="application / x-tex">(e.g., -P(=O)(OH)_2,< / annotation>< / semantics>< / com:Math> <com:Math><semantics>−P(=O)(O−alkyl)2<annotation encoding="application / x-tex">-P(=O)(O-alkyl)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−P(=O)(OH)(O−alkyl)<annotation encoding="application / x-tex">-P(=O)(OH)(O-alkyl)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−P(=O)(OH)(O−Y)<annotation encoding="application / x-tex">-P(=O)(OH)(O-Y)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−P(=O)(O−alkyl)(O−Y)<annotation encoding="application / x-tex">-P(=O)(O-alkyl)(O-Y)< / annotation>< / semantics>< / com:Math>. In certain embodiments, G<com:Sup>2< / com:Sup> is an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, benzoyl). In certain embodiments, G<com:Sup>2< / com:Sup> is hydrogen. In certain embodiments, G<com:Sup>2< / com:Sup> is optionally substituted alkyl. In certain embodiments, G<com:Sup>2< / com:Sup> is optionally substituted acyl. In certain embodiments, G<com:Sup>2< / com:Sup> is optionally substituted optionally substituted phosphate <com:Math><semantics>(e.g.,−P(=O)(OH)2,−P(=O)(O−alkyl)2,−P(=O)(OH)(O−alkyl)2<annotation encoding="application / x-tex">(e.g., -P(=O)(OH)_2, -P(=O)(O-alkyl)_2, -P(=O)(OH)(O-alkyl)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>−P(=O)(OH)(O−Y)<annotation encoding="application / x-tex">-P(=O)(OH)(O-Y)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−P(=O)(O−alkyl)(O−Y)<annotation encoding="application / x-tex">-P(=O)(O-alkyl)(O-Y)< / annotation>< / semantics>< / com:Math>). In certain embodiments, <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> is an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, benzoyl). In certain embodiments, <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> is optionally substituted aryl, e.g., optionally substituted phenyl. In certain embodiments, <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> is unsubstituted aryl, e.g., unsubstituted phenyl. In certain embodiments, <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> is optionally substituted heteroaryl, <com:Math><semantics>e.g.<annotation encoding="application / x-tex">e.g.< / annotation>< / semantics>< / com:Math>, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered bicyclic heteroaryl. In certain embodiments, G<com:Sup>2< / com:Sup> is unsubstituted heteroaryl, e.g., unsubstituted 5- 6 membered heteroaryl, or unsubstituted 9-10 membered bicyclic heteroaryl.

[00139] In general, increasing PPE hydrophobicity decreases the gelation temperature, and accelerates gelation kinetics. Hydrophobicity of the PE monomer may be tuned by selection of pendent group Y (See, e.g., Figure 7). In certain embodiments, greater numbers of hydrophobic domains will make the polymer more resistant to the effect of the CPEs on micelle formation than P407. The fact that P407-PPE may form gels not only by micelle formation but also by the hydrophobic PPE domains forming a cross-linked network

[46] may also have a similar effect, and create an additional means of tuning phase transition behavior. It is noted that excessively hydrophobic PPE blocks may induce polymer aggregation in water, which could be undesirable for administration.

[00140] The bioadhesion of P407 can be enhanced by the conjugation of poly(acrylic acid) (PAA), or other reactive groups. In certain embodiments, PE monomers are functionalized with carbonyl and / or with acrylate groups (See, e.g., Figure 7). In certain embodiments, PE monomers with hydrophobic groups and PE monomers with bioadhesion groups are both incorporated in the matrix forming agent. In some embodiments, the hydrophobic groups and bioadhesion groups are incorporated in the same polymer. In some embodiments, the hydrophobic groups and bioadhesion groups are incorporated in separate polymers. <com:Math><semantics>𝑹𝟏<annotation encoding="application / x-tex">\mathbf{R^1}< / annotation>< / semantics>< / com:Math>

[00141] Phosphoester monomers and polyphosphoester blocks described herein may comprise R<com:Sup>1< / com:Sup>. In certain embodiments, each R<com:Sup>1< / com:Sup> is the same substituent. In certain embodiments, each R<com:Sup>1< / com:Sup> in a polymer is one of two specific substituents. In certain embodiments, each R<com:Sup>1< / com:Sup> in a polymer is one of three specific substituents. In certain embodiments, each R<com:Sup>1< / com:Sup> in a polymer is one of four specific substituents. In certain embodiments, each R<com:Sup>1< / com:Sup> in a polymer is one of five specific substituents. In certain embodiments, each R<com:Sup>1< / com:Sup> in a polymer is one of six specific substituents. In certain embodiments, each R<com:Sup>1< / com:Sup> in a polymer is one of seven or more specific substituents.

[00142] As generally described herein each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain embodiments, each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen or optionally substituted alkyl. In certain embodiments, each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen or unsubstituted alkyl.

[00143] In certain embodiments, R<com:Sup>1< / com:Sup> is hydrogen. In certain embodiments, R<com:Sup>A1< / com:Sup> is a non-hydrogen group.

[00144] In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl, e.g., optionally substituted <com:Math><semantics>C1−<annotation encoding="application / x-tex">C_{1-}< / annotation>< / semantics>< / com:Math> 6 alkyl, optionally substituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C2−3<annotation encoding="application / x-tex">C_{2-3}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C4−5<annotation encoding="application / x-tex">C_{4-5}< / annotation>< / semantics>< / com:Math> alkyl, or optionally substituted <com:Math><semantics>C5−6<annotation encoding="application / x-tex">C_{5-6}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is unsubstituted alkyl, e.g., unsubstituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted C<com:Sub>2-3< / com:Sub> alkyl, unsubstituted C<com:Sub>3-4< / com:Sub> alkyl, unsubstituted C<com:Sub>4-5< / com:Sub> alkyl, or unsubstituted C<com:Sub>5-6< / com:Sub> alkyl. In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is unsubstituted <com:Math><semantics>C1−20<annotation encoding="application / x-tex">C_{1-20}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is unsubstituted <com:Math><semantics>C1−12<annotation encoding="application / x-tex">C_{1-12}< / annotation>< / semantics>< / com:Math> alkyl. In In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is methyl. In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is ethyl, propyl, or butyl. In certain embodiments, R<com:Sup>1< / com:Sup> is haloalkyl, e.g., -CHF<com:Sub>2< / com:Sub>, -CHCl<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CHF<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CHCl<com:Sub>2< / com:Sub>. In certain embodiments, R<com:Sup>1< / com:Sup> is perhaloalkyl, e.g., -CF<com:Sub>3< / com:Sub>, -CF<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>, -CCl<com:Sub>3< / com:Sub>. In certain embodiments, R<com:Sup>1< / com:Sup> is hydroxyalkyl, e.g., -CH<com:Sub>2< / com:Sub>OH, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>OH, -CH<com:Sub>2< / com:Sub>OR<com:Sup>b< / com:Sup>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>OR<com:Sup>b< / com:Sup>. In certain embodiments, R<com:Sup>1< / com:Sup> is aminoalkyl, e.g., -CH<com:Sub>2< / com:Sub>NH<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>NH<com:Sub>2< / com:Sub>, <com:Math><semantics>−CH2NMe2<annotation encoding="application / x-tex">-CH_2NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CH2NMe2<annotation encoding="application / x-tex">-CH_2CH_2NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2N(Rb)2<annotation encoding="application / x-tex">-CH_2N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CH2N(Rb)2<annotation encoding="application / x-tex">-CH_2CH_2N(R^b)_2< / annotation>< / semantics>< / com:Math>.

[00145] In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is optionally substituted alkenyl, e.g., optionally substituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyl. In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is unsubstituted alkenyl, e.g., unsubstituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyl. In certain embodiments, R<com:Sup>1< / com:Sup> is vinyl, allyl, or prenyl. In certain embodiments, R<com:Sup>1< / com:Sup> is optionally substituted alkynyl, e.g., optionally substituted C<com:Sub>2-6< / com:Sub> alkynyl. In certain embodiments, R<com:Sup>1< / com:Sup> is unsubstituted alkynyl, <com:Math><semantics>e.g.<annotation encoding="application / x-tex">e.g.< / annotation>< / semantics>< / com:Math>, unsubstituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkynyl.

[00146] In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is unsubstituted, unbranched <com:Math><semantics>C1−20<annotation encoding="application / x-tex">C_{1-20}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is unsubstituted, branched <com:Math><semantics>C1−20<annotation encoding="application / x-tex">C_{1-20}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is of formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein each occurrence of n is independently an integer between 0 and 20, inclusive.

[00147] In certain embodiments, R<com:Sup>1< / com:Sup> is of formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein each occurrence of n is independently an integer between 0 and 20, inclusive.

[00148] In certain embodiments, R<com:Sup>1< / com:Sup> is of formula: [Image disponible dans le document PDF, Image available in the PDF document]

[00149] In certain embodiments, R<com:Sup>1< / com:Sup> is optionally substituted aryl, e.g., optionally substituted phenyl. In certain embodiments, R<com:Sup>1< / com:Sup> is unsubstituted aryl, e.g., unsubstituted phenyl. In certain embodiments, R<com:Sup>1< / com:Sup> is optionally substituted heteroaryl, e.g., optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered bicyclic heteroaryl. In certain embodiments, R<com:Sup>1< / com:Sup> is unsubstituted heteroaryl, e.g., unsubstituted 5-6 membered heteroaryl, or unsubstituted 9-10 membered bicyclic heteroaryl. <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math>

[00150] Phosphoester monomers and polyphosphoester blocks described herein may comprise <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>. In certain embodiments, each <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> in a copolymer is the same substituent. In certain embodiments, each <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> in a copolymer is one of two specific substituents. In certain embodiments, each <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> in a copolymer is one of three specific substituents. In certain embodiments, each <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> in a copolymer is one of four specific substituents. In certain embodiments, each <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> in a copolymer is one of five specific substituents. In certain embodiments, each <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> in a copolymer is one of six specific substituents. In certain embodiments, each <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> in a copolymer is one of seven or more specific substituents.

[00151] As generally described herein, each occurrence of L<com:Sup>2< / com:Sup> is optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene. In certain embodiments, each L<com:Sup>2< / com:Sup> is independently optionally substituted alkylene. In certain embodiments, each L<com:Sup>2< / com:Sup> is independently optionally substituted alkylene, and each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl. In certain embodiments, each L<com:Sup>2< / com:Sup> is independently unsubstituted alkylene. In certain embodiments, each L<com:Sup>2< / com:Sup> is independently unsubstituted alkylene, and each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl.

[00152] In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is optionally substituted alkylene, e.g., optionally substituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkylene, optionally substituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkylene, optionally substituted <com:Math><semantics>C2−3<annotation encoding="application / x-tex">C_{2-3}< / annotation>< / semantics>< / com:Math> alkylene, optionally substituted <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> alkylene, optionally substituted <com:Math><semantics>C4−5<annotation encoding="application / x-tex">C_{4-5}< / annotation>< / semantics>< / com:Math> alkylene, or optionally substituted <com:Math><semantics>C5−6<annotation encoding="application / x-tex">C_{5-6}< / annotation>< / semantics>< / com:Math> alkylene. In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is unsubstituted alkylene, e.g., unsubstituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkylene, unsubstituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkylene, unsubstituted <com:Math><semantics>C2−3<annotation encoding="application / x-tex">C_{2-3}< / annotation>< / semantics>< / com:Math> alkylene, unsubstituted <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> alkylene, unsubstituted <com:Math><semantics>C4−5<annotation encoding="application / x-tex">C_{4-5}< / annotation>< / semantics>< / com:Math> alkylene, or unsubstituted <com:Math><semantics>C5−6<annotation encoding="application / x-tex">C_{5-6}< / annotation>< / semantics>< / com:Math> alkylene. In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is methylene. In certain embodiments, L<com:Sup>2< / com:Sup> is ethylene, propylene, butylene, pentylene, or hexylene.

[00153] In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is optionally substituted alkenylene, e.g., optionally substituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenylene. In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is unsubstituted alkenylene, e.g., unsubstituted C<com:Sub>2-6< / com:Sub> alkenylene. In certain embodiments, L<com:Sup>2< / com:Sup> is vinylene, allylene, or prenylene. In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is optionally substituted alkynylene, e.g., optionally substituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkynylene. In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is unsubstituted alkynylene, e.g., unsubstituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkynylene.

[00154] In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is optionally substituted heteroalkylene, e.g., optionally substituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkylene. In some embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is unsubstituted heteroalkylene, wherein the heteroalkylene contains one oxygen atom. In some embodiments, L<com:Sup>2< / com:Sup> is unsubstituted heteroalkylene, wherein the heteroalkylene contains one nitrogen atom. In certain embodiments, <com:Math><semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>< / com:Math> is optionally substituted heteroalkenylene, e.g., optionally substituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkenylene. In some embodiments, L<com:Sup>2< / com:Sup> is unsubstituted heteroalkenylene, wherein the heteroalkenylene contains one oxygen atom. In some embodiments, L<com:Sup>2< / com:Sup> is unsubstituted heteroalkenylene, wherein the heteroalkylene contains one nitrogen atom.

[00155] As generally described herein each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group. In certain embodiments, each R<com:Sup>2< / com:Sup> is independently optionally substituted acyl. In certain embodiments, each R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, and each occurrence of L<com:Sup>2< / com:Sup> is independently optionally substituted alkylene.

[00156] In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is optionally substituted carbocyclyl, e.g., optionally substituted C<com:Sub>3-6< / com:Sub> carbocyclyl, optionally substituted C<com:Sub>3-4< / com:Sub> carbocyclyl, optionally substituted C<com:Sub>4-5< / com:Sub> carbocyclyl, or optionally substituted <com:Math><semantics>C5−6<annotation encoding="application / x-tex">C_{5-6}< / annotation>< / semantics>< / com:Math> carbocyclyl. In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is unsubstituted carbocyclyl, e.g., unsubstituted C<com:Sub>3-6< / com:Sub> carbocyclyl. In some embodiments, R<com:Sup>2< / com:Sup> is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In certain embodiments, R<com:Sup>2< / com:Sup> is optionally substituted heterocyclyl, e.g., optionally substituted 3-6 membered heterocyclyl, optionally substituted 3-4 membered heterocyclyl, optionally substituted 4-5 membered heterocyclyl, or optionally substituted 5-6 membered heterocyclyl. In certain embodiments, R<com:Sup>2< / com:Sup> is unsubstituted heterocyclyl, e.g., unsubstituted 3-6 membered heterocyclyl, unsubstituted 3-4 membered heterocyclyl, unsubstituted 4-5 membered heterocyclyl, or unsubstituted 5-6 membered heterocyclyl.

[00157] In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is optionally substituted aryl, e.g., optionally substituted phenyl. In certain embodiments, R<com:Sup>2< / com:Sup> is unsubstituted aryl, e.g., unsubstituted phenyl. In certain embodiments, R<com:Sup>2< / com:Sup> is optionally substituted heteroaryl, e.g., optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered bicyclic heteroaryl. In certain embodiments, R<com:Sup>2< / com:Sup> is unsubstituted heteroaryl, e.g., unsubstituted 5-6 membered heteroaryl, or unsubstituted 9-10 membered bicyclic heteroaryl.

[00158] In certain embodiments, R<com:Sup>2< / com:Sup> is optionally substituted acyl, e.g., -CHO, -CO<com:Sub>2< / com:Sub>H, or -C(=O)NH<com:Sub>2< / com:Sub>. In certain embodiments, R<com:Sup>2< / com:Sup> is optionally substituted carbonyl. In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)Rb<annotation encoding="application / x-tex">-C(=O)R^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORb<annotation encoding="application / x-tex">-C(=O)OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)NH(Rb)<annotation encoding="application / x-tex">-C(=O)NH(R^b)< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(=O)N(Rb)2<annotation encoding="application / x-tex">-C(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>. In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)Rb<annotation encoding="application / x-tex">-C(=O)R^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl, e.g., <com:Math><semantics>−C(=O)Me<annotation encoding="application / x-tex">-C(=O)Me< / annotation>< / semantics>< / com:Math>. In certain embodiments, R<com:Sup>2< / com:Sup> is -C(=O)R<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -C(=O)R<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, heterocyclyl, aryl, or heteroaryl. In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)ORb<annotation encoding="application / x-tex">-C(=O)OR^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -C(=O)OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -C(=O)OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, heterocyclyl, aryl, or heteroaryl. In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)N(Rb)2<annotation encoding="application / x-tex">-C(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, and at least one <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -C(=O)NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)NHRb<annotation encoding="application / x-tex">-C(=O)NHR^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -C(=O)NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, heterocyclyl, aryl, or heteroaryl. In certain embodiments, R<com:Sup>2< / com:Sup> is optionally substituted vinylcarbonyl (e.g., <com:Math><semantics>−C(=O)CH=CH2<annotation encoding="application / x-tex">-C(=O)CH=CH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)CM=CH2<annotation encoding="application / x-tex">-C(=O)CM=CH_2< / annotation>< / semantics>< / com:Math>). In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, benzoyl)

[00159] In certain embodiments, R<com:Sup>2< / com:Sup> is -OR<com:Sup>b< / com:Sup>, e.g., -OH. In certain embodiments, R<com:Sup>2< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is unsubstituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl optionally substituted heteroaryl. In certain embodiments, R<com:Sup>2< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is unsubstituted carbocyclyl, unsubstituted heterocyclyl, unsubstituted aryl unsubstituted heteroaryl. In certain embodiments, R<com:Sup>2< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted acyl, e.g., R<com:Sup>2< / com:Sup> is <com:Math><semantics>−OC(=O)Rb<annotation encoding="application / x-tex">-OC(=O)R^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)ORb<annotation encoding="application / x-tex">-OC(=O)OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>. In certain embodiments, R<com:Sup>2< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, benzoyl).

[00160] In certain embodiments, R<com:Sup>2< / com:Sup> is -N(R<com:Sup>b< / com:Sup>)<com:Sub>2< / com:Sub>, e.g., -NH<com:Sub>2< / com:Sub>, -NHR<com:Sup>b< / com:Sup>. In certain embodiments, R<com:Sup>2< / com:Sup> is -NH(R<com:Sup>b< / com:Sup>), and R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -N(R<com:Sup>b< / com:Sup>)<com:Sub>2< / com:Sub>, and at least one R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -NH(R<com:Sup>b< / com:Sup>), and R<com:Sup>b< / com:Sup> is unsubstituted alkyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -N(R<com:Sup>b< / com:Sup>)<com:Sub>2< / com:Sub>, and at least one R<com:Sup>b< / com:Sup> is unsubstituted alkyl. In certain embodiments, R<com:Sup>2< / com:Sup> is -NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R<com:Sup>2< / com:Sup> is -NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is unsubstituted carbocyclyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl. In certain embodiments, R<com:Sup>2< / com:Sup> is -NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted acyl, e.g., R<com:Sup>2< / com:Sup> is -NHC(=O)R<com:Sup>b< / com:Sup>, -NHC(=O)OR<com:Sup>b< / com:Sup>, or -NHC(=O)NHR<com:Sup>b< / com:Sup>. In certain embodiments, R<com:Sup>2< / com:Sup> is -N(R<com:Sup>b< / com:Sup>)<com:Sub>2< / com:Sub>, and at least one R<com:Sup>b< / com:Sup> is a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts). In certain embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, and both <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring. In certain embodiments, R<com:Sup>2< / com:Sup> is <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, and both <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> are joined to form an unsubstituted heterocyclic or unsubstituted heteroaryl ring.

[00161] In certain embodiments, <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> is of formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein n is an integer between 0 and 20, inclusive.

[00162] In certain embodiments, <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> is of formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein n is an integer between 0 and 20, inclusive.

[00163] In certain embodiments, <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> is of formula: [Image disponible dans le document PDF, Image available in the PDF document]

[00164] In certain embodiments, <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math> is of formula: [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>

[00165] Polymers of Formula (I) comprise R<com:Sup>3< / com:Sup>. In certain embodiments, each R<com:Sup>3< / com:Sup> is the same substituent. In certain embodiments, each R<com:Sup>3< / com:Sup> in a polymer is one of two specific substituents. In certain embodiments, each R<com:Sup>3< / com:Sup> in a polymer is one of three specific substituents. In certain embodiments, each R<com:Sup>3< / com:Sup> in a polymer is one of four specific substituents. In certain embodiments, each R<com:Sup>3< / com:Sup> in a polymer is one of five specific substituents. In certain embodiments, each R<com:Sup>3< / com:Sup> in a polymer is one of six specific substituents. In certain embodiments, each R<com:Sup>3< / com:Sup> in a polymer is one of seven or more specific substituents.

[00166] As generally described herein each occurrence of R<com:Sup>3< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>. In certain embodiments, each occurrence of R<com:Sup>3< / com:Sup> is independently unsubstituted alkyl.

[00167] In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl, e.g., optionally substituted <com:Math><semantics>C1−<annotation encoding="application / x-tex">C_{1-}< / annotation>< / semantics>< / com:Math> 6 alkyl, optionally substituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C2−3<annotation encoding="application / x-tex">C_{2-3}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C4−5<annotation encoding="application / x-tex">C_{4-5}< / annotation>< / semantics>< / com:Math> alkyl, or optionally substituted <com:Math><semantics>C5−6<annotation encoding="application / x-tex">C_{5-6}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is unsubstituted alkyl, e.g., unsubstituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted C<com:Sub>2-3< / com:Sub> alkyl, unsubstituted C<com:Sub>3-4< / com:Sub> alkyl, unsubstituted C<com:Sub>4-5< / com:Sub> alkyl, or unsubstituted C<com:Sub>5-6< / com:Sub> alkyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is unsubstituted <com:Math><semantics>C1−20<annotation encoding="application / x-tex">C_{1-20}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is unsubstituted <com:Math><semantics>C1−12<annotation encoding="application / x-tex">C_{1-12}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is methyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is ethyl, propyl, or butyl. In certain embodiments, R<com:Sup>3< / com:Sup> is haloalkyl, e.g., -CHF<com:Sub>2< / com:Sub>, -CHCl<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CHF<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CHCl<com:Sub>2< / com:Sub>. In certain embodiments, R<com:Sup>3< / com:Sup> is perhaloalkyl, e.g., -CF<com:Sub>3< / com:Sub>, -CF<com:Sub>2< / com:Sub>CF<com:Sub>3< / com:Sub>, -CCl<com:Sub>3< / com:Sub>. In certain embodiments, R<com:Sup>3< / com:Sup> is hydroxyalkyl, e.g., -CH<com:Sub>2< / com:Sub>OH, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>OH, -CH<com:Sub>2< / com:Sub>OR<com:Sup>b< / com:Sup>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>OR<com:Sup>b< / com:Sup>. In certain embodiments, R<com:Sup>3< / com:Sup> is aminoalkyl, e.g., -CH<com:Sub>2< / com:Sub>NH<com:Sub>2< / com:Sub>, -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>NH<com:Sub>2< / com:Sub>, <com:Math><semantics>−CH2NMe2<annotation encoding="application / x-tex">-CH_2NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CH2NMe2<annotation encoding="application / x-tex">-CH_2CH_2NMe_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2N(Rb)2<annotation encoding="application / x-tex">-CH_2N(R^b)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2CH2N(Rb)2<annotation encoding="application / x-tex">-CH_2CH_2N(R^b)_2< / annotation>< / semantics>< / com:Math>.

[00168] In certain embodiments, R<com:Sup>3< / com:Sup> is optionally substituted alkenyl, e.g., optionally substituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is unsubstituted alkenyl, e.g., unsubstituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is vinyl, allyl, or prenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is optionally substituted alkynyl, e.g., optionally substituted C<com:Sub>2-6< / com:Sub> alkynyl. In certain embodiments, R<com:Sup>3< / com:Sup> is unsubstituted alkynyl, <com:Math><semantics>e.g.<annotation encoding="application / x-tex">e.g.< / annotation>< / semantics>< / com:Math>, unsubstituted <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkynyl.

[00169] In certain embodiments, R<com:Sup>3< / com:Sup> is optionally substituted aryl, e.g., optionally substituted phenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is unsubstituted aryl, e.g., unsubstituted phenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is optionally substituted heteroaryl, e.g., optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered bicyclic heteroaryl. In certain embodiments, R<com:Sup>3< / com:Sup> is unsubstituted heteroaryl, e.g., unsubstituted 5-6 membered heteroaryl, or unsubstituted 9-10 membered bicyclic heteroaryl.

[00170] In certain embodiments, R<com:Sup>3< / com:Sup> is optionally substituted acyl, e.g., -CHO, -CO<com:Sub>2< / com:Sub>H, or -C(=O)NH<com:Sub>2< / com:Sub>. In certain embodiments, R<com:Sup>3< / com:Sup> is optionally substituted carbonyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)Rb<annotation encoding="application / x-tex">-C(=O)R^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)ORb<annotation encoding="application / x-tex">-C(=O)OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)NH(Rb)<annotation encoding="application / x-tex">-C(=O)NH(R^b)< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(=O)N(Rb)2<annotation encoding="application / x-tex">-C(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)Rb<annotation encoding="application / x-tex">-C(=O)R^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl, e.g., <com:Math><semantics>−C(=O)Me<annotation encoding="application / x-tex">-C(=O)Me< / annotation>< / semantics>< / com:Math>. In certain embodiments, R<com:Sup>3< / com:Sup> is -C(=O)R<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -C(=O)R<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, heterocyclyl, aryl, or heteroaryl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)ORb<annotation encoding="application / x-tex">-C(=O)OR^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -C(=O)OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -C(=O)OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, heterocyclyl, aryl, or heteroaryl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)N(Rb)2<annotation encoding="application / x-tex">-C(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>, and at least one <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -C(=O)NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−C(=O)NHRb<annotation encoding="application / x-tex">-C(=O)NHR^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -C(=O)NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, heterocyclyl, aryl, or heteroaryl. In certain embodiments, R<com:Sup>3< / com:Sup> is optionally substituted vinylcarbonyl (e.g., <com:Math><semantics>−C(=O)CH=CH2<annotation encoding="application / x-tex">-C(=O)CH=CH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)CMe=CH2<annotation encoding="application / x-tex">-C(=O)CMe=CH_2< / annotation>< / semantics>< / com:Math>).

[00171] In certain embodiments, R<com:Sup>3< / com:Sup> is -OR<com:Sup>b< / com:Sup>, e.g., -OH. In certain embodiments, R<com:Sup>3< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is unsubstituted C<com:Sub>1-6< / com:Sub> alkyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted alkenyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl optionally substituted heteroaryl. In certain embodiments, R<com:Sup>3< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is unsubstituted carbocyclyl, unsubstituted heterocyclyl, unsubstituted aryl unsubstituted heteroaryl. In certain embodiments, R<com:Sup>3< / com:Sup> is -OR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted acyl, e.g., R<com:Sup>3< / com:Sup> is <com:Math><semantics>−OC(=O)Rb<annotation encoding="application / x-tex">-OC(=O)R^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)ORb<annotation encoding="application / x-tex">-OC(=O)OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−OC(=O)N(Rb)2<annotation encoding="application / x-tex">-OC(=O)N(R^b)_2< / annotation>< / semantics>< / com:Math>. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, benzoyl).

[00172] In certain embodiments, R<com:Sup>3< / com:Sup> is -N(R<com:Sup>b< / com:Sup>)<com:Sub>2< / com:Sub>, e.g., -NH<com:Sub>2< / com:Sub>, -NHR<com:Sup>b< / com:Sup>. In certain embodiments, R<com:Sup>3< / com:Sup> is -NH(R<com:Sup>b< / com:Sup>), and R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -N(R<com:Sup>b< / com:Sup>)<com:Sub>2< / com:Sub>, and at least one R<com:Sup>b< / com:Sup> is optionally substituted alkyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -NH(R<com:Sup>b< / com:Sup>), and R<com:Sup>b< / com:Sup> is unsubstituted alkyl. In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, and at least one <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> is unsubstituted alkyl. In certain embodiments, R<com:Sup>3< / com:Sup> is -NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R<com:Sup>3< / com:Sup> is -NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is unsubstituted carbocyclyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl. In certain embodiments, R<com:Sup>3< / com:Sup> is -NHR<com:Sup>b< / com:Sup>, and R<com:Sup>b< / com:Sup> is optionally substituted acyl, e.g., R<com:Sup>3< / com:Sup> is -NHC(=O)R<com:Sup>b< / com:Sup>, -NHC(=O)OR<com:Sup>b< / com:Sup>, or -NHC(=O)NHR<com:Sup>b< / com:Sup>. In certain embodiments, R<com:Sup>3< / com:Sup> is -N(R<com:Sup>b< / com:Sup>)<com:Sub>2< / com:Sub>, and at least one R<com:Sup>b< / com:Sup> is a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts). In certain embodiments, <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, and both <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring. In certain embodiments, R<com:Sup>3< / com:Sup> is <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, and both <com:Math><semantics>Rb<annotation encoding="application / x-tex">R^b< / annotation>< / semantics>< / com:Math> are joined to form an unsubstituted heterocyclic or unsubstituted heteroaryl ring. Synthesis of the Polyphosphoester Block Copolymer

[00173] The block copolymers described herein may be prepared by sequential polymerization of monomers corresponding to each block. For example, polymerization of propylene oxide, followed by polymerization of ethylene oxide starting at the terminal groups of the polypropylene oxide, followed by polymerization of phosphoester monomers starting at the terminal groups of the polypropylene oxide-polyethylene oxide polymer. In certain embodiments, a poloxamer comprising polyethylene and polypropylene blocks is treated with a phosphoester monomer precursor. In some embodiments, the precursor is hydroxydioxaphospholane or a dioxaphospholane ester. In certain embodiments, the copolymer of Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] is prepared by contacting a polymer of Formula (P): · · · [Image disponible dans le document PDF, Image available in the PDF document] with a compound of Formula (A), or a mixture of compounds of Formula (A): [Image disponible dans le document PDF, Image available in the PDF document] wherein p, q, r, s, t, <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math>, and Y are as defined herein.

[00174] In certain embodiments, the step of contacting a polymer of Formula (P) with a compound of Formula (A) is performed in the presence of a catalyst. In some embodiments, the catalyst is an organocatalyst. In some embodiments, the catalyst is a base. In some embodiments, the catalyst is an organic base. In some embodiments, the catalyst is a non-nucleophlic base. In some embodiments, the catalyst is N,N-diisopropylethylamine (DIPEA, Hünig's base), 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU), 2,6-di-tert-butylpyridine, or a phosphazene (e.g., BEMP, t-Bu-P4). In some embodiments, the catalyst is 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).

[00175] In some embodiments, the polymer is treated with a compound of Formula (A-i): [Image disponible dans le document PDF, Image available in the PDF document] A mixture of compounds of Formula (A-i) may also be used, e.g., with different R<com:Sup>1< / com:Sup>, or a single compound may be used.

[00176] In some embodiments, the polymer is treated with a compound Formula (A-ii): [Image disponible dans le document PDF, Image available in the PDF document] A mixture of compounds of Formula (A-ii) may also be used, e.g., with different R<com:Sup>1< / com:Sup>, or a single compound may be used.

[00177] In some embodiments, the polymer is treated with a mixture of compounds of Formula (A-i) and (A-ii). [Image disponible dans le document PDF, Image available in the PDF document] A mixture of compound of Formula (A-i) may also be used, e.g., with different R<com:Sup>1< / com:Sup>, or a single compound may be used. A mixture of compounds of Formula (A-ii) may also be used, e.g., with different R<com:Sup>1< / com:Sup>, or a single compound may be used.

[00178] In certain embodiments, a first compound of Formula (A) and a second compound of Formula (A) are contacted with a copolymer of Formula (P) simultaneously. For example, a compound of Formula (A-i) and a compound of Formula (A-ii) are added simultaneously to generate polyphosphoester blocks with a random monomer distribution. In other embodiments, a first compound of Formula (A) is contacted with a copolymer of Formula (P), and subsequently a second compound of Formula (A) is contacted with the product of contacting a compound of Formula (P) with the first compound of Formula (A). For example, a compound of Formula (A- i) is added to generate a first polyphosphoester block with a first monomer (e.g., a monomer of Formula (M-i), and subsequently a compound of Formula (A-ii) is added to generate a second polyphosphoester block with a second monomer (e.g., a monomer of Formula (M-ii).

[00179] The number of phosphoester monomers (e.g., variables p and t) in the resulting copolymer will be determined by the reaction conditions, reaction time, and the number of equivalents of compound(s) of Formula (A) vs. equivalents of the compound(s) of Formula (P).

[00180] In certain embodiments, the copolymer may be further modified after addition of the polyphosphoester blocks. In some embodiments, one or more group Y is modified after polymerization. In some embodiments, one or more group Y is deprotected after polymerization. In some embodiments, group <com:Math><semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>< / com:Math> is modified after polymerization. Permeation Enhancers

[00181] Permeation enhancer refers to any agent that increases the flux of a therapeutic agent across a barrier (e.g., membrane, layer of cells). In some embodiments, the barrier is skin. In some embodiments, the barrier is the tympanic membrane. Permeation enhancers may include, but are not limited to, surfactants (anionic, cationic, nonionic, zwitterionic), terpenes, amino amides, amino esters, azide-containing compounds, and alcohols. Permeation enhancers may include, but are not limited to, surfactants (anionic, cationic, nonionic, zwitterionic), terpenes, amino amides, amino esters, azide-containing compounds, pyrrolidones, sulfoxides, fatty acids, and alcohols. In certain embodiments, the permeation enhancer is an anionic surfactant. In certain embodiments, the permeation enhancer is a cation surfactant. In certain embodiments, the permeation enhancer is nonionic surfactant. In certain embodiments, the permeation enhancer is a zwitterionic surfactant. In certain embodiments, the permeation enhancer is a terpene. In certain embodiments, the permeation enhancer is an amino amide. In certain embodiments, the permeation enhancer is an amino ester. In certain embodiments, the permeation enhancer is an azide-containing compound. In certain embodiments, the permeation enhancer is a pyrrolidone. In certain embodiments, the permeation enhancer is a sulfoxide. In certain embodiments, the permeation enhancer is a fatty acid. In certain embodiments, the permeation enhancer is an alcohol. In certain embodiments, the permeation enhancer is sodium lauroyl sarcosinate. In certain embodiments, the permeation enhancer is sorbitan monooleate. In certain embodiments, the permeation enhancer is octoxynol-9. In certain embodiments, the permeation enhancer is diethyl sebacate. In certain embodiments, the permeation enhancer is sodium polyacrylate (2500000 molecular weight (MW)). In certain embodiments, the permeation enhancer is octyldodecanol.

[00182] Surfactant permeation enhancers may include, but are not limited to, sodium dodecyl sulfate, ammonium lauryl sulfate, sodium laureth sulfate, cetyl trimethlammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80, and benzalkonium chlorides. In some embodiments, the permeation enhancer is sodium dodecyl sulfate, sodium lauryl sulfate, or sodium octyl sulfate. In some embodiments, the permeation enhancer is sodium dodecyl sulfate. In some embodiments, the permeation enhancer is octyl-trimethyl-ammonium bromide or dodecyl-trimethyl-ammonium bromide. In some embodiments the permeation enhancer is Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80. In some embodiments the permeation enhancer is a benzalkonium chloride.

[00183] In certain embodiments, the permeation enhancer is sodium lauroyl sarcosinate, sorbitan monooleate, octoxynol-9, diethyl sebacate, sodium polyacrylate (2500000 molecular weight (MW)), or octyldodecanol. In certain embodiments, the permeation enhancer is sodium lauroyl sarcosinate. In certain embodiments, the permeation enhancer is sorbitan monooleate. In certain embodiments, the permeation enhancer is octoxynol-9. In certain embodiments, the permeation enhancer is diethyl sebacate. In certain embodiments, the permeation enhancer is sodium polyacrylate (2500000 molecular weight (MW)). In certain embodiments, the permeation enhancer is octyldodecanol.

[00184] In various embodiments, the permeation enhancer is an azone-like compound. In certain embodiments, the permeation enhancer is a compound similar to azone (e.g., laurocapram) of the [Image disponible dans le document PDF, Image available in the PDF document] formula: . In certain embodiments, the permeation enhancer is 1-benzyl-4-(2-((1,1-biphenyl)-4-yloxy)ethyl)piperazine.

[00185] In various embodiments, the permeation enhancer is a lipid. In certain embodiments, the lipid used in the composition is selected from the group consisting of phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acids; fatty acid amides; sorbitan trioleate (Span 85) glycocholate; surfactin; a poloxamer; a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebrosides; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl- amine; acetyl palmitate; glycerol ricinoleate; hexadecyl sterate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; and phospholipids. In certain embodiments, the lipid used in the composition is selected from the group consisting of phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acids; fatty acid amides; sorbitan trioleate (Span 85) glycocholate; surfactin; a poloxamer; a fatty ester (e.g., stearyl methacrylate) a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebrosides; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl sterate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; and phospholipids. In certain embodiments, the permeation enhancer is a fatty ester. In certain embodiments, the permeation enhancer is stearyl methacrylate. The lipid may be positively charged, negatively charged, or neutral. In certain embodiments, the lipid is a combination of lipids. Phospholipids useful in the inventive compositions include negatively charged phosphatidyl inositol, phosphatidyl serine, phosphatidyl glycerol, phosphatic acid, diphosphatidyl glycerol, poly(ethylene glycol)- phosphatidyl ethanolamine, dimyristoylphosphatidyl glycerol, dioleoylphosphatidyl glycerol, dilauryloylphosphatidyl glycerol, dipalmitotylphosphatidyl glycerol, distearyloylphosphatidyl glycerol, dimyristoyl phosphatic acid, dipalmitoyl phosphatic acid, dimyristoyl phosphitadyl serine, dipalmitoyl phosphatidyl serine, phosphatidyl serine, and mixtures thereof. Useful zwitterionic phospholipids include phosphatidyl choline, phosphatidyl ethanolamine, sphingomyeline, lecithin, lysolecithin, lysophatidylethanolamine, cerebrosides, dimyristoylphosphatidyl choline, dipalmitotylphosphatidyl choline, distearyloylphosphatidyl choline, dielaidoylphosphatidyl choline, dioleoylphosphatidyl choline, dilauryloylphosphatidyl choline, 1-myristoyl-2-palmitoyl phosphatidyl choline, 1-palmitoyl-2-myristoyl phosphatidyl choline, 1-palmitoyl-phosphatidyl choline, 1-stearoyl-2-palmitoyl phosphatidyl choline, dimyristoyl phosphatidyl ethanolamine, dipalmitoyl phosphatidyl ethanolamine, brain sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin, and mixtures thereof. Zwitterionic phospholipids constitute any phospholipid with ionizable groups where the net charge is zero. In certain embodiments, the lipid is phosphatidyl choline.

[00186] Exemplary surfactants include, but are not limited to, sodium dioctyl sulfo succinate, sodium dodecyl sulfate, cocoamidopropyl betaine, and sodium laureth sulfate, alkyl and alkyl ether sulfates (e.g., sodium coconut alkyl triethylene glycol ether sulfate; lithium tallow alkyl triethylene glycol ether sulfate; sodium tallow alkyl hexaoxyethylene sulfate), succinamates, sulfosuccinamates (e.g., disodium N-octadecyl-sulfosuccinamate, tetrasodium N-(1,2- dicarboxyethyl)-N-octadecylsulfosuccinamate, diamyl ester of sodium sulfosuccinic acid, dihexyl ester of sodium sulfosuccinic acid, dioctyl esters of sodium sulfosuccinic acid), olefin sulfonates, hydroxy-alkanesulfonates, beta-alkyloxy alkane sulfonates (e.g., potassium-<com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>- methoxydecanesulfonate, sodium 2-methoxytridecanesulfonate, potassium 2- ethoxytetradecylsulfonate, sodium 2-isopropoxyhexadecylsulfonate, lithium 2-t- butoxytetradecylsulfonate, sodium <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-methoxyoctadecysulfonate, ammonium <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-n-propoxy- dodecylsulfonate), dioctyl esters of sodium sulfosuccinic acid, alkyl ethoxylated sulfates, alkyl sulfates, aliphatic secondary and tertiary amines (e.g., sodium 3-dodecylaminopropionate, N- alkyltaurines, stearamido propyl dimethyl amine, diethyl amino ethyl stearamide, dimethyl stearamine, dimethyl soyamine, soyamine, myristyl amine, tridecyl amine, ethyl stearylamine, N- tallowpropane diamine, ethoxylated (5 moles E.O) stearylamine, dihydroxy ethyl stearylamine, and arachidylbehenylamine), alkyl amphoglycinates (e.g., cocoamphoglycinate, lauroamphocarboxyglycinate, cocoamphocarboxyglycinate); alkyl amphopropionates (e.g., isostearoamphopropionate, cocoamphocarboxypropionic acid); alkyl ethoxylated sulfates; alkyl sulfates; aliphatic quaternary ammonium compounds (e.g., tallow propane diammonium dichloride, dialkyldimethylammonium chlorides, ditallowdimethyl ammonium chloride, ditallowdimethyl ammonium methyl sulfate, dihexadecyl dimethyl ammonium chloride, di(hydrogenated tallow) dimethyl ammonium chloride, dioctadecyl dimethyl ammonium chloride, dieicosyl dimethyl ammonium chloride, didocosyl dimethyl ammonium chloride, di(hydrogenated tallow) dimethyl ammonium acetate, dihexadecyl dimethyl ammonium chloride, dihexadecyl dimethyl ammonium acetate, ditallow dipropyl ammonium phosphate, ditallow dimethyl ammonium nitrate, and di(coconutalkyl benzyl ammonium chloride); aliphatic phosphonium compounds, aliphatic sulfonium compounds, alkyl amino sulfonates, alkyl betaines (e.g., coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, lauryl bis-(2- hydroxyethyl) carboxy methyl betaine, stearyl bis-(2-hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis-(2-hydroxypropyl) alpha-carboxyethyl betaine), sulfo betaines (e.g., coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis(2-hydroxyethyl) sulfopropyl betaine), alkyl amido betaines, 4-[N,N-di(2-hydroxyethyl)-N-octadecylammonio]-butane-1-carboxylate; 5-[S-3- hydroxypropyl-S-hexadecylsulfonio]-3-hydroxy-pentanel-sulfate; 3-[P,P-diethyl-P-3,6,9- trioxatetradexoxylphosphonio]-2-hydroxy-propane-1-phosphate; 3-[N,N-dipropyl-N-3- dodecoxy-2-hydroxypropylammonio]-propane-1-phosphate; 3-(N,N-dimethyl-N-- hexadecylammonio)propane-1-sulfonate; 3-(N,N-dimethyl-N-hexadecylammonio)-2-hydroxy- propane-1-sulfonate; 4-[N,N-di-(2-hydroxy-ethyl)-N-(2-hydroxydodecyl)ammonio]-butane-1- carboxyl ate; 3-[S-ethyl-S-(3-dodecoxy-2-hydroxypropyl)sulfonio]-propane-1-phosphate; 3- [P,P-dimethyl-P-dodecylphosphonio]-propane-1-phosphonate; and 5-[N,N-di(3-hydroxypropyl)- N-hexadecylammonio]-2-hydroxypentane-1-sulfate, sodium 3-dodecylaminopropane sulfonate; alkyl amphosulfonates; alkyl amphosulfosuccinates; oleoamphopropylsulfonate, and cocoamphopropylsulfonate; polyethylene oxide condensates; long chain tertiary phosphine oxides; long chain dialkyl sulfoxides; Silicone copolyols (e.g., dimethicone copolyols), stearamide diethanolamide (DEA), cocamide monoethanolamide (MEA), glyceryl monoleate, sucrose stearate, Cetheth-2, Poloxamer 181, hydrogenated tallow amide DEA, polyoxyethylene 4 sorbitol beeswax derivative (ATLAS 6-1702), polyoxyethylene 2 cetyl ether (BRIJ 52), polyoxyethylene 2 stearyl ether (BRIJ 72), polyoxyethylene 2 oleyl ether (BRIJ 92), polyoxyethylene 2 oleyl ether (BRIJ 93), sorbitan monopalmitate (SPAN 40), sorbitan monostearate (SPAN 60), sorbitan tristearate (SPAN 65), sorbitan monoleate, NF (SPAN 80) sorbitan trioleate (SPAN 85), fluorinated alkyl quaternary ammonium iodide; mixed mono- and bis-perfluoroalkyl phosphates, ammonium salts; mixed mono- and bis-fluoroalkyl phosphate, ammonium salts, complexed with aliphatic quaternary methosulfates; perfluoroalkyl sulfonic acid, ammonium salts; mixed telomer phosphate diethanolamine salts; amine perfluoroalkyl sulfonates; ammonium perfluoroalkyl sulfonates; potassium perfluoroalkyl sulfonates; potassium fluorinated alkyl carboxylates; ammonium perfluoroalkyl sulfonates; and ammonium perfluoroalkyl carboxylates; sodium dioctyl sulfosuccinate; magnesium dioctyl sulfosuccinate; ammonium dioctyl sulfosuccinate; magnesium dodecyl sulfate; ammonium dodecyl sulfate; cocoamidopropyl betaine sodium dinonyl sulfo succinate; sodium alpha olefin sulfonate; sodium laureth sulfate; magnesium laureth sulfate; ammonium laureth sulfate; cocoamidopropyl betaine; polyethoxylated glycol ether of glyceryl isostewarate; polyethoxylated glycol ether of glyceryl monooleate; PEG-30 glyceryl isostearate; polyoxyethylene glycerol monoleate; polyethylene glycol; PPG-18; PPG-10; 18 dimethicone; 1 dimethicon; cetyl polyethylene glycol; glyceryl monostearate; laureth-23; and PEG 75 lanolin. In certain embodiments, the surfactant is a silicon-containing chemical compound. Exemplary silicon-based detergents, emulsifiers, or surfactants useful in cosmetic compositions include dimethicone, cyclopentasiloxane, cyclohexasiloxane, PEG / dimethicone copolymers, PPG / dimethicone copolymers, phenyltrimethicone, alkyl silicones, amodimethicone, silicone quaternium-18, and dimethiconol.

[00187] Terpene permeation enhancers may include, but are not limited to, limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, and ethylpiperazine carboxylate. Any terpene or terpeniod compound may be used as a permeation enhancer in the inventive compositions. In certain embodiments, the permeation enhancer is limonene.

[00188] Alcohol permeation enhancers may include, but are not limited to, methanol, ethanol, propanol, isopropanol, butanol, isobutyl alcohol, and tert-amyl alcohol. In certain embodiments, the permeation enhancer is a compound with more than one hydroxyl group (e.g., glycerol). For example, the permeation enhancer may contain two, three, four, five, or more hydroxyl groups. In certain embodiments, the permeation enhancer is a hydroxyl-containing polymer.

[00189] In certain embodiments, an amino amide or amino ester permeation enhancers is an anesthetic agent. Amino amide and amino ester permeation enhancers may include, but are not limited to bupivicaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivicaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, and trimecaine. In certain embodiments, the permeation enhancer is bupivacaine.

[00190] In certain embodiments, the composition comprises a combination of permeation enhancers. In certain embodiments, the combination comprises permeation enhancers of the same type (e.g., both surfactants, both terpenes). In certain embodiments, the combination comprises permeation enhancers of different types (e.g., a surfactant and a terpene). In certain embodiments, combination comprises a surfactant and a terpene. In certain embodiments, the combination comprises a cationic surfactant and a terpene. In certain embodiments, the combination comprises an anionic surfactant and a terpene. In certain embodiments, the combination comprises a nonionic or zwitterionic surfactant and a terpene.

[00191] In certain embodiments, the combination comprises a surfactant and an amino amide or amino ester. In certain embodiments, the combination comprises a cationic surfactant and an amino amide or amino ester. In certain embodiments, the combination comprises an anionic surfactant and an amino amide or amino ester. In certain embodiments, the combination comprises a nonionic or zwitterionic surfactant and an amino amide or amino ester. In certain embodiments, the combination comprises is a terpene and an amino amide or amino ester. In some embodiments, the amino amide or amino ester is an anesthetic agent. In some embodiments, the anesthetic agent is bupivacaine.

[00192] In some embodiments, the permeation enhancer is a combination of compounds selected from two or three of groups (i) to (iii): (i) a surfactant selected from: sodium dodecyl sulfate, ammonium lauryl sulfate, sodium laureth sulfate, cetyl trimethlammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80, and benzalkonium chlorides; (ii) a terpene selected from: limonene, cymene, pinene, camphor, menthol, comphone, phellandrine, sabinene, terpinene, borneol, cineole, geraniol, linalol, pipertone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucakytol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid; ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, or ethylpiperazine carboxylate; (iii) and an anesthetic selected from: bupivicaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivicaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, and trimecaine. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium octyl sulfate, sodium dodecyl sulfate, octyl trimethylammonium bromide, dodecyl trimethylammonium bromide, Polysorbate 20, or Polysorbate 80 as a surfactant. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium dodecyl sulfate as a surfactant. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii) listed above, and includes limonene as a surfactant. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes bupivacaine as an anesthetic. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium dodecyl sulfate, octyl trimethylammonium bromide, dodecyl trimethylammonium bromide, Polysorbate 20, or Polysorbate 80 as a surfactant, and limonene as a terpene. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium dodecyl sulfate as a surfactant, and limonene as a terpene. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium dodecyl sulfate, octyl trimethylammonium bromide, dodecyl trimethylammonium bromide, Polysorbate 20, or Polysorbate 80 as a surfactant, and bupivacaine as an anesthetic. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium dodecyl sulfate as a surfactant, and bupivacaine as an anesthetic. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes limonene as a terpene, and bupivacaine as an anesthetic. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium dodecyl sulfate, octyl trimethylammonium bromide, dodecyl trimethylammonium bromide, Polysorbate 20, or Polysorbate 80 as a surfactant, limonene as a terpene, and bupivacaine as an anesthetic. In some embodiments, permeation enhancer is a combination of compounds from at least two of the groups (i) to (iii), listed above, and includes sodium dodecyl sulfate as a surfactant, limonene as a terpene, and bupivacaine as an anesthetic.

[00193] In certain embodiments, the percent weight of permeation enhancer in the composition is between about 0.1% to about 1%, between about 1% to about 3%, or between about 3% to about 10%. In certain embodiments, the percent weight of permeation enhancer in the composition is between about 0.1% to about 1%. In certain embodiments, the percent weight of permeation enhancer in the composition is between about 1% to about 3%. In certain embodiments, the percent weight of permeation enhancer in the composition is between about 0.1% to about 10%. In certain embodiments, the percent weight of permeation enhancer in the composition is between 0.1% to about 1%, between about 1% to about 2%, between about 2% to about 3%, between about 3% to about 4%, between about 4% to about 5%, between about 5% to about 6%, between about 6% to about 7%, between about 7% to about 8%, between about 8% to about 9%, or between about 9% to about 10%.

[00194] In some embodiments, the percent weight of sodium dodecyl sulfate in the composition is between about 0.1% to about 3%. In some embodiments, the percent weight in the composition of sodium dodecyl sulfate is about 1%. In some embodiments, the percent weight of bupivicaine in the composition is between about 0.1 to about 3%. In some embodiments, the percent weight in the composition of bupivicaine is about 0.5%. In some embodiments, the percent weight of limonene in the composition is between about 0.1% to about 3%. In some embodiments, the percent weight in the composition of limonene is about 0.5%. Therapeutic Agents

[00195] A therapeutic agent can be any agent used to treat any ear disease, or symptom of an ear disease. Therapeutic agents may include antimicrobial agents. Therapeutic agents may include, but are not limited to, antimicrobial agents, antibiotics, anesthetics, anti-inflammatories, analgesics, anti-fibrotics, anti-sclerotics, and anticoagulants. Therapeutic agents may include, but are not limited to, antibiotics, anesthetics, anti-inflammatories, analgesics, anti-fibrotics, anti- sclerotics, and anticoagulants. In certain embodiments, the therapeutic agent is an antimicrobial agent. In certain embodiments, the therapeutic agent is an antibiotic agent. In certain embodiments, the therapeutic agent is an anesthetic agent. In certain embodiments, the therapeutic agent is an anti-inflammatory agent. In certain embodiments, the therapeutic agent is an analgesic agent. In certain embodiments, the therapeutic agent is an anti-fibrotic agent. In certain embodiments, the therapeutic agent is an anti-sclerotic agent. In certain embodiments, the therapeutic agent is an anticoagulant agent.

[00196] In various aspects, the therapeutic agents may comprise between about 0.01 percent to about 10 percent of the composition. In various embodiments, the therapeutic agents may comprise between about 0.01 percent to about 1 percent of the composition, comprise between about 1 percent to about 2 percent of the composition, comprise between about 2 percent to about 3 percent of the composition, comprise between about 3 percent to about 4 percent of the composition, comprise between about 4 percent to about 5 percent of the composition, comprise between about 5 percent to about 6 percent of the composition, comprise between about 6 percent to about 7 percent of the composition, comprise between about 7 percent to about 8 percent of the composition, comprise between about 8 percent to about 9 percent of the composition, or comprise between about 9 percent to about 10 percent of the composition.

[00197] The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the particular compound, its mode of administration, its mode of activity, condition being treated, and the like. The compositions described herein are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compounds and compositions will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

[00198] In certain embodiments, the therapeutic agent is an antimicrobial agent. In certain embodiments, the therapeutic agent is an antibiotic. Any antibiotic may be used in the inventive system. In certain embodiments the antibiotic is approved for use in humans or other animals. In certain embodiments the antibiotic is approved for use by the U.S. Food & Drug Administration. In certain embodiments, the antibiotic may be selected from the group consisting of cephalosporins, quinolones, polypeptides, macrolides, penicillins, and sulfonamides. Exemplary antibiotics may include, but are not limited to, ciprofloxacin, cefuroxime, cefadroxil, cefazolin, cefalotin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftobiprole, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, bacitracin, colistin, polymyxin B, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, meticillin, nafcillin, oxacillin, penicillin, piperacillin, ticarcillin, mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, and trimethoprim-sulfamethoxazole.

[00199] In certain embodiments, the antibiotic is a quinolone. In certain embodiments, the antibiotic is a carbapenem. In certain embodiments, the antibiotic is In certain embodiments, the antibiotic is amoxicillin, azithromicicn, cefuroxime, ceftriaxone, trimethoprim, levofloxacin, moxifloxacin, meropenem, or ciprofloxacin. In some embodiments, the antibiotic is ciprofloxacin. In some embodiments, the antibiotic is ciprofloxacin and pharmaceutically acceptable salts thereof. In some embodiments, the antibiotic is ciprofloxacin hydrochloride. In some embodiments, the antibiotic is levofloxacin.

[00200] Exemplary antibiotics, include, but are not limited to: Abamectin, Actinomycin (e.g., Actinomycin A, Actinomycin C, Actinomycin D, Aurantin), Alatrofloxacin mesylate, Amikacin sulfate, Aminosalicylic acid, Anthracyclines (e.g., Aclarubicin, Adriamycin, Doxorubicin, Epirubicin, Idarubicin), Antimycin (e.g., Antimycin A), Avermectin, BAL 30072, Bacitracin, Bleomycin, Cephalosporins (e.g., 7-Aminocephalosporanic acid, 7- Aminodeacetoxycephalosporanic acid, Cefaclor, Cefadroxil, Cefamandole, Cefazolin, Cefepime, Cefixime, Cefmenoxime, Cefmetazole, Cefoperazone, Cefotaxime, Cefotetan, Cefotiam, Cefoxitin, Cefpirome, Cefpodoxime proxetil, Cefsulodin, Cefsulodin sodium, Ceftazidime, Ceftizoxime, Ceftriaxone, Cefuroxime, Cephalexin, Cephaloridine, Cephalosporin C, Cephalothin, Cephalothin sodium, Cephapirin, Cephradine), Ciprofloxacin, Enrofloxacin, Clarithromycin, Clavulanic acid, Clindamycin, Colicin, Cyclosporin (e.g. Cyclosporin A), Dalfopristin / quinupristin, Daunorubicin, Doxorubicin, Epirubicin, GSK 1322322, Geneticin, Gentamicin, Gentamicin sulfate, Gramicidin (e.g. Gramicidin A), Grepafloxacin hydrochloride, Ivermectin, Kanamycin (e.g. Kanamycin A), Lasalocid, Leucomycin, Levofloxacin, Linezolid, Lomefloxacin, Lovastatin, MK 7655, Meropenem, Mevastatin, Mithramycin, Mitomycin, Monomycin, Natamycin, Neocarzinostatin, Neomycin (e.g. Neomycin sulfate), Nystatin, Oligomycin, Olivomycin, Pefloxacin, Penicillin (e.g. 6-Aminopenicillanic acid, Amoxicillin, Amoxicillin-clavulanic acid, Ampicillin, Ampicillin sodium, Azlocillin, Carbenicillin, Cefoxitin, Cephaloridine, Cloxacillin, Dicloxacillin, Mecillinam, Methicillin, Mezlocillin, Nafcillin, Oxacillin, Penicillin G, Penicillin G potassium, Penicillin G procaine, Penicillin G sodium, Penicillin V, Piperacillin, Piperacillin-tazobactam, Sulbactam, Tazobactam, Ticarcillin), Phleomycin, Polymyxin (e.g., Colistin, Polymyxin B), Pyocin (e.g. Pyocin R), RPX 7009, Rapamycin, Ristocetin, Salinomycin, Sparfloxacin, Spectinomycin, Spiramycin, Streptogramin, Streptovaricin, Tedizolid phosphate, Teicoplanin, Telithromycin, Tetracyclines (e.g. Achromycin V, Demeclocycline, Doxycycline, Doxycycline monohydrate, Minocycline, Oxytetracycline, Oxytetracycline hydrochloride Tetracycline, Tetracycline hydrochloride), Trichostatin A, Trovafloxacin, Tunicamycin, Tyrocidine, Valinomycin, (-)-Florfenicol, Acetylsulfisoxazole, Actinonin, Amikacin sulfate, Benzethonium chloride, Cetrimide, Chelerythrine, Chlorhexidine (e.g., Chlorhexidine gluconate), Chlorhexidine acetate, Chlorhexidine gluconate, Chlorothalonil, Co-Trimoxazole, Dichlorophene, Didecyldimethylammonium chloride, Dihydrostreptomycin, Enoxacin, Ethambutol, Fleroxacin, Furazolidone, Methylisothiazolinone, Monolaurin, Oxolinic acid, Povidone-iodine, Spirocheticides (e.g., Arsphenamine, Neoarsphenamine), Sulfaquinoxaline, Thiamphenicol, Tinidazole, Triclosan, Trovafloxacin, Tuberculostatics (e.g., 4-Aminosalicylic acid, AZD 5847, Aminosalicylic acid, Ethionamide), Vidarabine, Zinc pyrithione, and Zirconium phosphate.

[00201] In certain embodiments, the therapeutic agent is an Food and Drug Administration (FDA) approved drug for treating infections or infectious diseases. Exemplary FDA approved agents include, but are not limited to: Avycaz (ceftazidime-avibactam), Cresemba (isavuconazonium sulfate), Evotaz (atazanavir and cobicistat, Prezcobix (darunavir and cobicistat), Dalvance (dalbavancin), Harvoni (ledipasvir and sofosbuvir), Impavido (miltefosine), Jublia (efinaconazole), Kerydin (tavaborole), Metronidazole, Orbactiv (oritavancin), Rapivab (peramivir injection), Sivextro (tedizolid phosphate), Triumeq (abacavir, dolutegravir, and lamivudine), Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir), Xtoro (finafloxacin), Zerbaxa (ceftolozane + tazobactam), Luzu (luliconazole), Olysio (simeprevir), Sitavig (acyclovir), Sovaldi (sofosbuvir), Abthrax (raxibacumab), Afinitor (everolimus), Cystaran (cysteamine hydrochloride), Dymista (azelastine hydrochloride and fluticasone propionate), Fulyzaq (crofelemer), Jetrea (ocriplasmin), Linzess (linaclotide), Qnasl (beclomethasone dipropionate) nasal aerosol, Sirturo (bedaquiline), Sklice (ivermectin), Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), Tudorza Pressair (aclidinium bromide inhalation powder), Complera (emtricitabine / rilpivirine / tenofovir disoproxil fumarate), Dificid (fidaxomicin), Edurant (rilpivirine), Eylea (aflibercept), Firazyr (icatibant), Gralise (gabapentin), Incivek (telaprevir), Victrelis (boceprevir), Egrifta (tesamorelin), Teflaro (ceftaroline fosamil), Zymaxid (gatifloxacin), Bepreve (bepotastine besilate), Vibativ (telavancin), Aptivus (tipranavir), Astepro (azelastine hydrochloride nasal spray), Intelence (etravirine), Patanase (olopatadine hydrochloride), Viread (tenofovir disoproxil fumarate), Isentress (raltegravir), Selzentry (maraviroc), Veramyst (fluticasone furoate), Xyzal (levocetirizine dihydrochloride), Eraxis (anidulafungin), Noxafil (posaconazole), Prezista (darunavir), Tyzeka (telbivudine), Veregen (kunecatechins), Baraclude (entecavir), Fuzeon (enfuvirtide), Lexiva (fosamprenavir calcium), Reyataz (atazanavir sulfate), Clarinex, Hepsera (adefovir dipivoxil), Pegasys (peginterferon alfa-2a), Sustiva, Vfend (voriconazole), Zelnorm (tegaserod maleate), Avelox (moxifloxacin hydrochloride), Cancidas, Invanz, Peg-Intron (peginterferon alfa-2b), Rebetol (ribavirin), Spectracef, Tavist (clemastine fumarate), Twinrix, Valcyte (valganciclovir HCl), Xigris (drotrecogin alfa), ABREVA (docosanol), Cefazolin, Kaletra, Lamisil (terbinafine hydrochloride), Lotrisone (clotrimazole / betamethasone diproprionate), Lotronex (alosetron HCL), Trizivir (abacavir sulfate, lamivudine, zidovudine AZT), Synercid, Synagis, Viroptic, Aldara (imiquimod), Bactroban, Ceftin (cefuroxime axetil), Combivir, Condylox (pokofilox), Famvir (famciclovir), Floxin, Fortovase, INFERGEN (interferon alfacon-1), Intron A (interferon alfa-2b, recombinant), Mentax (butenafine HCl), Norvir (ritonavir), Omnicef, Rescriptor (delavirdine mesylate), Taxol, Timentin, Trovan, VIRACEPT (nelfinavir mesylate), Zerit (stavudine), AK-Con-A (naphazoline ophthalmic), Allegra (fexofenadine hydrochloride), Astelin nasal spray, Atrovent (ipratropium bromide), Augmentin (amoxicillin / clavulanate), Crixivan (Indinavir sulfate), Elmiron (pentosan polysulfate sodium), Havrix, Leukine (sargramostim), Merrem (meropenem), Nasacort AQ (triamcinolone acetonide), Tavist (clemastine fumarate), Vancenase AQ, Videx (didanosine), Viramune (nevirapine), Zithromax (azithromycin), Cedax (ceftibuten), Clarithromycin (Biaxin), Epivir (lamivudine), Invirase (saquinavir), Valtrex (valacyclovir HCl), Zyrtec (cetirizine HCl), Acyclovir, Penicillin (penicillin g potassium), Cubicin (Daptomycin), Factive (Gemifloxacin), Albenza (albendazole), Alinia (nitazoxanide), Altabax (retapamulin), AzaSite (azithromycin), Besivance (besifloxacin ophthalmic suspension), Biaxin XL (clarithromycin extended-release), Cayston (aztreonam), Cleocin (clindamycin phosphate), Doribax (doripenem), Dynabac, Flagyl ER, Ketek (telithromycin), Moxatag (amoxicillin), Rapamune (sirolimus), Restasis (cyclosporine), Tindamax (tinidazole), Tygacil (tigecycline), and Xifaxan (rifaximin).

[00202] In certain embodiments, the therapeutic agent is an anesthetic. Any anesthetic may be used in the inventive system. In certain embodiments the anesthetic is approved for use in humans or other animals. In certain embodiments the anesthetic is approved for use by the U.S. Food & Drug Administration. Exemplary anesthetics may include, but are not limited to bupivicaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocain, levobupivicaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, and trimecaine. In certain embodiments, the anesthetic is bupivicaine.

[00203] In certain embodiments, the therapeutic agent is an anti-inflammatory agent. The anti- inflammatory agent may be a non-steroidal anti-inflammatory agent or a steroidal anti- inflammatory agent. In certain embodiments, the therapeutic agent is a steroidal anti- inflammatory agent. In certain embodiments, the therapeutic agent is a steroid. Exemplary anti- inflammatory agents may include, but are not limited to, acetylsalicylic acid, amoxiprin, benorylate / benorilate, choline magnesium salicylate, diflunisal, ethenzamide, faislamine, methyl salicylate, magnesium salicylate, salicyl salicylate, salicylamide, diclofenac, aceclofenac, acemetacin, alclofenac, bromfenac, etodolac, indometacin, nabumetone, oxametacin, proglumetacin, sulindac, tolmetin, ibuprofen, alminoprofen, benoxaprofen, carprofen, dexibuprofen, dexketoprofen, fenbufen, fenoprofen, flunoxaprofen, flurbiprofen, ibuproxam, indoprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, pirprofen, suprofen, tiaprofenic acid, mefenamic acid, flufenamic acid, meclofenamic acid, tolfenamic acid, phenylbutazone, ampyrone, azapropazone, clofezone, kebuzone, metamizole, mofebutazone, oxyphenbutazone, phenazone, phenylbutazone, sulfinpyrazone, piroxicam, droxicam, lornoxicam, meloxicam, tenoxicam, hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, and aldosterone.

[00204] In various embodiments, combinations of various permeation enhancers and therapeutic agents have been observed to have a synergistic and heightened efficacy. In various aspects, such combinations may include, but are not limited to, ciprofloxacin and limonene. In various aspects, such combinations may include, but are not limited to, ciprofloxacin and sodium dodecyl sulfate. In various aspects such combinations may include, but are not limited to, sodium dodecyl sulfate, limonene, bupivacaine, and ciprofloxacin. In various aspects, such combination may include, but are not limited to, sodium dodecyl sulfate, limonene and ciprofloxacin.

[00205] In another aspect, provided herein are pharmaceutical compositions comprising at least one of the compounds as described herein, or a pharmaceutically acceptable derivative thereof. In certain embodiments, the pharmaceutical composition includes a combination of therapeutic agents. In certain embodiments, the composition includes an antibiotic and an additional therapeutic agent. In certain embodiments, the composition includes an antibiotic agent and an anti-inflammatory agent. In other embodiments, the composition includes an antibiotic agent and an anesthetic agent. In certain embodiments, the composition includes more than one antibiotic agent.

[00206] In certain embodiments, the additional therapeutic agent is an anti-inflammatory agent (e.g., a steroid). In certain embodiments, the first therapeutic agent is an antibiotic and the additional therapeutic agent is an anti-inflammatory agent. In certain embodiments, the first therapeutic agent is an antibiotic and the additional therapeutic agent is a steroid. Steroids include, but are not limited to, cortisol, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, prednisone, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, halcinonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-valerate, halometasone, alclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone- 17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, fluprednidene acetate, hydrocortisone-17-butyrate, hydrocortisone-17-aceponate, hydrocortisone-17-buteprate, ciclesonide, and prednicarbate. In some embodiments, the additional anti-inflammatory agent is dexamethasone.

[00207] In certain embodiments, the additional therapeutic agent is a <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactamase inhibitor. In certain embodiments, the first therapeutic agent is an antibiotic (e.g., a <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactam) and the additional therapeutic agent is a <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactamase inhibitor. <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-Lactamase inhibitors include, but are not limited to, avibactam, clavulanic acid, tazobactam, and sulbactam. The β-lactamase inhibitor may be particularly useful in compositions comprising a <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactam antibiotic. The <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactamase inhibitor may increase the efficacy of a <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactam antibiotic or allow for the <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-lactam antibiotic to be present in the composition in a lower concentration than for compositions not containing a <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>- lactamase inhibitor.

[00208] Furthermore, after formulation with an appropriate pharmaceutically acceptable carrier in a desired dosage, the pharmaceutical compositions can be administered to humans and other animals.

[00209] Dosage forms include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, and perfuming agents. In certain embodiments, the composition comprises a solubilizing agents such an Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.

[00210] It will also be appreciated that the compositions described herein can be employed in combination therapies, that is, the compounds and pharmaceutical compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and / or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another anticancer agent), or they may achieve different effects (e.g., control of any adverse effects).

[00211] In certain embodiments, the composition comprises a diagnostic agent. In some embodiments, the diagnostic agent is a X-ray contrast agent. In some embodiments, the diagnostic agent comprises a radioactive isotope. In some embodiments, the diagnostic agent is a dye. Other Additives

[00212] In certain embodiments, the composition comprises one or more additional additives. For example, an additional additive may be a diluent, binding agent, preservative, buffering agent, lubricating agent, perfuming agent, antiseptic agent, or oil.

[00213] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.

[00214] Exemplary binding agents include starch (e.g., cornstarch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum<com:Sup>®< / com:Sup>), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and / or mixtures thereof.

[00215] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent. In certain embodiments, the preservative is benzalkonium chloride.

[00216] Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.

[00217] Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.

[00218] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.

[00219] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

[00220] Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant<com:Sup>®< / com:Sup> Plus, Phenonip<com:Sup>®< / com:Sup>, methylparaben, Germall<com:Sup>®< / com:Sup> 115, Germaben<com:Sup>®< / com:Sup> II, Neolone<com:Sup>®< / com:Sup>, Kathon<com:Sup>®< / com:Sup>, and Euxyl<com:Sup>®< / com:Sup>.

[00221] Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and mixtures thereof.

[00222] Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.

[00223] Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.

[00224] In addition to the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[00225] The composition may comprise water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[00226] Formulations suitable for administration (e.g., to the ear canal) include, but are not limited to, liquid and / or semi-liquid preparations such as liniments, lotions, oil-in-water, and / or water-in-oil emulsions such as creams, ointments, and / or pastes, and / or solutions and / or suspensions. Topically administrable formulations may, for example, comprise from about 1% to about 10% (w / w) therapeutic agent, although the concentration of the therapeutic agent can be as high as the solubility limit of the active ingredient in the solvent. Polysaccharide Matrix Forming Agents

[00227] Also provided herein are compositions comprising a polysaccharide based matrix forming agent. The matrix forming agent may form a hydrogel by crosslinking of a first polysaccharide derivative and a second polysaccharide derivative, wherein the first and second polysaccharides are different. For example, the first polysaccharide may be an hyaluronic acid (HA) derivative comprising a first cross-linkable functional group, and the second polysaccharide may be a cellulose derivative comprising a second cross-linkable functional group. To give but another example, the first polysaccharide is an HA derivative comprising a first cross-linkable functional group, and the second polysaccharide is a dextran derivative comprising a second cross-linkable functional group. In certain embodiments, the first and second cross-linkable functional groups are selected from the group consisting of amines, amides, aldehydes, esters, ketones, hydroxyls, hydrazines, hydrazides, maleimides, or sulfhydryls. In some embodiments, the first functional group is an amine, and the second functional group is an aldehyde. In some embodiments, the first functional group is an amine, and the second functional group is a ketone. In some embodiments, the first functional group is an amine, hydroxyl, or sulfhydryl, and the second functional group is an ester. In some embodiments, the first functional group is a maleimide, and the second functional group is a sulfhydryl. In some embodiments, the first functional group is a hydrazine or hydrazide, and the second functional group is an aldehyde or ketone. In some embodiments, the first functional group is a hydrazide, and the second functional group is an aldehyde.

[00228] The hydrogels may formed by crosslinking a first polysaccharide derivative and a second polysaccharide derivative, wherein the first and second polysaccharides are the same and wherein the first polysaccharide derivative comprises a first cross-linkable functional group, and the second polysaccharide derivative comprises a second cross-linkable functional group, wherein the first and second cross-linkable functional groups are capable of crosslinking to one another. The polysaccharide may be, e.g., glycosaminoglycan, HA, cellulose, dextran, or a derivative of either.

[00229] HA, also referred to as hyaluronan or hyaluronate, is an unbranched polysaccharide containing repeating disaccharide subunits composed of N-acetyl-D glucosamine and D- glucuronic acid. (See Laurent, T. C. (Ed)., Chemistry, Biology and Medical Applications of Hyaluronan and Its Derivatives, London: Portland Press, 1998). HA also refers to any of its salts, e.g., sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, etc. The term "HA derivative" refers to HA that has been chemically modified from the native form.

[00230] Cellulose is a linear polymer of <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-D-glucopyranose units joined to one another (Kamide, Cellulose And Cellulose Derivatives: Molecular Characterization and Its Applications, Elsevier, 2005). The term "cellulose derivative" refers to cellulose that has been chemically modified from this native form. In certain embodiments, the polysaccharide is a cellulose derivative such as methylcellulose (MC), carboxymethylcellulose (CMC), hydroxymethylcellulose (HMC), hydroxypropylcellulose (HPC), hydroxyethyl cellulose (HEC), or hydroxypropyl methylcellulose (HPMC), in which one or more of the OH groups is replaced by OR, wherein R represents any of a variety of moieties.

[00231] Dextran is a complex, branched polysaccharide. Dextran includes many glucose moieties joined together via <com:Math><semantics>α1→6<annotation encoding="application / x-tex">\alpha 1 \rightarrow 6< / annotation>< / semantics>< / com:Math> glycosidic linkages to form straight chains. Branches typically begin from <com:Math><semantics>α1→3<annotation encoding="application / x-tex">\alpha 1 \rightarrow 3< / annotation>< / semantics>< / com:Math> linkages, but they may also begin from <com:Math><semantics>α1→2<annotation encoding="application / x-tex">\alpha 1 \rightarrow 2< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>α1→4<annotation encoding="application / x-tex">\alpha 1 \rightarrow 4< / annotation>< / semantics>< / com:Math> linkages. The term "dextran derivative" refers to dextran that has been chemically modified from this native form. In certain embodiments, the polysaccharide is a dextran derivative, in which one or more of the OH groups is replaced by OR, wherein R represents any of a variety of moieties.

[00232] Modifications to the polysaccharides may include the addition or creation of new functional groups (e.g., amine, amide, aldehyde, ester, ketone, hydroxy, hydrazine, hydrazide, maleimide, sulfhydryl, etc.), in which case the polysaccharide is said to be "functionalized." The proportion of sugar subunits that are modified can vary, and the degree of modification can be selected in order to control properties such as gelation time, half-life, stiffness, etc. Certain modifications retain the native sugar backbone structure while other modifications open at least some of the sugar rings. In some embodiments, the polysaccharide derivative is an aldehyde- containing derivative in which polysaccharide has been treated with periodate.

[00233] It will be appreciated that in any of the polysaccharide derivatives, only a fraction of the sugar moieties in the polysaccharide are modified. The extent of modification can vary. For example, in certain embodiments, between 5% and 99-100% of the relevant sugar moieties (e.g., glucuronic acid moieties in the case of the HA) are modified. In certain embodiments, between 10% and 75% of the relevant sugar moieties are modified. The extent of modification can be controlled by a variety of methods. For example, the temperature, pH, and time during which the reaction is allowed to proceed can be varied, as can the concentration of the reagents (e.g., carbodiimide, amide, dihydrazide, etc.). To achieve a high degree of modification an excess of the modifying agent(s), e.g., dihydrazide and / or carboiimide, may be used. For example, in one embodiment a 10-100 fold excess of dihydradize is added to a solution comprising HA, and / or a 2-100 fold excess of carbodiimide reagent is then added to the reaction mixture. In certain embodiments, values for these parameters are selected so as to achieve a relatively high degree of modification, e.g., between 50% and 99-100% of the relevant sugar moieties are modified. For example, between 50% and 80% of the relevant sugar moieties may be modified. However, the degree of modification is kept low enough so that the solution will remain in a suitably fluid state rather than becoming too viscous for easy manipulation and syringibility. In certain embodiments, between 10% and 30%, or between 30% and 50% of the relevant sugar moieties are modified.

[00234] A variety of polysaccharide derivatives may be used. In certain embodiments, at least one of the polysaccharide derivatives is a derivative of HA. In certain embodiments, both of the polysaccharide derivatives are derivatives of HA. In certain embodiments, the matrix forming agent is separated into a first and second polysaccharide derivative which form a matrix or gel upon mixing. In some embodiments, the first polysaccharide derivative comprises a first type of cross-linkable functional group, and the second polysaccharide derivative comprises a second type of cross-linkable functional group, wherein the two types of cross-linkable functional groups form cross-links between the two polysaccharide derivative upon mixing. The polysaccharide derivatives may be kept separate as two components of the compositions, which are mixed during administration, e.g., during application to the ear canal with a double barrel syringe. In certain embodiments, the polysaccharide is one that is not specifically degraded by an enzyme endogenous to human beings.

[00235] In certain embodiments, at least one of the polysaccharide derivatives is a derivative of cellulose. For example, in certain embodiments, the first polysaccharide derivative is a derivative of HA, and the second polysaccharide derivative is a derivative of cellulose.

[00236] In certain embodiments, at least one of the polysaccharide derivatives is a derivative of dextran. For example, in certain embodiments, the first polysaccharide derivative is a derivative of HA, and the second polysaccharide derivative is a derivative of dextran.

[00237] The first and second polysaccharide derivatives comprise first and second functional groups, respectively, that react with one another to form covalent bonds that join the first and second polysaccharide derivatives to one another. The solutions are thus applied as liquids and are contacted with one another and optionally mixed together either immediately before or at the time of administration or contact one another following administration. Formation of a sufficient number of crosslinks causes a transition from a liquid to a semi-solid or gel-like state.

[00238] In certain embodiments, a polysaccharide derivative comprising at least two different cross-linkable functional groups is employed, wherein the cross-linkable functional groups react with one another to form crosslinks under physiological conditions. The cross-linkable functional groups may be selected so that they substantially do not react with one another until exposed to physiological conditions of pH, temperature, and / or salt concentration. Thus it will be appreciated that matrix forming agent does not require two distinguishable HA derivatives but may instead employ a single species that comprises multiple different functional groups capable of becoming crosslinked.

[00239] A variety of different polysaccharide derivatives (e.g., HA derivatives) are of use in the composition. In certain embodiments, the first and second cross-linkable functional groups react in sufficient amounts and with sufficient rapidity so as to allow hydrogel formation within a time frame following contact of the solutions with one another. In certain embodiments, the hydrogel forms within between 1-3 seconds and 5 minutes, between 1-3 seconds and 3 minutes, between 1-3 seconds and 60 seconds, between 1-3 seconds and 30 seconds, or between 1-3 seconds and 15 seconds, following contact of the solutions with one another, e.g., following administration. Typically the solutions are mixed together either immediately before or concurrently with their administration to a site within the body (e.g., ear canal). For example, the solutions may be administered using a multiple barrel injection device, e.g., a multiple barrel syringe, wherein each solution is contained in a separate receptacle or barrel prior to administration. The solutions may contact each other during the administration process and / or thereafter. Preferably the derivatives become crosslinked under physiological conditions, e.g., in an aqueous environment at a pH between 6.0 and 8.0.

[00240] A variety of cross-linkable polysaccharide derivatives and methods for forming them may be employed. In certain embodiments, the polysaccharide derivatives become crosslinked to one another without needing a separate crosslinking agent, e.g., the first and second derivatives comprise functional groups that react with one another to form a covalent bond. In certain embodiments, the polysaccharide derivatives react with one another to produce a nontoxic, biocompatible product, e.g., water. In certain embodiments, neither of the polysaccharide derivatives is modified by using a crosslinking agent. In certain embodiments, the polysaccharide derivatives become crosslinked without requiring light.

[00241] It will be appreciated that in any of the above embodiments, only a fraction of the available functional groups on the first and second polysaccharide derivatives will become crosslinked. The crosslinking density can be controlled, e.g., by appropriately selecting the molecular weights of the polysaccharide derivatives. Exemplary crosslinking densities range from about <com:Math><semantics>1×106<annotation encoding="application / x-tex">1\times10^6< / annotation>< / semantics>< / com:Math> to about <com:Math><semantics>1×108<annotation encoding="application / x-tex">1\times10^8< / annotation>< / semantics>< / com:Math> mol / cm<com:Sup>3< / com:Sup>. In certain embodiments, the crosslinking density ranges from <com:Math><semantics>3−50×107<annotation encoding="application / x-tex">3-50\times10^7< / annotation>< / semantics>< / com:Math> mol / cm<com:Sup>3< / com:Sup>.

[00242] Polysaccharide derivatives functionalized as described above can be crosslinked by allowing derivatives comprising different functional groups to react with one another. For example, (i) a first polysaccharide derivative comprising an aldehyde can react with a second polysaccharide derivative comprising an amine; (ii) a first polysaccharide derivative comprising an active ester such as an NHS ester can react with a second polysaccharide derivative comprising an amine; (iv) a first polysaccharide derivative comprising a hydrazide can react with a second HA derivative comprising an aldehyde, etc. In one embodiment of particular interest the first solution contains a polysaccharide derivative functionalized with a dihydrazide, and the second solution contains polysaccharide oxidized to form aldehyde groups (See, e.g., Figure 8).

[00243] In certain embodiments, the composition comprises a matrix forming agent comprising a polysaccharide derivative in solution, wherein the concentration of the polysaccharide derivative is greater than 5 mg / ml, e.g., up to 150 mg / ml. In certain embodiments, the concentration of the polysaccharide derivative is greater than 10 mg / ml. In other embodiments, the concentration of the polysaccharide derivative is greater than 15 mg / ml, greater than 20 mg / ml, or greater than 25 mg / ml. Herein, a polysaccharide derivative greater than 25 mg / ml is referred to as a "high concentration." The solution preferably has a sufficiently low viscosity such that it can be readily manipulated, e.g., so that easy syringibility exists.

[00244] In certain embodiments, at least one of the polysaccharide derivatives suitable for in situ crosslinking to form a gel, comprises a portion that comprises a non-polysaccharide polymer, e.g., the polysaccharide derivative comprises a polysaccharide or derivative thereof covalently attached to one or more non-polysaccharide polymers. Non-polysaccharide means that the polymer contains less than 1% sugar monomers by weight, number, or both, e.g., the polymer contains essentially no sugars. In certain embodiments, the non-polysaccharide portion comprises between 1% and 10%-90% of the polymer by weight and / or between 1% and 10%- 90% of the monomers are non-sugar monomers. The attachment may occur at any position in the polysaccharide chain, e.g., either of the ends of the chain or at one of the internally located sugar moieties resulting in either a linear or branched structure. The non-polysaccharide polymer can be any of a variety of polymers, e.g., any non-polysaccharide polymer capable of serving as a hydrogel precursor when covalently attached to a polysaccharide derivative.

[00245] In certain embodiments, the matrix forming agent comprises first and second crosslinkable hydrogel precursors, wherein one of the hydrogel precursors comprises or consists of a polysaccharide derivative such as an HA, cellulose, or dextran derivative and the other hydrogel precursor comprises or consists of a non-polysaccharide polymer (i.e., less than 1% of the polymer by weight, or less than 1% of the monomers are sugars). Exemplary non- polysaccharide polymers capable of becoming crosslinked to a polysaccharide derivative to form a hydrogel include but are not limited to polyethers such as polyethylene glycol (PEG) or polypropylene glycol (PPG), polyethylene oxides (PEO), polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), polypeptides such as gelatin, chitosan, or poly(1-glutamic acid), and derivatives of any of these, or conjugates, blends, or composites comprising any of these.

[00246] While polysaccharide derivatives are described in detail, in yet other embodiments, the hydrogel is formed by crosslinking two non-polysaccharide polymers in situ. in a hydrogel that inhibits adhesions. Each of the non-polysaccharide polymers comprises a functional group, wherein the functional groups are capable of reacting with one another to form covalent bonds. Suitable functional groups are those described above for crosslinking of polysaccharide derivatives. Exemplary non-polysaccharide polymers include those described above that contain or may be modified to contain suitable functional groups for crosslinking. Matrix Forming Agents (and Compositions Thereof)

[00247] In one aspect, provided herein are matrix forming agents described herein. In certain embodiments, the matrix forming agent comprises a polymer. In certain embodiments, the matrix forming agent comprises polymers that gel via electrostatic interactions. In certain embodiments, the matrix forming agent comprises polymers that display shear thinning. In certain embodiments, the matrix forming agent comprises rheological blends of polymers. In certain embodiments, rheological polymer blends comprise two different polymers wherein the viscoelastic properties of the rheological polymer blends are more gel-like than those of the constituent polymers measured individually The polymer may be a block copolymer. In certain embodiments, the polymer is not a block copolymer. In certain embodiments, the polymer is a thermosensitive polymer. In certain embodiments, the polymer is poly(N-isopropylacrylamide) (NIPAAm). In certain embodiments, the matrix forming agent or combination of matrix forming agents is not modified by a polyphosphoester. In certain embodiments, the matrix forming agent or combination of matrix forming agents is modified by a polyphosphoester. In certain embodiments, the matrix forming agent or combination of matrix forming agents comprises a polymer of Formula: [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(𝑰′),<annotation encoding="application / x-tex">(\mathbf{I'}),< / annotation>< / semantics>< / com:Math> wherein each occurrence of Y is independently <com:Math><semantics>−R1<annotation encoding="application / x-tex">-R^1< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−L2R2<annotation encoding="application / x-tex">-L^2R^2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>1< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L<com:Sup>2< / com:Sup> is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R<com:Sup>2< / com:Sup> is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>, or an oxygen protecting group; each occurrence of R<com:Sup>3A< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, <com:Math><semantics>−ORb<annotation encoding="application / x-tex">-OR^b< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>b< / com:Sup> is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R<com:Sup>b< / com:Sup> taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G<com:Sup>1A< / com:Sup> and G<com:Sup>2A< / com:Sup> is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 0 and 200, inclusive, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1.

[00248] In certain embodiments, the matrix forming agent or combination of matrix forming agents comprises a polymer of Formula: [Image disponible dans le document PDF, Image available in the PDF document] (IA); wherein: each occurrence of Z is independently <com:Math><semantics>−R4<annotation encoding="application / x-tex">-R^4< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>4< / com:Sup> is independently optionally substituted alkyl; each of G<com:Sup>1A< / com:Sup> and G<com:Sup>2A< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 0 and 200, wherein the sum of p and t is at least 1, and the sum of q, r, and s is at least 1; the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is less than about 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers.

[00249] In some embodiments, the matrix forming agent comprises a poloxamer. Exemplary poloxamers include, but are not limited to: poloxamer 407, poloxamer 188, poloxalene, poloxamer 124, poloxamer 237, or poloxamer 338, Pluronic® 10R5, Pluronic® 17R2, Pluronic® 17R4, Pluronic® 25R2, Pluronic® 25R4, Pluronic® 31R1, Pluronic® F 108 Cast Solid Surfactant, Pluronic® F 108 NF, Pluronic® F 108 Pastille, Pluronic® F 108NF Prill Poloxamer 338, Pluronic® F 127 NF, Pluronic® F 127 NF 500 BHT Prill, Pluronic® F 127 NF Prill Poloxamer 407, Pluronic® F 38, Pluronic® F 38 Pastille, Pluronic® F 68, Pluronic® F 68 LF Pastille, Pluronic® F 68 NF, Pluronic® F 68 NF Prill Poloxamer 188, Pluronic® F 68 Pastille, Pluronic® F 77, Pluronic® F 77 Micropastille, Pluronic® F 87, Pluronic® F 87 NF, Pluronic® F 87 NF Prill Poloxamer 237, Pluronic® F 88, Pluronic® F 88 Pastille, Pluronic® FT L 61, Pluronic® L 10, Pluronic® L 101, Pluronic® L 121, Pluronic® L 31, Pluronic® L 35, Pluronic® L 43, Pluronic® L 61, Pluronic® L 62, Pluronic® L 62 LF, Pluronic® L 62D, Pluronic® L 64, Pluronic® L 81, Pluronic® L 92, Pluronic® L44 NF INH surfactant Poloxamer 124, Pluronic® N 3, Pluronic® P 103, Pluronic® P 104, Pluronic® P 105, Pluronic® P 123 Surfactant, Pluronic® P 65, Pluronic® P 84, Pluronic® P 85, Synperonic® PE / F 108, Synperonic® PE / P105, Synperonic® PE / P84, Synperonic®, Synperonic® PE / L31, Synperonic® PE / L61, Synperonic® PE / L101, Synperonic® PE / L121, Synperonic® PE / L42, Synperonic® PE / L62, Synperonic® PE / L92, Synperonic® PE / L44, Synperonic® PE / L64, Synperonic® PE / P84, Synperonic® PE / P75, Synperonic® PE / P103, Synperonic® PE / F87, Synperonic® PE / F127, Synperonic® PE / F38, Synperonic® PE / F68, Kolliphor® P 188, Kolliphor® P 407, Kolliphor® P 188 micro, Kolliphor® P 407 micro, Kolliphor® P237, Kolliphor® P 338, Kolliphor® EL, Kolliphor® HS 15, Kolliphor® PS 80, Kolliphor® PS 60, Kolliphor® RH 40, Kolliphor® TPG S, Kolliphor® CS L, Kolliphor® CS A, Kolliphor® CS S, Kolliphor® CS B, Kolliphor® CS 20, and Kolliphor® CS 12. In some embodiments, the matrix forming agent comprises any of the foregoing poloxamers, a derivative thereof, or a block copolymer thereof.

[00250] In certain embodiments, the matrix forming agent comprises poloxamer 407, poloxamer 188, poloxalene, poloxamer 124, poloxamer 237, or poloxamer 338. In certain embodiments, the block copolymer comprises poloxamer 407. In certain embodiments, the matrix forming comprises a poloxamer with phosphoester monomers. In certain embodiments, the matrix forming comprises poloxamer 407 with phosphoester monomers. In certain embodiments, the matrix forming agent or combination of matrix forming agents comprises a polymer of Formula: [Image disponible dans le document PDF, Image available in the PDF document] (II); wherein: each occurrence of Z is independently <com:Math><semantics>−R4<annotation encoding="application / x-tex">-R^4< / annotation>< / semantics>< / com:Math>; each occurrence of R<com:Sup>4< / com:Sup> is independently optionally substituted alkyl; each of G<com:Sup>1A< / com:Sup> and G<com:Sup>2A< / com:Sup> is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p and t is independently an integer between 0 and 200, inclusive, wherein the sum of p and t is at least 1; the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is less than about 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is greater than about 15% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers.

[00251] Polymers of Formula (I') comprise R<com:Sup>3A< / com:Sup>. In certain embodiments, each R<com:Sup>3A< / com:Sup> is the same substituent. In certain embodiments, each R<com:Sup>3A< / com:Sup> in a polymer is one of two specific substituents. In certain embodiments, each R<com:Sup>3A< / com:Sup> in a polymer is one of three specific substituents. In certain embodiments, each R<com:Sup>3A< / com:Sup> in a polymer is one of four specific substituents. In certain embodiments, each R<com:Sup>3A< / com:Sup> in a polymer is one of five specific substituents. In certain embodiments, each R<com:Sup>3A< / com:Sup> in a polymer is one of six specific substituents. In certain embodiments, each R<com:Sup>3A< / com:Sup> in a polymer is one of seven or more specific substituents.

[00252] As generally described herein each occurrence of R<com:Sup>3A< / com:Sup> is independently optionally hydrogen, substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, -OR<com:Sup>b< / com:Sup>, or <com:Math><semantics>−N(Rb)2<annotation encoding="application / x-tex">-N(R^b)_2< / annotation>< / semantics>< / com:Math>. In certain embodiments, each occurrence of <com:Math><semantics>R3A<annotation encoding="application / x-tex">R^{3A}< / annotation>< / semantics>< / com:Math> is independently unsubstituted alkyl.

[00253] In certain embodiments, R<com:Sup>3A< / com:Sup> is hydrogen. In certain embodiments, R<com:Sup>3A< / com:Sup> is optionally substituted alkyl, e.g., optionally substituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C2−3<annotation encoding="application / x-tex">C_{2-3}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> alkyl, optionally substituted <com:Math><semantics>C4−5<annotation encoding="application / x-tex">C_{4-5}< / annotation>< / semantics>< / com:Math> alkyl, or optionally substituted <com:Math><semantics>C5−6<annotation encoding="application / x-tex">C_{5-6}< / annotation>< / semantics>< / com:Math> alkyl. In certain embodiments, <com:Math><semantics>R3A<annotation encoding="application / x-tex">R^{3A}< / annotation>< / semantics>< / com:Math> is unsubstituted alkyl, e.g., unsubstituted <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted <com:Math><semantics>C1−2<annotation encoding="application / x-tex">C_{1-2}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted <com:Math><semantics>C2−3<annotation encoding="application / x-tex">C_{2-3}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> alkyl, unsubstituted <com:Math><semantics>C4−5<annota...

Claims

1. A composition comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is about 37 °C or less than 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is about 15% or greater than 15% of the storage modulus of the reference composition or about 500 Pa or greater than 500 Pa, whichever is smaller, at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 15% and about 150% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers; wherein the polymer is of Formula (I'): [Image disponible dans le document PDF, Image available in the PDF document] . . . . . 1 wherein: each occurrence of Y is independently − R 1 -R^1 or − L 2 R 2 -L^2R^2 ; each occurrence of R 1 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, − O R b -OR^b , − N ( R b ) 2 -N(R^b)_2 , or an oxygen protecting group; each occurrence of R 3 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, − O R b -OR^b , or − N ( R b ) 2 -N(R^b)_2 ; each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G 1A and G 2A is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive.

2. A composition comprising: (a) a therapeutic agent or a combination of therapeutic agents; (b) a permeation enhancer or a combination of permeation enhancers, wherein the permeation enhancer or combination of permeation enhancers increases the flux of the therapeutic agent or combination of therapeutic agents across a barrier; and (c) a matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer; wherein: the composition forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is about 37 °C or less than 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of the composition is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is about 15% or greater than 15% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of the permeation enhancer or combination of permeation enhancers; wherein the polymer is of Formula (I'): [Image disponible dans le document PDF, Image available in the PDF document] (I'), wherein: each occurrence of Y is independently − R 1 -R^1 or − L 2 R 2 -L^2R^2 ; each occurrence of R 1 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, − O R b -OR^b , − N ( R b ) 2 -N(R^b)_2 , or an oxygen protecting group; each occurrence of R 3 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, − O R b -OR^b , or − N ( R b ) 2 -N(R^b)_2 ; each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G 1A and G 2A is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive.

3. The composition of claim 1, wherein conditions (i) is met.

4. The composition of claim 1, wherein conditions (ii) is met.

5. The composition of claim 1, wherein conditions (iii) is met.

6. The composition of claim 1, wherein conditions (i) and (ii), (i) and (iii), or (ii) and (iii) are met.

7. The composition of claim 1, wherein each of conditions (i), (ii), and (iii) is met.

8. The composition of any one of claims 1-7, wherein the storage modulus is about 50% or greater than 50%, about 70% or greater than 70%, about 80% or greater than 80%, or about 90% or greater than 90% of the storage modulus of the reference composition at a temperature of about 37 °C.

9. The composition of any one of claims 1-7, wherein the storage modulus is about 100% or greater than 100% of the storage modulus of the reference composition at a temperature of about 37 °C.

10. The composition of any one of claims 1-9, wherein the phase transition temperature is less than the phase transition temperature of the reference composition.

11. The composition of any one of claims 1-10, wherein the phase transition temperature is about 10 °C or above 10 °C.

12. The composition of any one of claims 1-10, wherein the phase transition temperature is about 20 °C or above 20 °C.

13. The composition of any one of claims 1-10, wherein the phase transition temperature is about 30 °C or above 30 °C.

14. The composition of any one of claims 1-13, wherein the composition comprises about15. The composition of claim 14, wherein the composition comprises about 0.5% wt / vol or at least 0.5% wt / vol, about 1% wt / vol or at least 1% wt / vol, about 2% wt / vol or at least 2% wt / vol, about 3% wt / vol or at least 3% wt / vol, about 4% wt / vol or at least 4% wt / vol, or about 5% wt / vol or at least 5% wt / vol permeation enhancer.

16. The composition of any one of claims 1-14, wherein the polymer is a thermosensitive polymer.

17. The composition of any one of claims 1-14, wherein the composition has a high degree of hydrophobicity.

18. The composition of any one of claims 1-14, wherein the composition is optically transparent.

19. The composition of any one of claims 1-14, wherein each R 1 R^1 is unsubstituted C 1 − 20 C_{1-20} alkyl.

20. The composition of any one of claims 1-14 or 19, wherein each L 2 L^2 is a bond or unsubstituted C 1 − 6 C_{1-6} alkylene.

21. The composition of claim 20, wherein each L 2 L^2 is a bond.

22. The composition of claim 20, wherein each L 2 L^2 is unsubstituted C 1 − 6 C_{1-6} alkylene.

23. The composition of any one of claims 1-14 or 19-22, wherein each ℝ 2 \mathbb{R}^2 is optionally substituted carbonyl.

24. The composition of claim 23, wherein each R 2 R^2 is of formula: [Image disponible dans le document PDF, Image available in the PDF document]25. The composition of any one of claims 1-14, wherein the polymer is of formula: [Image disponible dans le document PDF, Image available in the PDF document] , wherein: each occurrence of Y is independently − R 1 -R^1 or − L 2 R 2 -L^2R^2 ; each occurrence of R 1 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, − O R b -OR^b , − N ( R b ) 2 -N(R^b)_2 , or an oxygen protecting group; each occurrence of R 3 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, − O R b -OR^b , or − N ( R b ) 2 -N(R^b)_2 ; each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G 1 and G 2 is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200.

26. The composition of claim 25, wherein the polymer is of the formula: [Image disponible dans le document PDF, Image available in the PDF document] •27. The composition of claim 26, wherein the polymer is of the formula: [Image disponible dans le document PDF, Image available in the PDF document] ı •28. The composition of claim 25, wherein each R 1 R^1 is unsubstituted C 1 − 20 C_{1-20} alkyl.

29. The composition of claim 25 or 26, wherein each L 2 L^2 is a bond or unsubstituted C 1 − 6 C_{1-6} alkylene.

30. The composition of claim 29, wherein each L 2 L^2 is a bond.

31. The composition of claim 29, wherein each L 2 L^2 is unsubstituted C 1 − 6 C_{1-6} alkylene.

32. The composition of any one of claims 25, 26, or 28-31, wherein each R 2 is optionally substituted carbonyl.

33. The composition of claim 32, wherein each R 2 R^2 is of formula: [Image disponible dans le document PDF, Image available in the PDF document]34. The composition of any one of claims 1-33, wherein the permeation enhancer is a surfactant, terpene, amino amide, amino ester, azide-containing compound, alcohol, pyrrolidone, sulfoxide, fatty acid, or anesthetic agent.

35. The composition of any one of claims 1-33, wherein the permeation enhancer is sodium dodecyl sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, cetyl trimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine oleyl, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

36. The composition of any one of claims 1-33, wherein the permeation enhancer is limonene, cymene, pinene, camphor, menthol, camphene, phellandrene, sabinene, terpinene, borneol, cineole, geraniol, linalol, piperitone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucalyptol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid, ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, or ethylpiperazine carboxylate.

37. The composition of any one of claims 1-33, wherein the permeation enhancer is sodium lauroyl sarcosinate, sorbitan monooleate, octoxynol-9, diethyl sebacate, sodium polyacrylate (2500000 MW), or octyldodecanol.

38. The composition of any one of claims 1-34, wherein the permeation enhancer is pyrrolidone.

39. The composition of any one of claims 1-34, wherein the permeation enhancer is dimethyl sulfoxide or a long chain dialkyl sulfoxide.

40. The composition of any one of claims 1-34, wherein the permeation enhancer is a fatty acid.

41. The composition of any one of claims 1-33, wherein the permeation enhancer is an azone-like compound.

42. The composition of claim 41, wherein the azone-like compound is 1-benzyl-4- ( 2 − ( ( 1 , 1 − (2-((1,1- biphenyl)-4-yloxy)ethyl)piperazine.

43. The composition of claim 16 or 36, wherein the permeation enhancer is a combination of sodium dodecyl sulfate, limonene, and bupivacaine.

44. The composition of claim 36, wherein the permeation enhancer is limonene, wherein the composition comprises 1.5-3% limonene by weight.

45. The composition of any one of claims 1-33, wherein the permeation enhancer is an amino amide anesthetic agent or amino ester anesthetic agent.

46. The composition of claim 34, wherein the permeation enhancer is an anesthetic selected from the group consisting of bupivacaine, tetracaine, procaine, proparacaine, propaycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivacaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, and trimecaine.

47. The composition of any one of claims 1-33, wherein the therapeutic agent is an antibiotic agent, anesthetic agent, anti-inflammatory agent, analgesic agent, anti-fibrotic agent, anti- sclerotic agent, anticoagulant agent, or diagnostic agent.

48. The composition of any one of claims 1-33, wherein the therapeutic agent is an antibiotic agent selected form the group consisting of ciprofloxacin, cefuroxime, cefadroxil, cefazolin, cefalotin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftobiprole, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, bacitracin, colistin, polymyxin B, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, meticillin, nafcillin, oxacillin, penicillin, piperacillin, ticarcillin, mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, and trimethoprim-sulfamethoxazole.

49. The composition of any one of claims 1-33, wherein the therapeutic agent is an anesthetic agent selected from the group consisting of bupivacaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivacaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, and trimecaine.

50. The composition of any one of claims 1-33, wherein the therapeutic agent is an anti- inflammatory agent selected from the group consisting of acetylsalicylic acid, amoxiprin, benorylate / benorilate, choline magnesium salicylate, diflunisal, ethenzamide, faislamine, methyl salicylate, magnesium salicylate, salicylate, salicylate, salicylamide, diclofenac, aceclofenac, acemetacin, alclofenac, bromfenac, etodolac, indometacin, nabumetone, oxametacin, proglumetacin, sulindac, tolmetin, ibuprofen, alminoprofen, benoxaprofen, carprofen, dexibuprofen, dexketoprofen, fenbufen, fenoprofen, flunoxaprofen, flurbiprofen, ibuproxam, indoprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, pirprofen, suprofen, tiaprofenic acid, mefenamic acid, flufenamic acid, meclofenamic acid, tolfenamic acid, phenylbutazone, ampyrone, azapropazone, clofezone, kebuzone, metamizole, mofebutazone, oxyphenbutazone, phenazone, phenylbutazone, sulfinpyrazone, piroxicam, droxicam, lornoxicam, meloxicam, tenoxicam, hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, and aldosterone.

51. The composition of any one of claims 1-33, further comprising an additional therapeutic agent.

52. The composition of claim 51, wherein the additional therapeutic agent is an anesthetic agent.

53. The composition of claim 52, wherein the additional therapeutic agent is bupivacaine.

54. The composition of claim 51, wherein the additional therapeutic agent is an anti- inflammatory agent.

55. The composition of claim 54, wherein the additional therapeutic agent is dexamethasone.

56. The composition of claim 51, wherein the additional therapeutic agent is a β \beta -lactamase inhibitor.

57. A matrix forming agent or a combination of matrix forming agents, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer of Formula (I'): [Image disponible dans le document PDF, Image available in the PDF document] (I'), wherein: each occurrence of Y is independently − R 1 -R^1 or − L 2 R 2 -L^2R^2 ; each occurrence of R 1 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, − O R b -OR^b , − N ( R b ) 2 -N(R^b)_2 , or an oxygen protecting group; each occurrence of R 3 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, − O R b -OR^b , or − N ( R b ) 2 -N(R^b)_2 ; each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G 1A and G 2A is independently hydrogen, halogen, optionally substituted amine, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200, inclusive.

58. The matrix forming agent or combination of matrix forming agents of claim 57, wherein the matrix forming agent or combination of matrix forming agents comprises a polymer of [Image disponible dans le document PDF, Image available in the PDF document] Formula: (IA); wherein: each occurrence of Z is independently − R 4 -R^4 ; each occurrence of R 4 is independently optionally substituted alkyl; each of G 1 A G^{1A} and G 2 A G^{2A} is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200; the matrix forming agent forms a gel at temperatures above a phase transition temperature; and the phase transition temperature is about 37 °C or less than 37 °C; and at least one of conditions (i), (ii), and (iii) are met: (i) the phase transition temperature of a composition comprising the matrix forming agent or combination of matrix forming agents is less than the phase transition temperature of a reference composition plus about 5 °C; (ii) the storage modulus of the composition is about 15% or greater than 15% of the storage modulus of the reference composition at a temperature of about 37 °C; and (iii) the loss modulus of the composition is between about 80% and about 120% of the loss modulus of the reference composition at a temperature of about 37 °C; wherein the reference composition is the composition in the absence of a permeation enhancer or combination of permeation enhancers.

59. The matrix forming agent or a combination of matrix forming agents of claim 58, wherein the polymer is of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: each of p and t is independently an integer between 1 and 200, inclusive.

60. The matrix forming agent or a combination of matrix forming agents of claim 57, wherein the polymer is of the formula: [Image disponible dans le document PDF, Image available in the PDF document] •61. The matrix forming agent or a combination of matrix forming agents of claim 57, further comprising a therapeutic agent.

62. A composition for treating an infectious disease comprising: (a) a therapeutic agent; (b) a permeation enhancer, wherein the permeation enhancer increases the flux of the therapeutic agent across a barrier; and (c) the matrix forming agent of claim 57.

63. A composition for treating an ear disease comprising: (a) a therapeutic agent; (b) a permeation enhancer, wherein the permeation enhancer increases the flux of the therapeutic agent across the tympanic membrane; and (c) the matrix forming agent of claim 57.

64. The composition of claim 62 or 63, wherein each R 1 R^1 is unsubstituted C 1 − 20 C_{1-20} alkyl.

65. The composition of any one of claims 62 − 64 62-64 , wherein each L 2 L^2 is a bond or unsubstituted C 1 − 6 C_{1-6} alkylene.

66. The composition of claim 65, wherein each L 2 L^2 is a bond.

67. The composition of claim 65, wherein each L 2 L^2 is unsubstituted C 1 − 6 C_{1-6} alkylene.

68. The composition of any one of claims 62-67, wherein each R 2 is optionally substituted carbonyl.

69. The composition of claim 68, wherein each R 2 R^2 is of formula: [Image disponible dans le document PDF, Image available in the PDF document]70. The composition of claim 60 or 61, wherein the polymer is of formula: [Image disponible dans le document PDF, Image available in the PDF document] , wherein: each occurrence of Y is independently − R 1 -R^1 or − L 2 R 2 -L^2R^2 ; each occurrence of R 1 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl; each occurrence of L 2 is independently a bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, or optionally substituted heteroalkynylene; each occurrence of R 2 is independently optionally substituted acyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, − O R b -OR^b , − N ( R b ) 2 -N(R^b)_2 , or an oxygen protecting group; each occurrence of R 3 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteryaryl, optionally substituted acyl, − O R b -OR^b , or − N ( R b ) 2 -N(R^b)_2 ; each occurrence of R b is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group, or a nitrogen protecting group, or two R b taken together with the nitrogen to which they are attached form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; each of G 1 and G 2 is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted phosphate, or an oxygen protecting group; and each of p, q, r, s, and t is independently an integer between 1 and 200.

71. The composition of claim 70, wherein each R 1 R^1 is unsubstituted C 1 − 20 C_{1-20} alkyl.

72. The composition of claim 70 or 71, wherein each L 2 L^2 is a bond or unsubstituted C 1 − 6 C_{1-6} alkylene.

73. The composition of claim 72, wherein each L 2 L^2 is a bond.

74. The composition of claim 72, wherein each L 2 L^2 is unsubstituted C 1 − 6 C_{1-6} alkylene.

75. The composition of any one of claims 70-74, wherein each R 2 is optionally substituted carbonyl.

76. The composition of claim 75, wherein each R 2 R^2 is of formula: [Image disponible dans le document PDF, Image available in the PDF document]77. The composition of any one of claims 62-76, wherein the permeation enhancer is a surfactant, terpene, amino amide, amino ester, azide-containing compound, alcohol, or anesthetic agent.

78. The composition of any one of claims 62-76, wherein the permeation enhancer is sodium dodecyl sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, cetyl trimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, cocamidopropyl betaine, cetyl alcohol, oleyl alcohol, octyl glucoside, decyl maltoside, sodium octyl sulfate, sodium decyl sulfate, sodium tetradecyl sulfate, sodium heptadecyl sulfate, sodium eicosyl sulfate, nicotine sulfate, sodium taurocholic sulfate, dimethyl sulfoxide, sodium tridecyl phosphate; decyldimethyl ammonio propane sulfonate, chembetaine, myristyldimethyl ammonio propane sulfonate; benzyl pyridinium chloride, dodecyl pyridinium chloride, cetyl pyridinium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl dodecyl ammonium chloride, benzyldimethyl myristyl ammonium chloride, benzyldimethyl stearyl ammonium chloride, octyltrimethylammonium bromide, dodecyltrimethylammonium bromide, Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

79. The composition of any one of claims 62-76, wherein the permeation enhancer is limonene, cymene, pinene, camphor, menthol, camphene, phellandrene, sabinene, terpinene, borneol, cineole, geraniol, linalol, piperitone, terpineol, eugenol, eugenol acetate, safrole, benzyl benzoate, humulene, beta-caryophylene, eucalyptol, hexanoic acid, octanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, cholic acid, ethyl undecanoate, methyl laurate, methyl myristate, isopropyl myristate, isopropyl palmitate, palmityl palmitate, diethyl sebaccate, glyceryl monolaurate, glyceryl monooleate, or ethylpiperazine carboxylate.

80. The composition of any one of claims 62-76, wherein the permeation enhancer is an amino amide anesthetic agent or amino ester anesthetic agent.

81. The composition of claim 80, wherein the permeation enhancer is an anesthetic selected form the group consisting of bupivacaine, tetracaine, procaine, proparacaine, propaycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivacaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, and trimecaine.

82. The composition of any one of claims 62-76, wherein the therapeutic agent is an antibiotic agent, anesthetic agent, anti-inflammatory agent, analgesic agent, anti-fibrotic agent, anti-sclerotic agent, anticoagulant agent, or diagnostic agent.

83. The composition of any one of claims 62-76, wherein the therapeutic agent is an antimicrobial agent, an antibiotic agent, anesthetic agent, anti-inflammatory agent, analgesic agent, anti-fibrotic agent, anti-sclerotic agent, anticoagulant agent, or diagnostic agent.

84. The composition of any one of claims 62-76, wherein the therapeutic agent is an antibiotic agent selected from the group consisting of ciprofloxacin, cefuroxime, cefadroxil, cefazolin, cefalotin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftobiprole, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, bacitracin, colistin, polymyxin B, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, meticillin, nafcillin, oxacillin, penicillin, piperacillin, ticarcillin, mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, and trimethoprim-sulfamethoxazole.

85. The composition of any one of claims 62-76, wherein the therapeutic agent is an anesthetic agent selected from the group consisting of bupivacaine, tetracaine, procaine, proparacaine, propoxycaine, dimethocaine, cyclomethycaine, chloroprocaine, benzocaine, lidocaine, prilocaine, levobupivacaine, ropivacaine, dibucaine, articaine, carticaine, etidocaine, mepivacaine, piperocaine, and trimecaine.

86. The composition of any one of claims 62-76, wherein the therapeutic agent is an anti- inflammatory agent selected from the group consisting of acetylsalicylic acid, amoxiprin, benorylate / benorilate, choline magnesium salicylate, diflunisal, ethenzamide, faislamine, methyl salicylate, magnesium salicylate, salicylate, salicylate, salicylamide, diclofenac, aceclofenac, acemetacin, alclofenac, bromfenac, etodolac, indometacin, nabumetone, oxametacin, proglumetacin, sulindac, tolmetin, ibuprofen, alminoprofen, benoxaprofen, carprofen, dexibuprofen, dexketoprofen, fenbufen, fenoprofen, flunoxaprofen, flurbiprofen, ibuproxam, indoprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, pirprofen, suprofen, tiaprofenic acid, mefenamic acid, flufenamic acid, meclofenamic acid, tolfenamic acid, phenylbutazone, ampyrone, azapropazone, clofezone, kebuzone, metamizole, mofebutazone, oxyphenbutazone, phenazone, phenylbutazone, sulfinpyrazone, piroxicam, droxicam, lornoxicam, meloxicam, tenoxicam, hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, and aldosterone.

87. The composition of claim 86, wherein the therapeutic agent is a steroid.

88. The composition of any one of claims 62-76, wherein the therapeutic agent is an anesthetic agent.

89. The composition of claim 88, wherein the therapeutic agent is bupivacaine.

90. The composition of claim any one of claims 62-76, further comprising an additional therapeutic agent.

91. The composition of claim 88, wherein the additional therapeutic agent is an anesthetic agent.

92. The composition of claim 91, wherein the additional therapeutic agent is bupivacaine.

93. The composition of claim 88, wherein the additional therapeutic agent is an anti- inflammatory agent.

94. The composition of claim 93, wherein the additional therapeutic agent is dexamethasone.

95. The composition of claim 88, wherein the additional therapeutic agent is a β \beta -lactamase inhibitor.

96. The composition of any claims 1-56 or 62-95, wherein the composition forms a gel at a phase transition temperature between about 0 °C and about 37 °C.

97. The composition for use of any one of claims 1-56 or 62-96 for treating an infectious disease in a subject.

98. The composition for use of any one of claims 1-56 or 62-96 for treating an ear disease in a subject.

99. The composition for use of claim 97 or 98, wherein the disease is a bacterial infection.

100. The composition for use of claim 99, wherein the bacterial infection is an H. influenzae, S. pneumoniae, or M. catarrhalis infection.

101. The composition for use of claim 98, wherein the ear disease is otitis media.

102. The composition for use of any one of claims 1-56 or 62-96 for eradicating a biofilm in a subject.

103. The composition for use of any one of claims 1-56 or 62-96, wherein the composition is for administration to an ear canal of a subject, such that it contacts the surface of a tympanic membrane.

104. The composition for use of any one of claims 1-56 or 62-96, wherein the composition is for administration to an ear canal of a subject.

105. The composition for use of claim 103, wherein the composition is for administration as drops placed into the ear canal, or is for administration as a dose placed into the ear canal using a catheter.

106. The composition for use of claim 103, wherein the composition is for administration into the ear canal using an applicator.

107. The composition for use of claim 103, wherein the composition is for administration as a first dose and a second dose, wherein the first dose is for administration to the ear canal without a local anesthetic, and the second dose is for administration to the ear canal without a local anesthetic.

108. The composition for use of claim 103, wherein the composition is for administration to the ear canal as a first composition including one or more therapeutic agents, one or more permeation enhancers, and one or more matrix forming agents; and a second composition comprising no therapeutic agents or one or more therapeutic agents, no permeation enhancers or one or more permeation enhancers, and no matrix forming agents or one or more matrix forming agents, and the second composition is for administration subsequent to the first composition.

109. The composition for use of claim 108 wherein the therapeutic agents, permeation enhancers, and matrix forming agents are the same in the first composition as in the second composition.

110. The composition for use of claim 108 wherein the therapeutic agents, permeation enhancers, and matrix forming agents are different in the first composition as in the second composition.

111. The composition for use of claim 103, wherein the composition is for administration as a first dose and a second dose, wherein the first dose is for administration to the ear canal with a local anesthetic, and the second dose is for administration to the ear canal without a local anesthetic.

112. The composition for use of claim 103, wherein the composition is for administration via addition of the matrix forming agent to the ear canal; addition of the permeation enhancer to the ear canal; addition of the therapeutic agent to the ear canal; and mixing of the matrix forming agent, the permeation enhancer, and the therapeutic agent on the ear canal.

113. The composition for use of claim 103, wherein the composition is for administration via addition of the matrix forming agent to the ear canal; addition of the permeation enhancer to the ear canal; addition of the therapeutic agent to the ear canal; addition of an additional therapeutic agent to the ear canal; and mixing of the matrix forming agent, the permeation enhancer, and the therapeutic agents on the ear canal.

114. The composition for use of claim 107, wherein the therapeutic agent and the permeation enhancer are formulated for administration to the ear canal by being sprayed into the ear canal.

115. The composition for use of claim 103, wherein the composition is formulated for administration into the ear canal by being placed into the ear canal with a double barrel syringe.

116. A kit for treating an ear disease comprising a container, a composition of any one of claims 1-96, and instructions for administering the composition to a subject in need thereof.

117. The kit of claim 116, further comprising a dropper, syringe, or catheter.

118. The kit of claim 116, further comprising a double barrel syringe.

Citation Information

Patent Citations

  • Tympanic membrane permeating ear drops and uses thereof

    US8822410B2